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2. ABSTRACT 
 
Cancer and neurodegeneration are linked by a relation of inverse comorbidity, cancer 
patients being at lower risk for neurodegenerative disorders and vice versa. Interestingly, 
many cellular processes and factors contribute to both pathologies, and a central role is 
played by the transcription factor p53. Best known for its antiproliferative activities 
following transformation-related stimuli, p53 acts to maintain genetic stability and prevent 
tumour onset by transcriptional and non-transcriptional mechanisms. Recently, a 
contribution of p53 also in neuronal development and death was unveiled. In the case of 
Huntington’s Disease (HD), p53 mediates cytotoxicity in HD cells and animal models, 
whereas its inhibition prevents this phenotype.  
On these premises, we were prompted to investigate the signalling pathways and protein 
interactions that modulate p53 activation in both cancer and neurodegeneration with the 
aim of identifying critical hubs as new targets for therapeutic intervention. We discovered 
that expression of HD causative agent, i.e. mutant Huntingtin (mHtt) protein, behaves like 
a genotoxic stimulus in inducing phosphorylation of p53 on Ser46, that leads to its 
modification by phosphorylation-dependent prolyl-isomerase Pin1 and consequent 
induction of apoptotic target genes. Inhibition of Ser46 phosphorylation by targeting 
HIPK2, PKCδ, or ATM kinases, as well as inhibition of Pin1, prevented mHtt-dependent 
apoptosis of neuronal cells. These results provide a rationale for the use of small-molecule 
inhibitors of stress-responsive kinases and Pin1 as a potential therapeutic strategy for HD 
treatment. 
On the other hand, we investigated the contribution of BRD7, a protein involved in 
epigenetic regulation, to the p53 pathway. We found that BRD7 is required for the onset of 
oncogene-induced senescence, a main tumour suppressive p53 activity. In addition, we 
found that upon oncogene activation BRD7 restrains, independently of p53, the acquisition 
of malignant phenotypes, such as migration/invasion and stem cell traits. We observed a 
strong induction of inflammatory genes after depletion of BRD7, whose contribution to the 
tumorigenic process is currently under investigation. BRD7 takes part into the SWI/SNF 
and PRC2 chromatin-modifying complexes, appealing targets for cancer therapy for their 
pleiotropic roles and multi-subunit composition. We will also discuss how this new 
generated knowledge could be exploited for the treatment of neurodegenerative diseases, 
in which chromatin alterations are now recognized as drivers of pathogenesis.
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3. INTRODUCTION 
 
3.1 Unveiling the link between cancer and neurodegeneration 
 
Medical research tends to adopt a reductionist approach by studying different disorders as 
isolated phenomena, thus often neglecting the alternative approach of exploring and 
highlighting those mechanisms that are either common or in inverse relationship to 
multiple pathological conditions. Back in the 1970s, the clinician, researcher and 
epidemiologist Alvan Feinstein defined the concept of comorbidity as “any distinct 
additional clinical entity that has existed or may occur during the clinical course of a 
patient who has the index disease under study” (Feinstein, 1970). This definition places 
one disease in a central position and treats all the other diseases in the same patient as 
secondary. For example, depression, thyroid disorders, sleep apnoea, osteoporosis and 
glaucoma are more common in patients with Alzheimer’s Disease than in matched 
individuals without Alzheimer’s Disease. If the mechanisms underlying the aetiology of 
this comorbidity were to be clarified, the potential for developing more specific therapies 
and improving patient quality of life would be enormous (Barnett et al., 2012). It is 
important to note that unveiling the mechanisms underlying comorbidity may be the key to 
comprehend the relationship between the genome and its phenotypic manifestations.   
In the recent years, the concept of the association between certain diagnoses and a lower-
than-expected probability of developing other diseases, termed inverse comorbidity, has 
emerged (Ukraintseva et al., 2010). In particular, numerous epidemiological and clinical 
studies reveal that Down’s syndrome, Parkinson’s Disease (PD), schizophrenia, 
Alzheimer’s Disease (AD), multiple sclerosis, Huntington’s Disease (HD), anorexia 
nervosa, diabetes and allergy-related diseases seem to protect against many forms of 
cancer, including solid tumours, smoking related tumours, prostate cancer and Hodgkin’s 
and non- Hodgkin’s lymphoma. A recent comprehensive review of the studies performed 
about the association of cancer risk with neurodegenerative diseases has been done 
(Catala-Lopez et al., 2014). This review, which comprises more than 40 studies, shows that 
patients with neurodegenerative disorders have a substantially lower overall risk of 
developing cancer.  
The mechanisms underlying the inverse comorbidity between CNS disorders and cancer 
are still a controversial matter of debate; indeed there are some interesting theories that 
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present the problem in an evolutionary perspective. This perspective refers to the concept 
of antagonistic pleiotropy (Campisi, 2005; Papazoglu and Mills, 2007) that is the 
hypothesis that genes or processes that were selected to benefit the health and fitness of 
young organisms can have unselected deleterious effects that manifest in older organisms 
and thereby contribute to degenerative processes during ageing (Campisi and d'Adda di 
Fagagna, 2007). Tumour suppressors, whose loss enhances tumour formation, are the main 
actors of the surveillance mechanism to avoid aberrant proliferation under normal 
conditions and represent a very good example of antagonistic pleiotropy, because they 
promote early-life survival by preventing the development of cancer, but eventually limit 
longevity due to the depletion of irreplaceable post-mitotic cells in non-renewable tissues 
or to the elimination of proliferating or stem cell pools in renewable tissues.  
In the following paragraphs, we will focus on the inverse comorbidity between CNS 
disorders and cancers with a particular focus on the possible molecular mechanisms and 
pathways underlying this phenomenon. A particular relevance will be given to p53, the 
prototypical tumour suppressor whose pathway is inactivated in most human cancers 
(Murray-Zmijewski et al., 2008) but whose persistent activation has been shown to play a 
role in promoting aging and age-related disease such as neurodegeneration. Indeed p53 is 
activated and integrates the multiple incoming signals that sense different forms of cellular 
stress, and reacts by orchestrating appropriate cellular fates depending on both the cellular 
context and the entity and duration of the stress stimulus. Cell responses may vary from 
DNA repair and antioxidant processes to antiproliferative responses including senescence 
and apoptosis, thus, it is conceivable that small deregulations towards either one or the 
other side, could favour survival/regeneration or death/senescence of the cells.  
 
Shared cellular pathways and major disease regulators 
 
The cell cycle hypothesis. Trying to define common cellular mechanisms shared by CNS 
disorders and cancer may be counterintuitive because these two pathologies are often 
thought as characterized by disease mechanisms lying at opposite ends of a spectrum. 
Indeed neurons, for their nature of cells that should maintain their integrity throughout the 
lifespan, are resistant to mitotic signals and, lacking key mitotic proteins, are completely 
incapable of cell division (Ackman et al., 2007) while cancer cells are defined primarily by 
	   	   	  	   	   	  INTRODUCTION	  
	   9	  
uncontrolled cell growth (Hanahan and Weinberg, 2011). Surprisingly however, 
inappropriate entry into the cell cycle seems to be a key, early event in the degenerating 
neurons from Alzheimer’s Disease, Parkinson’s Disease and other neurodegenerative 
syndromes (Busser et al., 1998; El-Khodor et al., 2003; Hoglinger et al., 2007; Husseman 
et al., 2000; McShea et al., 1997; Nagy et al., 1997a; Nagy et al., 1997b; Smith and Lippa, 
1995). Importantly, distortion of the cell division plane (which can be parallel or 
perpendicular to the proliferating epithelium) interferes with progenitor proliferation, 
which can lead to apoptosis in neurodevelopmental and neurodegenerative disorders such 
as lissencephaly (Bi et al., 2009) and Huntington’s Disease (Godin et al., 2010). HD is 
particularly interesting under this point of view because alteration of the protein Huntingtin 
modifies the primary cilia that regulate progenitor cells in the neuroepithelium, disrupting 
neuroblast migration and differentiation (Keryer et al., 2011). If this effect also occurred in 
epithelial cells, it would produce a disruption of tumour progression and metastasis leading 
to cancer regression.  
 
The DNA damage response. A shared hallmark of cancer and neurodegeneration is the 
presence of alterations in the DNA damage response (DDR) pathway. DDR, a hierarchical 
process that entails DNA damage sensors, transducers and downstream effectors, acts 
either by promoting the repair of the lesions or by depleting the cell form the proliferative 
pool fostering processes such as apoptosis and senescence depending on the length, the 
intensity and the nature of the damage (Jackson and Bartek, 2009). Being the first line of 
defence against DNA damage, DDR plays a pivotal role in the maintenance of genome 
stability and in sustaining cellular homeostasis in a variety of contexts such as 
development, differentiation and normal cell growth. Defects in the DDR in proliferating 
cells can lead to genomic instability and ultimately to cancer allowing the bypass of 
tumour suppressive mechanisms, while DDR defects or aberrant activation in neurons may 
result in neurodegeneration. Indeed neurons are unique in being terminally differentiated 
and in sustaining extreme metabolic pressure due to high rates of transcription and 
translation associated with high mitochondrial activity. This activity, along with high 
oxygen consumption, creates a stressful environment where reactive oxygen species (ROS) 
can lead to DNA damage. The inability to respond properly to this damage, therefore, can 
be detrimental for cell survival and ultimately lead to neuronal cell death, as for example 
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happens in the case of the deficiency of the apical kinase of the DDR, ATM, whose loss 
causes ataxia-telangiectasia (AT), characterized by progressive cerebellar degeneration 
(Barzilai, 2010). In other neurodegenerative pathologies, such as HD, the presence of 
pathogenic proteins is able to activate, via ROS generation, the DNA damage response 
towards apoptosis, ultimately leading to cell death (Illuzzi et al., 2009). 
Conversely, the robust activation of the DNA damage response in normal growing cells 
following various kind of cellular stress such as telomere attrition and oncogene activation 
is able to activate oncosuppressive processes among which a central part is played by 
cellular senescence (d'Adda di Fagagna, 2008). 
 
Cellular senescence: a link between cancer and neurodegeneration. The role of cellular 
senescence in neurodegeneration and cancer is an emerging topic of interest in ageing and 
age-related diseases and might provide additional insights into the molecular and genetic 
basis of the inverse relationship between these two classes of disorders (Campisi et al., 
2011). Cellular senescence is an established cellular stress response, defined as an 
essentially irreversible loss of proliferative ability, that acts both physiologically being 
activated by telomere attrition and leading to ageing but also to prevent the expansion of 
cells that experience potentially oncogenic stress. Cellular senescence is a good example of 
antagonistic pleiotropy. Indeed in this case a tumour suppressive mechanism, which is 
clearly beneficial early in life for tumour protection, becomes detrimental later in life when 
neurodegeneration tends to appear. For this aspect in particular there are a lot of evidences 
involving a cell non-autonomous effect of senescence, the senescence-associated secretory 
phenotype (SASP), which entails the secretion of numerous cytokines, growth factors and 
proteases (Coppe et al., 2008; Kuilman et al., 2008) that can have autocrine or paracrine 
effects. When senescence is activated as a tumour suppressive mechanism, SASP is 
beneficial because it attracts and activates cells of the immune system favouring the 
clearance of senescent cells from tissues in vivo (Xue et al., 2007) and reinforces the 
growth arrest (Acosta et al., 2008; Kuilman et al., 2008) thanks to the pro-inflammatory 
cytokines IL6 and IL8, the protease inhibitor plasminogen activator inhibitor-1 (PAI-1) and 
the pleiotropic protein insulin-like growth factor binding protein-7 (IGFBP-7). On the 
other hand SASP can be a detrimental mechanism for neurodegeneration as demonstrated 
by the fact that expression of a SASP by senescent astrocytes, which has been documented 
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both in cells that were made senescent in culture as well as cells that were isolated from 
aged brain tissue, has been proposed to initiate or contribute to neuroinflammation (Bitto et 
al., 2010; Salminen et al., 2011), a characteristic of many neurodegenerative diseases 
thought to cause or exacerbate the age-related decline in both cognitive and motor 
functions.  
 
Cellular pathways altered in cancer and neurodegeneration. In the past years there have 
been several evidences that important cellular signalling pathways are upregulated in 
cancer, while downregulated or dysfunctional in neurodegeneration and vice versa. To 
understand the extent of the deregulation in opposite directions of a common set of genes 
and pathways in cancer and neurodegeneration, Alfonso Valencia and co-workers recently 
(Ibanez et al., 2014) performed transcriptomic meta analyses of three CNS disorders 
(Alzheimer’s Disease, Parkinson’s Disease and schizophrenia) and three Cancer types 
(Lung, Prostate, Colorectal) previously described with inverse comorbidities according to 
population studies. Noteworthy, from this study it emerged that 89% of the pathways that 
were upregulated in cancers were downregulated in CNS disorders and mainly related to 
Metabolism and Genetic Information processing. By contrast, the pathways downregulated 
in cancers, found to be upregulated in CNS disorders, were related to the cell’s 
communication with its environment. Interestingly, the analysis also revealed pathways 
related to protein folding and protein degradation displaying patterns of downregulation in 
CNS disorders and upregulation in cancers; among these, a particular relevance has to be 
given to the Ubiquitin/Proteasome system (UPS). The link between the protein degradation 
system, cancer and neurodegeneration was already known by single-gene analysis. For 
example, the genes linked to familial PD (the PARK loci) are primarily involved in protein 
processing and clearance, but many also play a role in development and cell cycle 
regulation. Parkin (PARK2) and ubiquitin C-terminal hydrolase (UCHL1, or PARK5) form 
part of the ubiquitin-proteasome system (UPS), the primary cellular pathway by which 
intracellular proteins are degraded. Dysfunction of the UPS leads to the accumulation of 
intracellular proteins, the formation of Lewy bodies (the pathological hallmarks of PD) and 
eventually to apoptosis (Sherman and Goldberg, 2001). Proteasome dysfunction is also 
linked to sporadic PD (McNaught et al., 2003) and proteasome inhibition can cause PD in 
animal models (McNaught et al., 2004). In contrast, as already said, upregulation of UPS is 
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associated with many cancers (Montagut et al., 2006). Given these premises the ubiquitin 
proteasome system appears to be a common link between cancer and neurodegeneration 
and an exciting target for new therapies. Beginning with bortezomib for the treatment of 
multiple myeloma, proteasome inhibitors are already an established anti-cancer therapy 
(Crawford et al., 2011). Conversely, although largely unexplored, proteasome activation is 
an attractive area of research for therapeutic treatment of a variety of neurodegenerative 
diseases (Huang and Chen, 2009).  
 
Single genes. Many proteins when abnormally expressed or aberrantly regulated have been 
linked to cancer or neurodegeneration. A review of common factors and overlapping 
pathways identified in the progression of cancer and neurodegeneration is presented in 
Table 1. 
 
Gene Function Role in neurodegeneration Role in cancer 
α-synuclein 
(PARK1/4) 
Unclear Gain of function leads to PD, main 
component of Lewy bodies in PD. 
α-synuclein is aberrantly expressed and 
methylated in cancer. 
PINK1 
(PARK6) 
Kinase Loss of function leads to PD. Loss of 
PINK1 functions leads to mitochondrial 
deficits.  
Somatic mutations in cancer (COSMIC 
Web site). Tumour suppressor? Induced 
by PTEN. 
DJ-1 
(PARK7) 
Unclear Loss of function leads to PD. DJ-1 might 
act as a neuroprotective oxidative stress 
sensor. 
Oncogene. Regulates negatively PTEN. 
Over-expression in several tumous. 
LRRK2 
(PARK8) 
Kinase, 
GTPase 
Gain of function leads to PD. Enzymatic 
activity thought to play a key role in the 
disease. 
Somatic mutations in cancer (COSMIC 
Web site). Oncogene? 
ATP13A2 
(PARK9) 
ATPase Loss of function leads to PD. May alter 
autophagic lysosomal function.  
ALP plays an important role in cancer. 
PLA2G6 
(PARK14?) 
Phospholipase 
A2 
Mutations lead to infantile neuroaxonal 
dystrophy (INAD), idiopathic 
neurodegeneration with brain iron 
accumulation (NBIA) and dystonia-
parkinsonism . 
PLA2G6 was identified as a risk factor 
for melanoma. 
Tau (MAPT) Microtubule-
associated 
protein 
Mutations in Tau lead to AD and FTDP-17. 
Tau is the major component of 
neurofibrillary tangles in AD. 
Reduced expression in several tumours. 
APP/PS1,2 Unclear Gain of function leads to AD type. 
Mutations in APP and the presenilins 
increase production of Aβ, which is the 
main component of senile plaques in AD. 
APP is overexpressed in acute myeloid 
leukemia patients with complex 
karyotypes. 
SOD1 Superoxide 
dismutase 
Gain of function leads to ALS. Mutations 
thought to cause cell death via aggregation 
and oxidative damage. 
Controversial role in breast cancer. 
Huntingtin Unclear Gain of function leads to HD. The Huntington disease protein 
accelerates breast tumour development 
and metastasis through ErbB2/HER2 
signalling. 
Parkin 
(PARK2) 
E3 ubiquitin 
ligase 
Loss of function leads to PD. Parkin 
enzymatic activity is thought to play a key 
role in the disease. Loss of parkin function 
leads to mitochondrial deficits. 
Tumour suppressor. 
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ATM Kinase Mutations in the ATM gene cause ataxia-
telangiectasia. ATM inactivation leads to 
cerebellar neuron loss. 
Tumour suppressor. ATM mutations 
carriers at increased risk of developing 
cancer, especially breast cancer. Role in 
cell cycle and DNA damage. 
CDK5 Kinase CDK5 can phosphorylate Tau and parkin. 
Also associated with AD. 
Somatic mutations in cancer. 
PTEN Phosphatase Functional link between PTEN and PINK1, 
parkin and DJ-1. 
Tumour suppressor, mutated in 
sporadic and inherited tumours. 
mTOR Kinase May play a role in neurodegeneration 
through inhibition of autophagy. 
Autophagy can be both oncogenic as 
well as tumour suppressive. 
TSC1/TSC2 Vesicular 
transport 
May play a role in neurodegeneration 
through mTOR-dependent autophagy. 
Tumour suppressors. 
p53 Transcription 
factor 
Functional link between p53 and parkin, 
Aβ, APP and Huntingtin. 
Tumour suppressor. 
 
Table 1. Genetic determinants at the interface of cancer and neurodegeneration. Common factors and 
overlapping pathways can be identified in the progression of both cancer and neurodegeneration (Plun-
Favreau et al., 2010). 
 
As previously said, among the genetic determinants shared by cancer and 
neurodegeneration an important role is played by proteins implicated in DNA damage 
response and the downstream events of cell cycle arrest and apoptosis. In this context, a 
particular relevance has to be given to p53. Interestingly, although p53 function in 
repressing carcinogenesis is known since several years (Donehower et al., 1992), its 
association with neurodegenerative disorders, including HD, AD and PD (Davenport et al., 
2010; Dunys et al., 2009; Jacobs et al., 2006), is becoming increasingly evident and will be 
discussed in next paragraph.  
 
p53 at the crossroads between cancer and neurodegeneration 
 
A common hallmark of cancer is the inactivation of tumour suppressor genes among which 
a key role is played by p53. As mentioned previously, the p53 protein is activated 
following transformation-related stimuli (genotoxic damage, deregulated oncogenes, 
hypoxia, etc.), and acts to maintain genetic stability by transcriptional and non-
transcriptional mechanisms (Murray-Zmijewski et al., 2008). 
Confirming the importance of p53 for tumour suppression, on average TP53 is mutated in 
31% of all tumours included in the Catalogue of Somatic Mutations in Cancer (COSMIC) 
database (Forbes et al., 2011); mutations, however, occur more frequently in some types of 
tumours than in others, in particular in ovarian (50% of cases in COSMIC), large intestine 
(43%) and lung (36%) cancers. In other kind of tumours where p53 mutations occur less 
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frequently such as breast cancer, hotspot p53 mutations were reported to be associated with 
more aggressive malignancies and could confer novel phenotypes in vivo including an 
increased metastatic capacity and resistance to chemotherapies (Garritano et al., 2013). In 
most other cancer cases in which the TP53 gene is wild-type, genetic lesions in 
components of the p53 pathway interfere with its activation; a classical example is the 
increased turnover or sequestration of the p53 protein itself through overexpression of its 
negative regulator MDM2 (Levine and Oren, 2009). Indeed it has been found a single 
nucleotide polymorphism (SNP) in the human MDM2 gene (Bond et al., 2004) that confers 
higher expression levels of the protein; individuals carrying this polymorphism are 
predisposed to early-onset cancer, suggesting that subtle differences in basal p53 activity 
may be enough to affect cancer risk (Whibley et al., 2009).  
A further proof of p53 importance as a tumour suppressor is given by the fact that mice 
engineered to be deficient in TP53 are developmentally normal, but susceptible to 
spontaneous tumours (Donehower et al., 1992). In addition, knockout p53 mice (p53-/-) 
have a significantly higher number of proliferating cells (Meletis et al., 2006). 
Interestingly, these p53-null mice are also mildly resistant to neurotoxicity (Morrison et al., 
1996). Indeed, data from in vitro and in vivo models recently unveiled a possible central 
role of p53 in neuronal development and death. A strong correlation between p53 
expression and excitotoxic neuronal death induced by glutamate, kainic acid and N-
methyl-D-aspartate has been established (Cregan et al., 1999; Uberti et al., 1998; Xiang et 
al., 1998). Moreover, many studies demonstrated that inhibition of p53 prevents cell death 
in a variety of neurodegenerative models. For example pifithrin-α, a drug that inhibits the 
transcriptional activity of p53 (Bassi et al., 2002; Komarov et al., 1999), attenuated 
neuronal death in several different rodent models of stroke (Culmsee et al., 2003; Culmsee 
et al., 2001; Zhu et al., 2002) and in cultured neurons exposed to DNA-damaging agents, 
glutamate and Aβ peptide (Culmsee et al., 2001). In the next paragraphs we will provide a 
brief review on what is known about the involvement of p53 in some of the most common 
neurodegenerative diseases such as AD, PD, schizophrenia and HD.  
Alzheimer’s Disease. AD is accompanied by neurodegeneration and neuronal loss in the 
frontal cortex, leading to a slow but progressive deconstruction of cognition, namely 
memory, emotion, reasoning and judgement. The most common form of AD is usually 
characterized by the deposition of amyloid-β (Aβ) protein in the extracellular plaques 
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within the brain (Baloyannis, 2006; Pereira et al., 2004), which leads to neuronal death, 
and by intraneuronal neurofibrillary tangles composed of the microtubule-associated 
protein tau (Seyb et al., 2006; Zheng et al., 2002b). A minor percentage of AD cases is 
familial (accounting for less than 1% of cases). Most of autosomal dominant familial AD 
can be attributed to mutations in genes encoding APP (β-amyloid precursor protein) and 
presenilin-1 and/or presenilin-2, which are parts of the γ-secretase complex involved in the 
generation of the Aβ peptide from the amyloid precursor protein (APP) (Batelli et al., 
2008). The best known genetic risk factor of sporadic AD is the apolipoprotein E (APOE) 
ε4 isoform. Regardless of how the pathology is triggered, p53 is highly elevated in AD 
brains (Chung et al., 2000; Kitamura et al., 1997). Interestingly, in human neurons treated 
with β-amyloid peptides (Paradis et al., 1996) and Alzheimer’s brains (Su et al., 1997), it 
has been reported a decrease of the anti-apoptotic p53 target Bcl-2 with concomitant 
increase in pro-apoptotic Bax expression. Moreover, p53 appears to mediate apoptosis in 
primary human neurons expressing Aβ1-42 (Zhang et al., 2002a), and also microglial 
apoptosis seems to be mediated by p53 in AD (Davenport et al., 2010). Interestingly, a 
conformational isoform of p53 has been identified to be associated with AD (Lanni et al., 
2008), suggesting that p53 is either mutated or misfolded in AD. 
Parkinson’s Disease. The pathology of PD involves loss of neurons in the substantia 
nigra. It initially starts as a movement disorder that progresses into cognitive and language 
impairment and eventually dementia. As for AD, elevation in p53 levels is also seen in PD 
brains (Mogi et al., 2007). p53-mediated neuronal death is observed both in cellular (Lee et 
al., 2006) and animal (Martin et al., 2006) models. Strikingly, several PD associated genes 
play a role in inducing p53 expression and/or transcriptional activity and surprisingly, three 
of these genes are associated with autosomal recessive juvenile PD. For example, loss of 
parkin function leads to an increase in p53 mRNA levels and transcriptional activity (da 
Costa et al., 2009). Another trait associated with PD is loss of the function of the protein α-
synuclein as mutant α-synuclein expression serves as a murine model of PD. It is 
interesting to note that Syphilin-1, a binding partner of α-synuclein, inhibits p53 
transcriptional activity (Giaime et al., 2006). It has been suggested that α-synuclein may 
also have a role in inhibiting p53 activation and transcriptional activity (Alves Da Costa et 
al., 2002), and thus it is conceivable that its loss will foster p53 activity. Considering this, 
down-modulating neuronal p53 activity may be therapeutic in PD. 
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Schizophrenia. Schizophrenia is a complex neuropsychiatric syndrome with several 
symptomatic dimensions, including positive symptoms such as reality distortion (for 
example hallucinations), negative symptoms (e.g. social withdrawal) and cognitive 
impairments. It is important to underline that the relationships between schizophrenia and 
individual types of cancer are more complex than those between the other 
neurodegenerative pathologies and cancer (Tabares-Seisdedos and Rubenstein, 2013). For 
example, patients with schizophrenia have a lower risk of prostate cancer and melanoma 
but a higher risk of breast and lung cancers. Recent evidences suggest that p53 has a role in 
schizophrenia. More specifically, the genetic evidence of TP53 as a schizophrenia-
susceptibility gene is strong, with five out of six studies reporting a significant association 
(Tabares-Seisdedos and Rubenstein, 2009). The meaning of this association, however, still 
needs to be elucidated. 
Huntington’s Disease. HD is a genetically dominant neurodegenerative disease caused by 
an expanded, unstable CAG repeat sequence in the huntingtin gene leading to abnormal 
Huntingtin protein product (Htt) (The Huntington's Disease Collaborative Research Group, 
(1993). Mutant Huntingtin protein (mHtt) contains an elongated polyglutamine (polyQ) 
trait whose length correlates with an earlier age of disease onset. The disease manifests at a 
mean age of 35 years and is characterized by progressively worsening chorea, psychiatric 
impairment and cognitive decline (Ross and Shoulson, 2009). The most striking 
pathological manifestation of HD is a specific and gradual loss of medium-sized spiny 
neurons	   in the caudate and in the putamen, though the substantia nigra and the cortex, 
among the others, are affected by the presence of mHtt. The HD mutation, by virtue of the 
expanded glutamine tract, is likely to confer toxic properties to the mutant protein. A gain 
of function mechanism is indeed supported by genetic and experimental data. HD is a 
dominant disease and in knockout mouse models, complete Huntingtin deficiency does not 
cause an HD-like phenotype. In most cells, Huntingtin is primarily a cytoplasmic protein 
associated with various organelles including mitochondria, endoplasmic reticulum and 
Golgi complex, but a fraction is also found in the nucleus. The pathophysiology of HD has 
been linked to apoptotic insult, defect in the proteosomal apparatus, glutamate mediated 
excitotoxicity, and mitochondrial dysfunction (Grunewald and Beal, 1999; Sawa, 2001; 
Schapira, 1997), but nuclear disturbances are also implicated with HD (Hodgson et al., 
1999; Petersen et al., 1999; Schilling et al., 2004; Steffan et al., 2000): recent evidences 
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suggest that mutant Huntingtin may disrupt normal transcription program in neurons 
(Figure 1).  
In the last decades an involvement of p53 in HD has been clearly demonstrated. First, p53 
protein levels are elevated in the brains of Huntington’s Disease patients (Bae et al., 2005), 
while susceptibility of spiny neurons to mHtt-mediated injury was directly correlated to 
p53 elevation and indirectly correlated to the endogenous levels of the p53-repressed gene 
Bcl-2 (Liang et al., 2005). mHtt has also been found to interact with p53 in the inclusion 
body, both biochemically (Steffan et al., 2000) and genetically (Ryan et al., 2006). 
Moreover, genes regulated by p53 are among a large cohort of genes upregulated in cell 
cultures transfected with mHtt (Sipione et al., 2002). Confirming these evidences, in 2005 
it was demonstrated (Bae et al., 2005) that the DNA damage response engaged by mHtt 
and mediated by the activation of the ATM/ATR pathways (Illuzzi et al., 2009) is able to 
activate p53, that in turn mediates mitochondrial dysfunction and cytotoxicity in HD cells 
and in transgenic animal models whereas its inhibition (either genetic or pharmacologic) 
prevents these phenotypes. 
 
Figure 1. Key pathogenic mechanisms in Huntington’s disease (HD). A: the mutation in Huntingtin 
causes a conformational change of the protein that leads to partial unfolding or abnormal folding of the 
protein. Full-length mutant Huntingtin is cleaved by proteases in the cytoplasm. In an attempt to eliminate the 
toxic Huntingtin, fragments are ubiquitylated and targeted to the proteasome for degradation. However, the 
proteasome becomes less efficient in HD. Induction of the proteasome activity as well as of autophagy 
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protects against the toxic insults of mHtt proteins by enhancing its clearance. B: NH2-terminal fragments 
containing the polyQ stretch accumulate in the cell cytoplasm and interact with several proteins causing 
impairment of calcium signaling and homeostasis (C) and mitochondrial dysfunction (D). E: NH2-terminal 
mHtt fragments translocate to the nucleus where they impair gene transcription or form intranuclear 
inclusions. F: the mutation in Huntingtin alters vesicular transport and recycling (Zuccato et al., 2010).  
 
In the next session, we will summarize the vast knowledge about the tumour suppressor 
p53, in particular the cellular events that drive its activation and their different outcomes 
and the regulation of its activity. 
 
3.2 The tumour suppressor p53 
 
p53 in health and disease  
 
The p53 protein, encoded by the TP53 gene, is a tumour suppressor able to integrate 
different physiologic and pathologic stimuli and to orchestrate adequate cellular responses 
in order to maintain genomic stability. Discovered in 1979 (Chang et al., 1979; Kress et al., 
1979; Lane and Crawford, 1979; Linzer and Levine, 1979) as the main interacting partner 
of the viral SV40 T-antigen, only in the late 1980s its role as tumour suppressor was 
officially unveiled (Weisz et al., 2007). Since then, p53 has been one of the most 
intensively studied proteins worldwide, mainly due to the evidence that most of human 
malignancies bear the abovementioned alterations in its signalling pathway. Indeed, as 
said, genetic mutations inactivating normal p53 functions can be found in a consistent 
number of human tumours, with percentages that vary from nearly 50% in ovary cancer to 
5,8% in cervical tumours (IARC TP53 Mutation Database).  
Since its discovery the p53 protein has best been known and studied as a tumour 
suppressor for its ability to inhibit cell proliferation, by both blocking transiently or 
irreversibly cell cycle progression or promoting apoptotic cell death. The importance of 
these pathways for tumour suppression has been demonstrated in vivo by the study of the 
mechanisms of restoration of p53 in different mouse models (Martins et al., 2006; Ventura 
et al., 2007; Xue et al., 2007). Restoration of p53 in lymphomas led to their widespread 
apoptosis, whereas restoration of p53 in sarcomas and hepatocarcinomas led to a 
senescence-type response. These growth inhibitory functions of p53 are normally held 
dormant, and the p53 protein, present at low levels in the cells, gets stabilized and 
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activated in response to different kind of stimuli that a cell might encounter during 
malignant progression such as genotoxic damage, oncogene activation, loss of normal cell 
contacts and hypoxia (Oren, 2001). In unstressed cells, p53 activity is maintained at low 
levels through p53 degradation, principally mediated by the MDM2 E3-ubiquitin ligase 
and by the related protein MDM4 (known as MDMX in humans)(Finch et al., 2002; Lu 
and Levine, 1995; Momand et al., 1992; Wadgaonkar and Collins, 1999). Stress-induced 
post-translational modifications of both p53 and MDM2/MDM4 abolishes this interaction 
leading to p53 accumulation and the unleashing of its transcriptional activity (Toledo and 
Wahl, 2006); once active, the protein can mediate different biological phenomena 
depending on the entity and type of damage, among which the best characterized are 
temporary cell cycle arrest to favour DNA repair, programmed cell death (apoptosis) and 
permanent cell cycle arrest (senescence).  
It is now becoming apparent that the spectrum of p53 activities may be far broader than 
simply promoting antiproliferative responses to acute stress. Indeed the ability to prevent 
cancer has been suggested to be an “evolutionarily late” cooption of primordial p53 
activities that had initially evolved to protect the germline and monitor development 
(Aranda-Anzaldo and Dent, 2007; Vousden and Lane, 2007). In fact it is conceivable that 
protection against tumour formation was probably not the ancestral function of the p53 
regulatory network, and support for this idea comes from taking into account the existence 
of p53 family members in simple, short-lived organisms and protists (Lu et al., 2009). 
Moreover, the relatively late appearance of ARF gene (an MDM2 inhibitor) orthologues in 
the vertebrate lineage – they are absent from both zebrafish and puffer fish genomes 
(Gilley and Fried, 2001) - seems consistent with this deduction as the corresponding 
proteins arguably represent fundamental links between oncogenic stress and p53 (Martins 
et al., 2006). Also the rapid post-translational regulation of p53 activity by modulating its 
interactions with MDM2 and MDM4 is a peculiarly vertebrate acquisition: no direct 
counterparts of MDM2 or MDM4 exist in invertebrates, and invertebrate p53 homologues 
lack the key residues with which these protein interact (Nordstrom and Abrams, 2000).  
It is important to underline that, independently of the specific function, p53 is mainly 
acting as a transcription factor regulating both positively and negatively the expression of 
an elevated number of genes, directly binding in tetrameric form to specific target 
sequences on the DNA (p53-responsive elements, p53RE) (Bourdon et al., 1997; el-Deiry 
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et al., 1992; Funk et al., 1992; Laptenko and Prives, 2006). However, several transcription-
independent activities have been described, mainly involved in potentiating the pro-
apoptotic response acting in the cytoplasm and at mitochondria (Chipuk et al., 2005; Moll 
et al., 2005; Yee and Vousden, 2005).  
A snapshot of the stresses activating the p53 pathway and its outcome is reported in Figure 
2. 
 
 
Figure 2. Simplified scheme of the p53 pathway. The p53–MDM2 feedback loop is the ‘heart’ of the p53 
pathway. Under normal conditions, it maintains constantly low steady-state p53 levels and activity. Various 
stress signals related in many ways to carcinogenesis, impinge on this central loop to release p53 from 
MDM2-mediated inhibition. The downstream effects of p53 are largely due to its ability to transactivate and 
repress various subsets of target genes; however, at least in the case of apoptosis, protein–protein interactions 
in the cytoplasm (primarily with Bcl-2 family members) also have an important role. Recent evidence 
indicates that p53 also has an important role in enabling the cell to adjust its metabolism in response to mild 
normal physiological fluctuations, including those in glucose and other nutrient levels, oxygen availability 
and reactive oxygen species levels (Levine and Oren, 2009).  
 
The p53 family 
 
Three members of the p53 family are found in humans: p53, p63 and p73. As shown in 
Figure 3, all the members have an amino-terminal transactivation domain, a central DNA-
binding domain and a carboxy-terminal oligomerization domain, but their primary 
sequences do not share an elevated homology, being about 30% for the whole proteins 
while reaching 65% when only the DNA binding domain is considered (IARC TP53 
Database).  
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Figure 3. Conserved functional domains of the p53 family. The percentage indicates the degree of 
identity. AD: transactivation domains. PRD: proline-rich domain. DBD: DNA binding domain. NLS: nuclear 
localization signal. TD: tetramerization domain. BD: basic domain. SAM: sterile alpha motif(Harms and 
Chen, 2006).  
 
Notably, p63 and p73 contain a sterile alpha motif (SAM) domain at the extreme C-
terminus; this domain probably facilitates protein-protein interactions and, in the context of 
p73, has been implicated in protein turnover. The SAM domain is absent in p53 and 
therefore p63 and p73 share a more common ancestor.  
 
p63. The human TP63 gene is composed of 15 exons, spanning over 270.000 bp on 
chromosome 3q27. Altogether, the p63 gene expresses at least six mRNA variants, which 
encode for six different p63 protein isoforms (TAp63α, TAp63β, TAp63γ, ΔNp63α, 
ΔNp63β, and ΔNp63γ) (Figure 4). The TAp63 isoforms are able to activate transcription of 
p53 target genes and induce cell cycle arrest or apoptosis. The ΔNp63 isoforms can bind 
DNA and can exert dominant-negative effects over p53, p73 and p63 activities by either 
competing for DNA binding sites or by direct protein interaction (Bourdon, 2007b). 
ΔNp63 isoforms were also shown to directly activate specific gene targets not induced by 
TA isoforms. ΔNp63 are abundantly expressed in progenitor cell layers of skin, breast and 
prostate, while TA p63 isoforms are barely detectable, indicating a switch between 
isoforms expression during normal cellular differentiation. However, TAp63 isoforms have 
been found to be expressed also in early embryogenesis to foster the initiation of epithelial 
stratification and inhibit terminal differentiation in a complex interplay with ΔNp63 
isoforms.  
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p73. The human TP73 gene is composed of 15 exons spanning on chromosome 1p36.3. 
The p73 gene expresses at least seven alternatively spliced C-terminal isoforms (α, β, γ, δ, 
ε, ζ and µ) (Bourdon, 2007b) and at least four alternatively spliced N-terminal isoforms 
initiated at different ATG (Figure 4). Altogether, the p73 gene expresses at least 35 mRNA 
variants, which can encode theoretically 29 different p73 protein isoforms. As for what 
reported for p63, both ΔN and TA isoforms have transactivation capabilities, and ΔNp73 
can exert dominant negative functions over the other isoforms.   	  
 
 
 
Figure 4. Known isoforms of the p63 and p73 proteins(Bourdon, 2007b). 
 
As a consequence of the partial structural homology, p53 family members have some 
overlapping functions mediated by the transactivation of common targets (Stiewe, 2007). 
Indeed, p63 and p73 are able to trigger apoptosis upon DNA damage (Yang et al., 2000) 
and to induce senescence both in vitro and in vivo (Guo et al., 2009). Recently, a critical 
role of p63 in metastasis suppression has emerged (Adorno et al., 2009; Muller et al., 
2009). Consistently, the role of p63 and p73 in tumour suppression is highlighted by the 
findings that compound p63+/- p73+/- mice develop spontaneous tumours and that loss of 
p63 and p73 can also cooperate with loss of p53 in the development of specific tumour 
types (Flores et al., 2005). 
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In addition to their oncosuppressive activities p63 and p73 share with p53 the ability to 
control also embryonic development and differentiation. Although mice lacking p63 are 
born alive, they show the most severe developmental phenotype of all the p53 family 
members (Mills et al., 1999). The limbs are absent or truncated owing to a malfunction of 
the apical ectoderm ridge. Moreover, the mice fail to develop a stratified epidermis and 
most epithelial tissues (e.g. hair follicles, prostate and mammary glands) and eventually die 
from dehydration within hours after birth. 
p73 knockout mice are viable, but show a runting phenotype and a high mortality rate 
within the first two months (Yang et al., 2000). The animals suffer from several neurologic 
defects (hydrocephaly, hippocampal disgenesis and loss of sympathetic neurons) and have 
immunological problems characterized by chronic infections and inflammation. Moreover, 
these mice show abnormal reproductive and social behaviour, which is presumably due to 
defects in pheromone detection in the vomeronasal organ.  
 
p53 structure and isoforms 
 
p53 isoforms. The mouse p53 gene is composed of 11 exons, spanning over 12.000 bp 
(GenBank Accession Number: NC_000077) on chromosome 11, while the human p53 
gene is composed of 11 exons spanning over 19.200 bp (GenBank Accession Number: 
NC_000017) on chromosome 17p13.1. The primary transcript can be subjected to 
alternative splicing; moreover, the presence of alternative promoters allows the production 
of N-terminal truncated proteins, similarly to what happens for the other members of the 
family. The canonical form of the human protein, identified as p53α, comprises 393 
residues. 8 more isoforms have been described, that are differentially expressed in various 
tissues (Bourdon et al., 2005)(Figure 5). 
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Figure 5. p53 gene and isoforms. Genomic structure of p53: Alternative splicing (α, β, γ) and alternative 
promoters (P1, P10 and P2) are indicated (upper panel). p53 protein isoforms: p53, p53 β and p53 γ proteins 
encoded from P1 or P10 promoters contain the conserved N-terminal domain of transactivation (TA). 
Δ133p53 isoforms encoded from promoter P2 are amino-truncated proteins deleted of the entire TA domain 
and deleted of part of the DNA-binding domain. Translation is initiated at ATG-133. Δ40p53 protein 
isoforms encoded from P1 or P10 promoters are amino-truncated proteins due to alternative splicing of exon 
2 and/or alternative initiation of translation at ATG-40. Δp53 protein isoform is due to an alternative splicing 
between the exon 7 and 9 (adapted from (Bourdon, 2007a)). 
 
p53 isoforms can have distinct biochemical activities. p53β binds preferentially the p53-
responsive promoters p21 and Bax rather than MDM2, while p53 binds preferentially to 
MDM2 and p21 rather than Bax promoters. Co-transfection of p53 with p53β increases 
slightly p53-mediated apoptosis, while co-transfection of p53 with Δ133p53 strongly 
inhibits p53-mediated apoptosis in a dose dependent manner, consistently with the finding 
that it is frequently overexpressed in breast tumours. This suggests that a subtle and 
complex balance between the different p53 isoforms and p53 could regulate cellular fate 
outcome in response to p53 activation (Bourdon et al., 2005).  
Δ40p53 (also named p47 or ΔNp53) is an amino-terminally truncated p53 isoform deleted 
of the first 40 amino acids. The Δ40p53 protein still contains part of the p53 transactivation 
domain and can activate gene expression, but can also act in a dominant-negative manner 
towards full-length p53 inhibiting both p53 transcriptional activity and p53-mediated 
apoptosis (Mills, 2005; Rohaly et al., 2005). Moreover Δ40p53 can modify p53 cell 
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localization and inhibits p53 degradation by MDM2.  
 
Functional domains of the p53 protein. As many other transcription factors, p53 has a 
modular structure composed by evolutionarily conserved functional domains: an N-
terminal transactivation domain (aa 1-61), a proline-rich domain (aa 64-93), a central 
DNA-binding domain (aa 93- 292), an oligomerization domain (aa 325-355) and a C-
terminal regulatory domain (Figure 6). 
 
Figure 6. Schematic representation of p53 domains (Bode and Dong, 2004). 
 
The N-terminal transactivation domain of p53 contains two acidic domains (TAD1, aa 1-
40, and TAD2, aa 40-61) (Bode and Dong, 2004), both required to induce transcription of 
target genes. These two regions, indeed, interact with components of the transcriptional 
machinery, such as TBP (TATA box binding protein), TAFs (TBP-associated factors), the 
p62 subunit of the transcriptional/repair factor TFIIH and the transcriptional coactivators 
CBP (CREB binding protein) and p300 (Avantaggiati et al., 1997).  
The transactivation domain is followed by a proline-rich domain (PRD, aa 64-93), which 
contains five repeats of the amino acid motif PXXP (P= proline; X= any amino acid). The 
PRD is required for p53 stabilization (Zacchi et al., 2002; Zheng et al., 2002a) and is 
particularly involved in the ability of p53 to trigger apoptosis, both by transcriptional 
induction of pro-apoptotic genes (Bergamaschi et al., 2006; Venot et al., 1998) and by 
direct activity of p53 at mitochondria (Chipuk et al., 2004). 
In the PRD is also present the best-characterized p53 polymorphism: in humans, codon 72 
can encode either proline or arginine. The distribution of this polymorphism appears to 
follow a north/south gradient, with the frequency of the Pro72 allele increasing toward the 
equator, suggesting a possible selection of codon Pro72 variants in areas with high UV 
light exposure. This polymorphism affects p53 activity: Arg72 variant is more efficient 
than Pro72 in inducing apoptosis due to both its enhanced localization at mitochondria and 
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its lower affinity for the iASPP protein, which binds preferentially to the PRD and 
selectively blocks access of p53 to the promoters of apoptosis-related genes (Bergamaschi 
et al., 2006). Consistently, expression of p53 Arg72 is associated to a greater sensitivity of 
tumour cells to anticancer drugs and is predictive of a more favourable clinical response to 
chemotherapy in head and neck squamous cell carcinomas (Sullivan et al., 2004). 
The central core of p53 contains its DNA binding domain (DBD, aa 93-292), required to 
recognize and specifically bind to the cognate sequence 5’ – PuPuPuC(A/T)- (T/A) 
GPyPyPy – 3’ (el-Deiry et al., 1992). Besides the interaction with DNA, the DBD 
mediates the binding between p53 and crucial cofactors in defining p53 functions and 
activity. Proteins like 53BP1, Hzf, ASPP1 and ASPP2 positively affect p53 activity by 
interacting with its DBD (Das et al., 2007; Samuels-Lev et al., 2001), while other proteins 
bind to the DBD and negatively regulate p53. Indeed, MDM2 has been shown to interact 
also with residues in the DBD and the binding of MDM2 to full-length p53 is 10-fold 
stronger than binding to the N-terminal domain alone. The frequency of tumour-acquired 
mutations of TP53 is the highest within this domain, highlighting the critical importance of 
loss of DNA binding and interaction with pivotal partners for enabling tumour cells to 
evade stress-induced growth suppression (Brosh and Rotter, 2009). 
The oligomerization domain (OD, aa 325-355) is required for the formation of a high-
affinity DNA binding and transcriptional competent p53 tetramer.  
The C-terminal domain of p53, in particular the last 30 amino acids (CT, aa 364-393), has 
been historically called “regulatory domain”, since it contains several residues targeted 
by post-translational modifications that modulate p53 stability and function (Kruse and Gu, 
2009). In the C-terminus of p53 is present a cluster of three nuclear localization signals 
(NLS) that mediate the shuttling of the protein into the cell nucleus. NLSI (aa 316-322) is 
the most active signal while the other two NLSs, II and III (aa 370-384) appear to be less 
important for nuclear localization (Shaulsky et al., 1990). p53 contains also two putative 
nuclear export signals (NES), one in the N-terminus (nNES, aa 11-27) and the other in the 
OD (cNES, aa 340-351) (Stommel et al., 1999). For both NES, it has been proposed that 
when p53 needs to be activated, they are masked by the formation of the tetramer, or by 
direct phosphorylation by DNA-damage activated kinases. More generally, the 
oligomerization of p53 has been proposed as a mechanism that may regulate its nucleo-
cytoplasmic transport by affecting the accessibility of the cNES but also of the NLS to 
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their respective receptors (Stommel et al., 1999). 
 
Biological activities of p53 
 
In the context of tumour suppression, p53 induction can lead to different biological 
outcomes, depending on the context. For example, the continued expression of dominant 
oncogenes in vivo can lead to the irreversible withdrawal of cells from the proliferative 
cycle into a terminal state termed oncogene-induced senescence (Braig and Schmitt, 2006). 
Such a mechanism has been observed to occur in mouse model of prostate cancer and in 
human fibroblasts and mammary epithelial cells (Collado and Serrano, 2010). p53 can also 
suppress tumour development by initiating apoptosis, the major form of programmed cell 
death, which involves the ordered and rapid destruction of the cell in the absence of an 
inflammatory response (Benchimol, 2001). For example, p53-mediated apoptosis is 
thought to protect against the development of lymphoma and, interestingly, mice that 
express a p53 mutant protein lacking the ability to induce cell cycle arrest but retaining 
apoptosis-inducing functions are still efficiently protected from spontaneous tumour 
development (Toledo and Wahl, 2006). Key factors that determine the outcome of p53 
induction, at least in cultured cells, are the type and intensity of stress, the cell type and the 
genetic background. Crosstalk with other pathways, such as survival signalling or the 
retinoblastoma pathway, can tip the balance between growth arrest and apoptosis. Other 
mechanisms, such as the prevention of metastasis, are likely to contribute to tumour 
suppression. However, given the many hundreds of genes that are thought to be regulated 
by p53 (Vousden and Prives, 2009) and the many varied biological functions to which it is 
now known to contribute, we do not have a complete picture of how tumour suppression is 
mediated mechanistically in all instances. The common principle is the protection of the 
organism either by maintaining the integrity of the cell and its genome or by preventing the 
proliferation of cancer cells. 
 
Apoptosis. The term “apoptosis” defines the process of programmed cell death that the cell 
can undergo both physiologically (for example during development) and after pathologic 
stimuli that lead to irreparable damage. The apoptotic cell executes a genetic programme 
that leads to characteristic modifications such as nuclear condensation, DNA fragmentation 
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and dilatation of the endoplasmic reticulum; in the final phase of the process the different 
cellular components are enclosed into the so called “apoptotic bodies” and are 
phagocytised by macrophages and by nearby cells without causing an inflammatory 
response.  
Apoptosis can start both following the extrinsic route and via intrinsic activation; the first 
is caused by external stimuli as the Fas ligand that, interacting with specific receptors 
belonging to the TNF-R (tumour necrosis factor-receptor) family, activates the 
cytoplasmic effector proteins called caspases. The intrinsic route is fostered by internal 
signals as DNA damage or hypoxia (Green, 1998) and, through a direct activity at 
mitochondria that leads to mitochondrial outer membrane permeabilization (MOMP) and 
cytochrome c release, ends in caspases activation; indeed in the cytoplasm cytochrome c 
associates with APAF-1 (apoptotic protease-activating factor 1) starting the assembly of 
the apoptosome that in turn activates the caspases (Li et al., 1997; Zou et al., 1997).  
Mitochondrial proteins have a fundamental role in the intrinsic pathway, and in particular 
the Bcl-2 family proteins. The family is divided in anti-apoptotic members, such as Bcl-2, 
Bcl-xL and Mcl-1, which contain BH1, BH2, BH3 and BH4 domains, and the pro-
apoptotic members, which either contain BH1, BH2 and BH3 domains such as the MOMP 
effectors Bax and Bak, or the BH3-only domain class such as the activators tBid and Bim 
(Vaseva and Moll, 2009). To effectively induce apoptosis the effector proteins should 
undergo an activation that involves a conformational change and an homo-oligomerization, 
which in turn leads to their translocation and insertion into the outer mitochondrial 
membrane to generate pores that release pro-apoptotic factors from the mitochondrial 
intermembranous space (e.g. cytochrome c). The BH3-only class of proteins covers the 
role of favouring such activation, either by stimulating the oligomerization of Bak and Bax 
(tBid and Bim proteins) or inhibiting the binding between anti-apoptotic proteins and the 
effectors of apoptosis (Puma, Noxa and Bad proteins). 
p53 is able to induce apoptosis acting both on intrinsic and extrinsic pathways, mainly 
regulating transcriptionally the two routes. Indeed p53 activates the transcription of death 
receptors localized in the cytoplasmic membrane (among which Fas, DR4 and 
KILLER/DR5) but also of a number of genes belonging in the Bcl2 family, such as Bax, 
Bid, Puma, Noxa, p53AIP1 and represses the anti-apoptotic genes Bcl2 and Bcl-xL (p53-
target genes involved in apoptosis reviewed in (Vousden and Lu, 2002)). Moreover p53 
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induces the transcription of effectors of the apoptotic cascade such as Apaf-1 and caspase-
6 (MacLachlan and El-Deiry, 2002) (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Several apoptotic pathways are activated by p53. p53 can induce the expression of numerous 
apoptotic genes that can contribute to the activation of both death receptor and mitochondrial apoptotic 
pathways. p53 can also affect the efficiency of survival signalling (Vousden and Lu, 2002). 
 
In addition to these activities, a p53 transcription-independent route for MOMP has been 
discovered and starting from this in the last 20 years a lot of effort has been made in 
elucidating p53 pro-apoptotic activities in the cytoplasm. The hallmark of transcription-
independent apoptosis induction by p53 is the stress-dependent accumulation of the protein 
in the cytoplasm and mitochondria that directly activates the apoptosis effectors Bax and 
Bak.  
 
Cell cycle arrest. The activation of the p53 pathway can induce cell cycle arrest mostly 
promoting the induction of three critical target genes: p21, 14-3-3σ and GADD45. The 
cyclin-dependent kinase inhibitor p21Waf1/Cip1 has been the first identified transcriptional 
target of p53 (el-Deiry et al., 1993). Upon p53 activation, p21 increased levels result in cell 
cycle arrest in G1 phase due to inhibition of cyclinA/CDK2, cyclinE/CDK2 and 
cyclinD/CDK4 (Harper et al., 1993). p21 was demonstrated to participate also in the G2/M 
arrest after DNA damage, presumably by blocking PCNA function at replication 
forks(Ando et al., 2001). However, the p53-induced G2 arrest is mostly mediated by the 
activation of other two genes, i.e. GADD45 and 14-3-3σ (Hermeking et al., 1997). 
Regarding the other proteins, GADD45 is able to destabilize the complexes CDC2/cyclin 
B, whereas 14-3-3σ sequesters the complexes cyclinB1/CDK1 in the cytoplasm 
contributing to G2 arrest. Interestingly the inhibition of 14-3-3σ is sufficient to confer to 
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primary human epithelial cells the ability to grow indefinitely in culture (Dellambra et al., 
2000).  
 
Senescence. Senescence commonly describes a cellular response to different kind of 
stimuli characterized by the irreversible arrest of proliferation. Senescent cells, although 
remaining vital and metabolically active, lose the ability to divide and to progress in the 
cell cycle that usually is arrested in the G1 phase. In 1961 Hayflick and Moorhead 
(Hayflick and Moorhead, 1961) described for the first time the phenomenon of replicative 
senescence starting from the observation that human fibroblasts cultured in standard 
conditions (monolayer, broad space, presence of nutrients and growth factors) at first 
undergo a rapid cell division that rapidly declines following cellular passages, completely 
arresting after reaching the intrinsic limit of their replicative potential (“Hayflick limit”) 
given by excessive telomere shortening. In the last years it has emerged the concept that 
the same phenotype can be originated by various cellular stresses such as oncogene 
expression (Serrano et al., 1997), DNA damage (Di Leonardo et al., 1994) (Parrinello et 
al., 2003) or chromatin structure alteration (Munro et al., 2004; Ogryzko et al., 1996). In 
particular the overexpression of active oncogenes can induce a cellular response 
phenotypically indistinguishable from replicative senescence, independent from telomere 
shortening (Jones et al., 2000; Serrano et al., 1997), called oncogene-induced senescence 
(OIS). Oncogenes have the possibility to induce the transformation of a cell if combined 
with other mutations. An emblematic role is covered by Ras, a cytoplasmic protein able to 
transduce extracellular growth signals, which if expressed in the constitutively active form 
can cooperate with other oncogenes leading to cellular transformation (Malumbres and 
Barbacid, 2003); when the active form is expressed in an otherwise normal cell, however, 
it induces an irreversible growth arrest similar to senescence (Serrano et al., 1997). This 
first observation has been further extended to the various members of the Ras pathway 
such as the GTPase RAC1 and the kinases RAK1 and MEK whose alteration can induce 
senescence (Dimri et al., 2000; Michaloglou et al., 2005); it is important to underline that 
also the loss of PTEN, an inhibitor of the Ras pathway, is able to lead to the same effect 
(Chen et al., 2005).	   
Among the mechanisms that induce OIS an important role is played by PML 
(promyelocitic leukemia). This protein is a key component of nuclear structures called 
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nuclear bodies (NBs) (Borden, 2002; Salomoni and Pandolfi, 2002; Zhong et al., 2000). It 
has been demonstrated that the presence of an oncogenic form of Ras induces PML and 
that this event is necessary for the establishment of OIS in mouse embryo fibroblasts 
(Pearson et al., 2000). Moreover overexpression of a PML isoform, PML IV, is able to 
induce senescence in human and mouse fibroblasts and this activity is dependent on p53 
acetylation in the nuclear bodies (Pearson et al., 2000).  
A common characteristic of OIS is the alteration of DNA replication and the activation of 
DNA damage response (DDR). It has been demonstrated that the effect due to Ras 
activation on cell proliferation is biphasic in nature: at first the cells undergo hyper 
proliferation, rapidly followed by growth arrest and senescence establishment (Di Micco et 
al., 2006; Sarkisian et al., 2007). This is true also for other oncogenes such as BRAF 
(Dankort et al., 2007; Michaloglou et al., 2005), E2F (Lazzerini Denchi et al., 2005) and 
Myc (Dominguez-Sola et al., 2007; Grandori et al., 2003). The activation of DDR 
coincides with the end of hyper proliferation that is believed to cause replicative fork 
stalling thus generating DNA damage. Among the first proteins to respond to DSBs is 
ATM (Ataxia Telangiectasia Mutated). ATM substrates include H2AX, a nucleosomal 
histone variant, and p53 binding protein-1 (53BP1), which facilitates checkpoint activation 
and repair. Phosphorylated H2AX (γ-H2AX) and 53BP1 rapidly localize to DSBs, forming 
characteristic foci. ATM also phosphorylates the DDR kinase CHK2 (checkpoint kinase-
2), which promotes growth arrest; NBS1 (Nijmegen breakage syndrome), a member of the 
MRN (MRE11-RAD51-NBS1) complex that reinforces the DDR and participates in DNA 
repair; and p53, that orchestrates repair and cell cycle arrest. DSBs that cannot be repaired 
(e.g., uncapped telomeres) or replicative fork stalling following hyper proliferation driven 
by active oncogenes cause constitutive DDR signalling, prolonged p53-dependent growth 
arrest, and eventually an essentially irreversible senescence (d'Adda di Fagagna, 2008). A 
causal role has been demonstrated through the observation that inactivation of genes 
involved in DDR is able to avoid senescence and induce transformation following the 
expression of oncogenes (Bartkova et al., 2006; Di Micco et al., 2006; Mallette et al., 
2007). 
Senescence is established and maintained by p53 and pRb pathways (Figure 8).  
The INK4a/ARF locus is fundamental for the regulation of this process: it encodes for two 
proteins, p16INK4a and p14ARF (p19ARF in mouse). p16INK4a binds CDK4/CDK6 complex 
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and induces a conformational change able to disrupt the interaction with cyclin D. In this 
way pRb is maintained in hypo-phosphorylated form and induces cell cycle arrest in G1 
phase. On the other hand p14ARF binds mouse double minute 2 (MDM2) displacing its 
interaction with p53, thereby activating p53 transcriptional activity towards cell cycle 
arrest genes (Sherr, 1998). The main effector of this response is p21 (Brown et al., 1997). 
Experimental evidences have demonstrated that reduction of p53, p21 or DNA damage 
response proteins is able to prevent senescence induced by telomere shortening and DNA 
damage and in some cases can eventually revert the senescent state (d'Adda di Fagagna et 
al., 2003; Di Micco et al., 2006; Gire et al., 2004). 
Recently some new evidences on the role of other genes transcribed by p53 for senescence 
induction are emerging, for example the class of microRNAs miR-34 (He et al., 2007). In 
particular miR34a is induced or more expressed in senescent human fibroblasts and its 
absence augments their replicative potential. The mechanism of action has been proposed 
to involve inhibition of the deacetylase SIRT1 (Yamakuchi and Lowenstein, 2009). 
 
Figure 8. Senescence controlled by the p53 and p16–pRB pathways. Senescence-inducing signals, that 
usually trigger a DNA damage response (DDR), engage either the p53 or the p16–retinoblastoma protein 
(pRB) tumour suppressor pathways. Some signals, such as oncogenic Ras, engage both pathways. Active p53 
establishes the senescence growth arrest in part by inducing the expression of p21, a cyclin-dependent kinase 
(CDK) inhibitor that, among other activities, suppresses the phosphorylation and, hence, the inactivation of 
pRB. Senescence signals that engage the p16–pRB pathway generally do so by inducing the expression of 
p16, another CDK inhibitor that prevents pRB phosphorylation and inactivation. pRB halts cell proliferation 
by suppressing the activity of E2F, a transcription factor that stimulates the expression of genes that are 
required for cell-cycle progression. E2F can also foster proliferation by inducing ARF expression, which 
engages the p53 pathway. So, there is reciprocal regulation between the p53 and p16–pRB pathways 
(Campisi and d'Adda di Fagagna, 2007). 
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Other p53 functions.  In the recent years it has emerged the concept that p53 can regulate 
several aspects of cell metabolism (Shen et al., 2012; Vousden and Ryan, 2009) spanning 
from direct regulation of glucose metabolism and oxidative phosphorylation to its activity 
in controlling oxidative stress. Intriguingly, these p53 actions result from a coordination of 
transcriptional and cytoplasmic activities, whose net balance is not always easy to 
understand. Regarding the mitochondrial energetic regulation, p53 is able to promote both 
TCA cycle and oxidative phosphorylation (OXPHOS). Moreover, p53 also regulates 
glutaminolysis by activating the expression of mitochondrial glutaminase (GLS2), which 
promotes glutamine to glutamate conversion leading to the formation of α-ketoglutarate, a 
TCA cycle intermediate (Jiang et al., 2013). As for mitochondrial respiratory chain, p53 is 
able to foster the pathway by transcriptionally activating “synthesis of cytochrome c 
oxidase 2” (SCO2) expression, a regulator of complex IV, cytochrome c oxidase (COX) I 
subunit, and AIF, essential for mitochondrial respiratory complex I function. To counteract 
the reactive oxygen species produced by the enhancement of OXYPHOS, p53 upregulates 
antioxidant activities through metabolic processes, for example via the transcriptional 
induction of “TP53-induced glycolysis and apoptosis regulator” TIGAR (Bensaad et al., 
2006) that limits the activity of PFK1 so lowering the rate of glycolysis while promoting 
pentose phosphate pathway (PPP).  
The PPP is a central metabolic pathway that produces NADPH required for regeneration of 
reduced glutathione (GSH). Interestingly, it has been recently demonstrated that a core of 
cytoplasmic p53 can inhibit glucose-6-phosphate dehydrogenase (G6PDH), the rate-
limiting enzyme of PPP, through transient interactions. The net effect of nuclear and 
cytoplasmic activity is not clear and may be cell context and stress-dependent. It is 
conceivable that inactivation of p53 by different means in cancer cells accelerates glucose 
consumption and directs glucose for rapid production of macromolecules by an increase in 
PPP flux thus enhancing biosynthesis. In turn p53 loss could also contribute to the 
Warburg effect by fostering glycolysis.  
In the recent years it has been demonstrated that p53 can also control the process of 
autophagy, although in an ambiguous fashion (Maiuri et al., 2010). When exposed to 
stress, nuclear p53 can induce autophagy by regulating several genes involved in the 
autophagic cascade; first of all p53 can inhibit the negative regulator of autophagy mTOR 
through inducing transcription of its negative regulators such as TSC2 (tuberous sclerosis 
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2), the beta 1 and beta 2 subunits of AMP-activated protein kinase (AMPK), an 
evolutionarily conserved sensor of cellular energy levels which phosphorylates and thus 
activates TSC1 and TSC2, and sestrins 1 and 2, two main activators of AMPK. Another 
transcriptional target of p53 involved in autophagy induction is DRAM (damage-regulated 
autophagy modulator), a lysosomal protein that induces macroautophagy and is also able to 
regulate cell death. In contrast to the autophagy-promoting functions of p53 in the nucleus, 
the cytoplasmic pool of p53 suppresses autophagy in multiple experimental settings 
(Tasdemir et al., 2008), as demonstrated by the fact that pharmacological inhibition of p53 
can trigger autophagy in cytoplasts. In human, mouse and nematode cells depletion or 
inactivation of p53 by different means induced autophagy that relied on mTOR inhibition. 
Recently, p53 has also entered the stem cell arena. Indeed a role for p53 in differentiation 
and development had already been observed in Xenopus laevis, where p53 engages in 
complex interactions with the Smad transcriptional regulators to direct embryonic germ 
layer specification (Piccolo, 2008). Moreover when p53 is activated in mESCs, it binds to 
the promoter of Nanog, a master regulator of pluripotency, and represses its expression, 
leading to the differentiation of the cells and their elimination from the stem cells pool 
(Brandner, 2010). In addition to the Nanog promoter, p53 was also shown to bind the 
promoter of Oct4 and repress its expression. On the same line it was recently demonstrated 
that p53 regulates the polarity of self renewing divisions in mammary stem cells (Cicalese 
et al., 2009), pushing towards asymmetric division. 
 
Regulation of p53 levels and activities 
 
Given its potent growth suppressive activity, improper activation of p53 must be avoided 
in growing cells and this is obtained by precise mechanisms that control its stability and 
activity. When cells undergo stress, p53 stability, promoter recruitment and transcriptional 
activity are induced by means of multiple post-translational modifications and by 
interaction with activators and inhibitors (Levine and Oren, 2009). These include proteins 
that enhance the translation of p53 mRNA, that modify p53 for both stabilization and 
transcriptional activation, that reverse these modifications or that alter its sub-cellular 
localization. Rather than simply leading to its rapid activation, all these events finely 
modulate p53 functions, allowing it to adapt and to coordinate appropriate responses to 
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specific stimuli. 
Regulation of p53 transcription and translation. For a long time, the regulation of p53 
abundance has been associated only to its stabilization; nevertheless, relatively recently the 
modulation of p53 mRNA transcription and translation have also been shown to play a role 
in determining p53 expression levels. Indeed, despite p53 mRNA levels were originally 
reported to be almost unaffected by several stresses, p53 transcription was demonstrated to 
be regulated by BCL6, HOXA5 and CTCF in particular cellular contexts. p53 translation 
can be regulated by factors able to bind the 5’UTR and 3’UTR secondary structures of the 
p53 mRNA. Acting on the 5’UTR, p53 translation is modulated in response to DNA 
damage positively by the ribosomal protein L26(Ofir-Rosenfeld et al., 2008) and 
negatively by nucleolin.  
Regulation of p53 stability. Regulation of p53 abundance occurs mainly at the protein 
level: in physiological conditions, p53 levels are maintained low thanks to efficient 
degradation mediated by the ubiquitin-proteasome system and in particular this is induced 
by the product of the p53 target gene MDM2, whose E3 ubiquitin ligase activity 
establishes a negative feedback loop with p53, leading to attenuation of p53-mediated 
response under conditions of transient DNA damage. The relevance of MDM2 regulation 
on p53 function is underscored by the phenotype of MDM2 knockout mouse, whose 
embryonic lethality is rescued by simultaneous absence of p53 (Jones et al., 1995). 
Depending on its relative abundance with respect to p53, MDM2 can catalyze either mono- 
or poly-ubiquitylation of p53, leading to nuclear export and translocation to mitochondria 
or intranuclear proteasomal degradation, respectively (Li et al., 2003; Marchenko et al., 
2007). Connected to MDM2 activity, the tumour suppressor p14 (ARF) is a pivotal 
positive regulator of p53 stability being able to block MDM2 catalytic activity in vitro and 
the poly-ubiquitylation of p53 in vivo.  
During the last decade, several other p53’s E3-ubiquitin ligases have been described. 
Among them, Pirh2 and COP1 are, like MDM2, p53-inducible genes that participate in a 
comparable auto regulatory negative feedback loop (Dornan et al., 2004; Leng et al., 
2003). 
p53 ubitiquitylation can be reversed by the deubiquitylating enzyme HAUSP (herpes 
associated ubiquitin-specific protease, also known as USP7), which can stabilize and 
activate p53 by removing ubiquitin moieties from its C-terminus, thus counteracting 
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MDM2 function. Moreover, HAUSP is involved in rapid deubiquitylation of p53 at 
mitochondria, thus generating the apoptotically active non-ubiquitylated form of 
mitochondrial p53 (Marchenko et al., 2007). 
Post-translational modifications. p53 undergoes a great variety of post-translational 
modifications that influence its stability and its transcriptional activity. At the moment, it is 
known that more than 36 different amino acids within p53 are modified: the actual pattern 
of post-translational modifications is complicated since there could be competition for the 
same residue, which can indeed be modified in different ways by different enzymes 
(Figure 9). 
 
Figure 9. Schematic representation of p53 phosphorylation sites and of the enzyme involved in p53 
phosphorylation upon different stimuli. Post-translational modification sites (P, phosphorylation; Ac, 
acetylation; G, glycosylation; Me, mono(1) or di-(2) methylation; N8, neddylation; Ub, ubiquitylation; 
polyADP-R, poly-ADP-ribosylation) are indicated together with enzymes that can accomplish the 
modifications in vitro. The C-terminal six lysines (K370, K372, K373, K381, K382, and K386) are the 
primary site of ubiquitylation by MDM2; whereas K291 and K292 can be ubiqitylated by MKRN1 and K320 
is ubiqitylated by E4F1. K373, K372, and K373 are likely sites of attachment for the ubiquitin-like protein 
NEDD8, and Lys386 may be modified by conjugation with SUMO1, a ubiquitin-like peptide. Adapted from 
(Meek and Anderson, 2009). 
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Phosphorylation is the most extensively studied p53 post-translational modification. Many 
kinases, including ATM, ATR, Chk1, Chk2, CK1, CK2, JNK, Erk, p38, Aurora Kinase A, 
GSK3β, HIPK2 and DYRK2, have been shown to phosphorylate p53 after DNA damage 
(Vousden and Prives, 2009). The redundancies observed in p53 phosphorylation can be 
explained as a failsafe mechanism and also by the fact that distinctive combination of 
phosphorylated residues could be required for further modifications, leading to maximal 
activation. Indeed, only a few p53 sites are phosphorylated by one specific protein kinase, 
as, for example, Ser6, Ser9 and Thr18 by CK1 and Thr18 by JNK (Banin et al., 1998; 
Waterman et al., 1998). The best-characterized p53 phosphorylations are those at the N-
terminus of the protein, in particular modifications that affect Ser15, Thr18, Ser20 and 
Ser46. Ser15 is phosphorylated in an ATM-dependent manner in response to γ-irradiation 
(Banin et al., 1998; Waterman et al., 1998) and by ATR and p38 in response to UV light 
(Bulavin et al., 1999). After Ser15 phosphorylation, p53 is more transcriptionally active, 
also because of the increased interaction with the acetyltransferase CBP (Lambert et al., 
1998), and induces growth arrest and apoptosis (Shieh et al., 1997). Phosphorylation of 
Ser46 can be performed by several kinases, as HIPK2 (D'Orazi et al., 2006; Hofmann et 
al., 2002), DYRK2 (Taira et al., 2007), PKCδ (Yoshida et al., 2006) AMPK and p38. This 
phosphorylation determines selectivity of p53 recruitment to its target promoters, 
specifically promoting the induction of pro-apoptotic target genes (D'Orazi et al., 2006; 
Oda et al., 2000). It is likely that an ordered pattern and an interdependence of stress-
induced modifications of p53 exist.  
p53 can be acetylated at several lysines by different histone acetyltransferases (HATs) as 
p300/CBP and PCAF (p300/CBP-associated factor), which were shown to acetylate p53 in 
response to DNA damaging agents, such as UV- and γ-irradiation (Carter and Vousden, 
2009). In detail, CBP and p300 acetylate p53 at lysines within the C-terminal domain (Lys 
370, 372, 373, 381 and 382)(Avantaggiati et al., 1997). Acetylation at Lys 120 catalyzed 
by the MYST family acetyltransferases hMOF and TIP60 has also reported to confer 
promoter selectivity for apoptotic target genes/DNA binding specificity and has also been 
found involved in transcription-independent apoptotic activity of p53 (Carter and Vousden, 
2009). 
In the last years several works described the identification of novel p53 modifications 
mostly on lysines, such as methylation, ubiquitylation, neddylation and sumoylation.  
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Methylation of p53 by methyltransferases can occur at least at two different sites, reported 
to lead to opposing effects on p53 function. Indeed, while methylation at Lys372 by the 
methyltransferase Set9 increases the stability of p53, restricting it to the nucleus and 
enhancing p53-dependent transcription (Chuikov et al., 2004), the methylation of Lys370, 
catalyzed by the methyltransferase Smyd2, leads to repression of its transcriptional activity 
(Huang et al., 2006). 
Three lysines that are targeted for ubiquitylation (Lys 370, 372 and 373) are also subjected 
to NEDDylation. Sumoylation consists in the addition of the small ubiquitin-like protein 
SUMO1 to the ε-amino group of lysine. In the case of p53, several reports have described 
the sumoylation of Lys386: however it is still controversial whether this modification 
modulates p53 transcriptional activity in a positive fashion (Gostissa et al., 1999). 
 
Drugging the p53 pathway: novel insights into therapeutic approaches  
 
As previously said, p53 is inactivated by mutations in over 30% of all cancers (Vogelstein 
et al., 2000). A high percentage of those mutations is of the missense type, and disrupts its 
direct binding to DNA or leads to structural perturbations that prevent the correct folding 
or oligomerization of the tumour suppressor. At other times, loss of p53 function is due to 
overexpression of p53-regulatory proteins that suppress p53 activity, such as MDM2 and 
MDMX. Numerous strategies have been devised to correct a dysfunctional p53-regulatory 
pathway, although it is not a simple task, because p53 is neither a cell surface protein nor a 
typical enzyme and thus antibodies and low-molecular-mass enzyme inhibitors, which 
have served as the basis for almost all of the recently developed targeted anticancer 
therapies, are not pertinent options. In tumours that retain wild-type p53 but have defects 
in p53-regulatory pathways, such as overexpression or amplification of MDM2 or MDMX 
or epigenetic silencing of INK4A-ARF locus, the major approach for the restoration of p53 
activity has been to inhibit the function of negative regulators of the p53 
response(Roxburgh et al., 2012). Although a number of potential therapeutic opportunities 
have been identified, such as blocking E6-induced proteasomal degradation of p53 in 
human papillomavirus (HPV)-driven cancers using bortezomib, or inhibiting the enzymatic 
E3 ubiquitin-ligase activity of MDM2 (reviewed in (Hoe et al., 2014)) the vast majority of 
the current lines of research and clinical trials are focused on finding small-molecule drugs 
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that block the binding of p53 with MDM2 or MDMX. A breakthrough in the field was the 
development of nutlin, the first small molecule inhibitor of the p53-MDM2 interaction 
(Vassilev et al., 2004). A complementary approach led to the identification of the small 
molecule inhibitor RITA (Reactivation of p53 and Induction of Tumour cell Apoptosis); 
whereas nutlins bind to MDM2, RITA binds to p53 and prevents it from being attached by 
MDM2(Issaeva et al., 2004). RITA is particularly promising because it has a strong 
apoptotic effect on many tumour cell lines (Grinkevich et al., 2009; Sorrentino et al., 
2013). 
In cases where the p53 protein is mutated, attempts have been made to find molecules that 
may act as chaperones by binding to mutant p53 protein and stabilizing its conformation. 
Indeed, genetic studies that demonstrate reversion of the effects of common p53 mutations 
by second-site mutations have supported such an approach (Nikolova et al., 2000) by 
showing that alterations in different regions of p53 can correct the defect induced by the 
primary mutation. Moreover, about 8% of p53 mutations result in early termination of 
translation and “read-through drugs” such as the aminoglycoside antibiotic G418 (Hoe et 
al., 2014) can bypass the effect of stop codons introduced by mutations and thus restore the 
expression of p53. 
Attempts have also been made to manipulate the p53 pathway using gene therapy or 
immunological approaches (Brown et al., 2009). In particular, adenoviral vector-based 
delivery of TP53 was approved in China in 2004 for the treatment of head and neck cancer. 
An alternative gene therapy strategy was developed at Onyx, California, USA. This is 
constituted by an oncolytic Adenovirus that is deficient for E1B 55kDa, which binds and 
inactivates p53. Consequently, this virus can replicate in tumour cells that lack functional 
p53 and kill them. Although clinical trials yielded promising results, approval for clinical 
use still needs to be evaluated. A related oncolytic virus, operating on a similar principle, 
has been approved for cancer therapy in China (Hoe et al., 2014). 
As described above, a consistent therapeutic approach targeting p53 has been challenging 
to design, especially considering that the most desirable effect should be the induction of 
apoptotic death of cancer cells rather than senescence. Indeed it is still a matter of debate 
how p53 is instructed to choose between its growth arrest and pro-apoptotic functions and 
a detailed knowledge of the underlying pathways may help to design more specific and 
effective therapeutic approaches. Indeed deciphering the mechanisms driving the 
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multiplicity of p53 responses is of paramount importance in the clinical arena, where the 
apoptotic potential of p53 could be exploited for selective elimination of cancer cells. On 
the other hand, activation of p53-dependent apoptosis in healthy tissues as for example 
happens in neurodegenerative diseases or after chemotherapy is detrimental and should be 
avoided. Thus, a better comprehension of the mechanisms of p53 activation could provide 
also possible new targets to escape inappropriate p53 activation. 
A great interest comes from the evidence that genes tend to function as networks rather 
than individually, and this is particularly important for those that are master regulators of 
many pathways, like p53. Recent studies in model organisms have provided an updated 
view of gene networks based on flexibility, degeneracy, and redundancy. This is 
particularly obvious in disorders such as cancer and neurodegeneration. Indeed, a large 
number of p53 cofactors are emerging as relevant for both pathologies, and it is likely that 
future therapeutic approaches for these important diseases will rely on combinatorial 
strategies targeting gene networks. These advanced therapies, however, will require a deep 
understanding of gene networks relevant to cancer and neurodegeneration.  
In the next session we will discuss the importance of understanding the pathways that 
reinforce and modulate p53 activity; this will allow the development of anticancer 
therapies to target tumour-supportive cellular machineries but may also be exploited to 
block unwanted effects of p53 activation. 
 
3.3 The importance of cofactors in the regulation of p53 functions 
 
p53 activities are regulated by its interaction with a high number of cofactors whose 
different tissue distribution is likely to concur in generating the heterogeneity of p53 
responses. Some of these proteins bind the p53 DNA binding domain; an example is given 
by the members of the ASPP family: ASPP1, ASPP2 and iASPP. This evolutionarily 
conserved family of transcriptional regulators is able to regulate the proapoptotic function 
of the p53 family proteins. While ASPP1 and ASPP2 associate with p53 DBD and foster 
its binding to pro apoptotic promoters such as Bax and PIG3 (Samuels-Lev et al., 2001), 
iASPP binds also the proline rich domain of p53 and has the opposite effect of inhibiting 
apoptosis induced by p53 (Bergamaschi et al., 2003).  
Some p53 cofactors belong to large cellular machineries such as chromatin modification 
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complexes or signal transduction cascades whose relationships with both cancer and 
neurodegeneration are becoming increasingly evident. In this thesis we will analyse 
bromodomain-containing protein 7 (BRD7), a component of epigenetic regulatory 
complexes, and the prolyl-isomerase Pin1, an amplifier of phosphorylation-directed 
signalling pathways as paradigms of cofactors able to differently instruct p53 activity, 
thereby providing putative new targets for cancer and neurodegenerative disease therapies. 
 
Chromatin modifiers  	  
Alterations in the chromatin remodelling machinery are common events in cancer. 
Following physiologic or pathologic stimuli, chromatin can be modified either by histone 
modifications (including acetylation, methylation, ubiquitylation, sumoylation and 
phosphorylation), by exchange in histone variants or by ATP-dependent sliding of 
nucleosomes. Interestingly, proteins regulating all these processes have been found altered 
in human malignancies: for example the histone methyltransferase genes MLL2 and MLL3 
are the two most commonly mutated genes in medulloblastoma (Parsons et al., 2011), the 
histone variant macroH2A suppresses melanoma progression (Kapoor et al., 2010) and 43 
% of tumours bear mutations in DAXX or ATRX, that encode subunits for a chromatin 
remodelling complex (Jiao et al., 2011). This widespread pattern of alterations points 
towards a key role of chromatin remodelling in regulating transformation, as also 
demonstrated by the clinical success of drugs targeting chromatin modifiers. One of the 
best examples are histone deacetylase (HDAC) inhibitors (vorinostat and 
romidespin)(Dobbelstein and Moll, 2014), which have been approved by the FDA for the 
treatment of cutaneous T cell lymphoma (CTCL). Besides HDACs, also bromodomain-
containing proteins have recently received attention as targets for modulating chromatin 
dynamics. Bromodomains comprise an extensive family of evolutionarily conserved 
protein modules of 110aa that have the ability to bind to acetylated lysines with high 
specificity (Haynes et al., 1992; Zeng and Zhou, 2002). The bromodomain is found in 
many chromatin-associated proteins and derives its name from the Drosophila protein 
Brahma, where it was first identified (Elfring et al., 1998; Haynes et al., 1992). The finding 
that this domain has specific acetyl-lysine binding properties (Dhalluin et al., 1999; 
Hudson et al., 2000; Jacobson et al., 2000; Owen et al., 2000) highlighted how some 
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protein-protein interaction can be modulated by lysine acetylation, with broad implications 
in a wide variety of cellular processes including chromatin remodelling and transcriptional 
activation (Dyson et al., 2001; Winston and Allis, 1999).  
Some bromodomain proteins present additional domains with specific enzymatic activity, 
through which they may directly mediate chromatin modifications. Among these 
p300/CBP (Kraus et al., 1999; Manning et al., 2001), PCAF (Dhalluin et al., 1999), 
TAFII250 (Jacobson et al., 2000) have HAT activity, the transcriptional silencer Ash1L 
(Gregory et al., 2007) and the tumour suppressor RIZ1 (Steele-Perkins et al., 2001) have 
histone methyltransferase (HMT) activity and the SNF2α and β subunits of the SWI/SNF 
complex have ATP-dependent remodelling functions (Smith and Peterson, 2005). 
Conversely, other bromodomain proteins such as MTA1 (Nicolson et al., 2003), ACF1 
(Eberharter et al., 2001) and BRD7, that have no catalytic activity, may mediate 
communication between chromatin and multiprotein remodelling complexes. These 
scaffolding functions contribute to epigenetic regulation of transcription through a 
mechanism called the histone code (Rea et al., 2000; Strahl and Allis, 2000; Turner, 2000), 
wherein combination of specific histone modifications such as acetylation, mediates the 
recruitment of different chromatin-remodelling machinery. Interestingly, a bromodomain 
and extra-terminal (BET) domain protein, BRD4, holds promise as a target in acute 
myeloid leukaemia (AML)(Zuber et al., 2011). BRD4 was identified in a short hairpin 
RNA screen from a collection of epigenetic regulators and its downregulation suppressed 
AML progression in an in vivo model, and the same achievement was obtained by a BRD4 
inhibitor named JQ1.  
In search for novel interactors of p53, in our laboratory it was performed a Yeast Two-
Hybrid screening (Van Criekinge and Beyaert, 1999) by using a LexA-p53wt construct 
lacking the p53 transactivation domain (Δ11-69) as bait and a human foetal brain cDNA 
library cloned into the galactose-inducible expression vector pJG4–5 as prey (Gostissa et 
al., 2004).  A new p53 interactor isolated with this technique was the bromodomain-
containing protein BRD7. At the same time, our collaborators in the R. Agami’s group at 
NKI (Amsterdam) isolated BRD7 in a loss-of-function screening aimed at identifying 
genes required for p53-dependent oncogene-induced senescence (OIS). Specifically, 
primary human BJ fibroblasts expressing the catalytic subunit of human telomerase 
(hTERT) were used, and transduced with a vector encoding 4-OH-Tamoxifen (4OHT)-
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inducible oncogenic HRasV12 (BJ/ET/RasV12ER (Voorhoeve et al., 2006)). In this system 
induction of constitutively activated mutant RasV12 caused the onset of senescence in a 
p53-dependent fashion. Importantly, the acceleration of cell proliferation upon inhibition 
of p53 was mediated through p14ARF, while cellular transformation was completely 
independent of it (Voorhoeve and Agami, 2003). Therefore, to focus on genes acting in the 
transformation process, the screen was performed in BJ/ET/RasV12ER cells in which 
p14ARF was knocked down. Nineteen outliers were selected from which three endowed 
cells with a growth advantage in the presence of RasV12, all targeting the same gene, 
BRD7. 
 
The bromodomain-containing protein BRD7 
 
BRD7 is an evolutionarily conserved and ubiquitously expressed chromatin-binding 
protein (Staal et al., 2000). Under the name BRD7 fall two isoforms that differ for a single 
amino acid residue; isoform 1 comprises 652 amino acids while isoform 2 uses an alternate 
in-frame splice site in the 3' coding region and thus lacks one internal residue compared to 
isoform 1. The molecular mass of both isoforms is about 75 kDa. The proteins bear a 
single central bromodomain (Staal et al., 2000), through which they bind specifically to 
acetylated lysines 9 and 14 on histone H3 and acetylated lysines 8, 12 and 16 on histone 
H4 (Peng et al., 2006; Sun et al., 2007) (Figure 10). 
 
 
 
Figure 10. BRD7 structure. Schematic representation of BRD7 protein structure in which is highlighted the 
bromodomain in position 129-238.  
 
Interestingly, BRD7 is frequently lost in human malignancies. Indeed BRD7 loss is a 
common hallmark of nasopharyngeal carcinoma (NPC), where its reduced expression has 
been ascribed to either loss-of-heterozygosity (LOH) on the chromosomal locus hosting 
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the BRD7 gene (that is one of the most frequent genomic events in NPC) or to aberrant 
methylation of the BRD7 gene itself (Liu et al., 2008).  
Interestingly, loss of BRD7 in other tumour types has been correlated with the acquisition 
of highly malignant tumoral phenotypes. In high-grade ovarian carcinoma BRD7 mRNA 
levels have been found decreased compared to normal epithelial tissue or low-grade 
carcinoma (Bae et al., 2013), whereas in colorectal cancer downregulation of BRD7 
protein expression with respect to adjacent normal tissue was found to be significantly 
correlated with advanced tumour stage and poor pathologic differentiation, as well as with 
unfavourable prognosis (Wu et al., 2013).  
This may be due in part to the fact that BRD7 acts as a negative regulator of cell 
proliferation. Its ectopic expression in nasopharyngeal carcinoma-derived cell lines lacking 
endogenous BRD7 is able to inhibit G1-S progression as a consequence of altering the 
expression of components of Ras/MEK/ERK and Rb/E2F pathways at the transcriptional 
level (Zhou et al., 2004). In this experimental system BRD7 has also been shown to 
negatively regulate cell growth by means of reducing the expression of Cyclin D1, E2F3, 
MEK (and consequently ERK1/2 phosphorylation) and c-jun and to upregulate expression 
of α-catenin that retains β-catenin in the cytoplasm thus blocking its translocation into the 
nucleus (Peng et al., 2007). Furthermore, BRD7 was found to inhibit the growth of prostate 
cancer cells by decreasing the transcriptional activity of androgen receptor (AR) via 
inhibition of TRIM proteins (Kikuchi et al., 2009). 
In another report BRD7 was shown to interact with the tumour suppressor protein BRCA1, 
contributing to the transcriptional regulation of a subset of its target genes including 
oestrogen receptor α (ERα) and the DNA repair gene Rad51. In this set of experiments 
BRD7 depletion was associated to acquisition of breast cancer cells’ resistance to the 
antiproliferative effects of the antiestrogen drug fulvestrant (Harte et al., 2010). 
In addition to repressing cell proliferation, BRD7 appears to be also responsible for other 
tumour suppressive functions. As mentioned above, it was recently found that 
overexpression of BRD7 leads to decreased invasiveness of an ovarian cancer-derived cell 
line in vitro, and this appeared to associate with reduced expression and secretion of 
MMP2 (Bae et al., 2013).  
In contrast to the tumour suppressive activities reported for BRD7, however, an overview 
of BRD7 gene alterations in human cancers as obtained by analysis of large-scale cancer 
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genomics data sets reveals a more complex picture, with occurrence of gene deletions, 
mutations, and amplifications in many different tumour types. This opens the possibility 
that under particular circumstances, even increased levels of BRD7 may be beneficial for 
cancer growth and progression. 
BRD7 has been shown to participate in both chromatin-modifying complexes, in particular 
to the histone methyltransferase Polycomb PRC2 complex (Tae et al., 2011), and the 
chromatin remodeling (SWI/SNF PBAF) complexe (Kaeser et al., 2008), and to interact 
with several transcription and chromatin-associated factors. In this respect, it has been 
proposed that BRD7 may provide promoter specificity for the recruitment of epigenetic 
regulators on its target genes, thereby promoting either activation or repression of a large 
number of genes in a promoter- and context-specific fashion. Indeed BRD7 participates in 
SWI/SNF and PRC2 chromatin remodelling complexes, that have been demonstrated to 
regulate a high number of processes. 
For instance, some evidences point towards a role of BRD7 in development; indeed it was 
demonstrated that BRD7 and the SWI/SNF complex PBAF it belongs to are essential for 
the neural development of Xenopus laevis and drive the formation of multipotent migratory 
neural crest (NC), a transient cell population that is ectodermal in origin but undergoes a 
major transcriptional reprogramming event to acquire a remarkably broad differentiation 
potential and ability to migrate throughout the body, giving rise to craniofacial bones and 
cartilages, the peripheral nervous system, pigmentation and cardiac structures (Bajpai et 
al., 2010).  
 
Modulating signal transduction 
 
The reversible phosphorylation of proteins is one of the most important and widespread 
regulatory mechanism in the cell (Ryo et al., 2003a). Therefore, the ability to define the 
regulatory components of the phosphorylation/dephosphorylation cascades and their 
interactions with other cellular networks are critical to our understanding of the molecular 
mechanisms underlying diverse biological processes and human diseases. Indeed, 
reversible phosphorylation of certain serine or threonine residues preceding a proline 
(pSer/Thr-Pro) represents a key switch for controlling the function of many signalling 
molecules in various cellular processes. Upon Ser/Thr-Pro phosphorylation, proteins 
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undergo conformational modifications that affect their structure, stability and functions. 
This depends on the activity of a unique enzyme, the phosphorylation-dependent peptidyl 
prolyl isomerase (PPIase) Pin1, that catalyses cis/trans isomerization at Ser-Pro or Thr-Pro 
motifs in which the first amino acid is phosphorylated (pSer/pThr-Pro).  
 
The prolyl-isomerase Pin1  
 
Pin1 structure and functions. The human Pin1 gene maps to chromosome 19p13 and 
encodes a protein of 163 amino acids with a mass of 18kDa. From a functional point of 
view, Pin1 is composed of two domains: an amino terminal WW domain (amino acids 1– 
39) and a carboxy-terminal PPIase domain (amino acids 45–163), which are separated by a 
short flexible linker region (Figure 11). The N-terminal WW region is characterized by 
two conserved tryptophan residues and mediates the interaction with the substrates on 
pSer/Thr-Pro sites, which cannot be bound by any other isomerase (Ranganathan et al., 
1997; Yaffe et al., 1997). As a consequence of the interaction, the WW domain targets the 
Pin1 catalytic domain close to its substrates, so that the PPIase domain can isomerize 
specific pSer/Thr-Pro motifs and induce conformational changes.  
 
 
 
Figure 11. Structure and activity of the prolyl-isomerase Pin1 (Yeh and Means, 2007). 
 
By modification of a plethora of cellular substrates Pin1 governs a variety of cellular 
processes including cell cycle, transcription and splicing, RNA editing, DNA damage and 
oxidative stress responses, germ cell development, stem cells self renewal/expansion and 
neuronal survival (Brenkman et al., 2008; Pinton et al., 2007; Rustighi et al., 2014; Yeh 
and Means, 2007). 
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Pin1 mouse models. Pin1 is highly conserved during evolution and is essential for life in 
X.Laevis, S.Cerevisiae, C.Albicans and A.Nidulans, but it is not an essential protein in 
metazoans such as D.Melanogaster or M.Musculus (Fujimori et al., 1999; Maleszka et al., 
1996). Indeed the absence of dodo, the Pin1 homologue in Drosophila, results in no 
obvious phenotypic consequences, but developmental defects in the dorsal-ventral 
patterning of the egg chamber. Knockout mice for Pin1 gene have been produced in two 
different backgrounds. The first model, which was obtained in a mixed background 
(129SvJae/C57BL/6), displays tissue defects that are reminiscent of aging. Along with 
decreased body weight and testicular atrophy, the most striking alterations involve retina 
and mammary gland. Indeed, Pin1-/- mice show dramatic impairment in cell survival and 
proliferation in the retina. Moreover, in pregnant Pin1-/- females, mammary epithelial cells 
fail to undergo massive proliferation in the development of alveolar structures and ductal 
side branching (Liou et al., 2002). In a second Pin1-/-  model obtained in C57BL/6 
background, both male and female Pin1-null mice display a reduced number of germ cells 
owing to impairment in primordial germ cell (PGC) expansion, thereby causing a profound 
decrease in fertility (Atchison and Means, 2003).  
 
Pin1 in cancer. In line with its role in sustaining cell proliferation and self-renewal, at least 
in some cell types, Pin1 expression is induced downstream of oncogenic pathways such as 
Ras/E2F. Accordingly, Pin1 is found overexpressed in breast, prostate, lung, colon, 
oesophageal, ovarian and cervical cancers, human oral squamous cell cancer, glioblastoma 
and melanoma (Atkinson et al., 2009; Bao et al., 2004; Jin et al., 2011; Miyashita et al., 
2003).  In some cancer subtypes, Pin1 also functions as a prognostic marker (Ayala et al., 
2003; Fukuchi et al., 2006; Girardini et al., 2011; Tan et al., 2010; Wulf et al., 2001). 
All these evidences underscore a prominent role of Pin1 in up-regulating key cellular 
pathways that are central during oncogenesis (Lu and Zhou, 2007) (Figure 12). 
Pin1 is able to directly raise cyclin D1 levels by fostering its transcription, moreover up-
regulation of cyclin D1 expression induced by oncogenic stimuli the Ras, Her2/Neu and 
Wnt signalling pathways and by NF-κB requires the presence of Pin1 which in turn is 
indispensable for full activity of these pathways (Liou et al., 2002; Lu and Zhou, 2007; 
Ryo et al., 2001; Ryo et al., 2003b; Wulf et al., 2001). Pin1 can bind to phosphorylated c-
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Jun, β-catenin and NF-κB boosting their protein levels and transcriptional activity, with 
the consequence of increasing cyclin D1 gene expression. Moreover, Pin1 is able to shield 
β-catenin and NF-κB from their negative regulators, APC (adenomatous polyposis coli 
gene product) and IkB, respectively.  
 One of the key signalling pathways induced upon activation of growth factor receptors is 
the MAPKs cascade. In response to growth stimuli Ras activates the Raf kinase, which in 
turn controls the MAPKs. As for other signalling pathways, this kinases cascade must be 
turned off by a negative feedback mechanism in which MAPKs phosphorylate and 
inactivate Raf. Notably, Pin1 prevents this negative feedback, by promoting Raf 
dephosphorylation and consequently maintaining an activated MAPKs cascade (Dougherty 
et al., 2005).  
In the context of triple negative breast cancer it has been demonstrated that Pin1 
cooperates with two oncogenes important for this malignancy, namely Notch1 (Rustighi et 
al., 2009) and mutant-p53 (Girardini et al., 2011). Notch1 is a membrane-bound 
heterodimeric receptor, normally inactive, that becomes activated upon interaction with its 
specific ligand (Ranganathan et al., 2011). Pin1 interacts with the Notch1 receptor and 
increases its stimulus-induced cleavage mediated by γ-secretase, allowing full activation of 
the pathway and boosting its oncogenic activity both in vitro and in vivo. Also in this case 
a positive loop is generated since activated Notch is directly recruited on the Pin1 gene 
promoter thus inducing Pin1 expression. As a consequence, in human breast cancer 
samples there is a strong correlation between high levels of activated Notch and Pin1 
overexpression (Rustighi et al., 2009). Moreover it was recently demonstrated that Pin1 
can modulate Notch levels also post-transcriptionally by regulating the detachment from its 
negative regulator Fbw7 (Rustighi et al., 2014). 
 
Pin1 and p53. In contrast with its activities in amplifying oncogenic pathways, in normal 
conditions Pin1 has a central role in transducing genotoxic stimuli and likely also 
oncogenic stress into full activation of wild-type p53 functions. In particular, Pin1 is 
indispensable for transducing stress-induced phosphorylation of p53 into conformational 
changes that affect its stability and function. While almost undetectable in normal 
conditions, the interaction between p53 and Pin1, mediated by the N-terminal WW domain 
of the isomerase, can be promoted by several stimuli activating p53, such as γ- and UV 
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irradiation, treatment with chemotherapeutic drugs and overexpression of activated 
oncogenes, that result in phosphorylation of different Ser/Thr-Pro motifs in p53, rendering 
them sites for Pin1 binding. Within the p53 sequence six Ser/Thr-Pro sites are present 
(Ser33-Pro34, Ser46-Pro47, Thr81-Pro82, Ser127-Pro128, Thr150-Pro151 and Ser315-
Pro316). It has been shown that UV irradiation or treatment of cells with doxorubicin 
recruits Pin1 to Ser33, Thr81 and Ser315 of p53, while γ-irradiation and molecules such as 
RITA (Sorrentino et al., 2013) stimulate also Pin1 interaction with Ser46. The structural 
change mediated by Pin1 can trigger various functional outcomes, depending on the 
specific phosphorylation events and on the cellular context. As a result, many p53 
downstream responses, such as transcriptional activation of endogenous target genes as 
well as induction of apoptosis and growth arrest, are impaired in cells lacking Pin1. 
The catalytic activity of Pin1 can modify p53 conformation and this mediates efficient 
detachment of Mdm2 from p53, resulting in full stabilization of the protein (Zacchi et al., 
2002). Accordingly, p53 accumulation following genotoxic stress is reduced in the absence 
of Pin1 and its half-life is shortened. In addition, it has also been demonstrated that Pin1 is 
required for efficient binding of p53 to its REs on p21 and Bax promoters upon stress 
(Mantovani et al., 2007). Moreover, it was shown that Pin1 itself is recruited by p53 on its 
cognate promoters where it acts enhancing p53 acetylation by p300. Indeed, it was 
observed that acetylation of chromatin-bound p53 on Lys373 and Lys382 increased upon 
stress only in the presence of Pin1 (Berger et al., 2005). Another site which may be crucial 
for Pin1 effect on p53-mediated apoptosis is Ser46-Pro47, as also suggested by the reduced 
apoptotic potential displayed by the Ser47 allele of the Pro/Ser47 polymorphism (Li et al., 
2005).  
Pin1 is also an essential regulator of the pro-apoptotic function of the p53-family member 
p73. Indeed, it has been demonstrated by our group that the binding between Pin1 and p73 
is stimulated upon stress conditions by c-Abl and p38 kinases and that this association 
increases p73 acetylation by p300, thereby stimulating its transcriptional activity towards 
apoptotic target genes, such as p53AIP1 (Mantovani et al., 2004). 
On the other hand, Pin1 has been linked to mestastasis, aggressiveness and poor prognosis 
in triple negative breast cancer through cooperation with mutant p53 following oncogenic 
stress. In particular, it has been described that Pin1 binds to phosphorylated mutant p53 in 
breast cancer cell lines and tumours and boosts its oncogenic functions, by favouring 
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mutant p53-dependent inhibition of the antimetastatic factor p63 as well as induction of a 
mutant p53 transcriptional program to increase aggressiveness. This cooperation correlates 
with poor prognosis in breast cancer patients and promotes migration and metastasis in 
vivo. Thus, ablation of Pin1 lowers the oncogenic gain of function of mutant p53 with 
reduced formation of breast cancer metastasis into the lung (Girardini et al., 2011).  
 
Pin1 in neurodegeneration. As opposed to the majority of highly differentiated cells in the 
body, where Pin1 levels are greatly reduced, Pin1 expression is induced during neuronal 
differentiation and is observed in neurons at considerable high levels. Recent studies have 
indicated that Pin1 regulates several neuronal substrates (among them, noteworthy are tau 
and amyloid precursor protein) (Figure 12), and that it plays an important role in age-
dependent neurodegeneration. However, the role of Pin1 in healthy neurons and during 
development of the nervous system remains largely unknown.  
Although Pin1 is expressed in most human neurons, in human AD neurons it has been 
found to be inhibited or its levels downregulated (Wang et al., 2007), underlying AD 
associated neurofibrillary tangle and amyloidogenic Aβ formation (Lu et al., 1999; 
Pastorino et al., 2012). It has been demonstrated that Pin1 activity can directly restore the 
conformation and function of phosphorylated tau by indirectly promoting its 
dephosphorylation. Specifically, Pin1 acts on the phosphorylated Thr231-Pro in tau to 
promote PP2A-mediated dephosphorylation and restore its microtubule binding function. 
In addition, Pin1 also regulates APP processing and Aβ production. In mouse brain, the 
absence of Pin1 increases amyloidogenic APP processing and elevates the toxic species of 
Aβ 42 in an age-dependent manner.  
In Parkinson’s Disease Pin1 accumulates in Lewy bodies and enhances the formation of α-
synuclein inclusions by protecting α-synuclein from degradation (Ryo et al., 2006). It has 
been discovered that Pin1-mediated prolyl-isomerization modulates α-synuclein 
aggregation indirectly by acting on its regulatory protein, Synphilin-1. However, the 
mechanisms underlying the role of Pin1 in PD remain largely unknown (Ghosh et al., 
2013). 
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Figure 12. PIN1 regulates many substrates involved in cancer and neurodegeneration (Lu and Zhou, 
2007).  
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4. AIM OF THE THESIS 
 
Neoplastic and neurodegenerative disorders are two fields of research in which, although 
massive efforts to obtain a clear comprehension of the underlying molecular pathways 
have recently resulted in several specific therapeutic advances, still raises a profound need 
for innovative and more powerful approaches. Interestingly, a number of cellular pathways 
contribute to both pathologies, although with inverse effects, and this suggests the 
possibility of translating the knowledge obtained in one field to the other.  
One of the genes that stand at the crossroads between cancer and neurodegeneration is the 
tumour suppressor p53 whose key roles in preventing cancer development have been 
extensively studied in the last 30 years. Intriguingly, p53 is strongly emerging as a 
regulator of neuronal cell death.  
Aim of this thesis is to understand the pathways through which the p53 response is finely 
orchestrated and regulated during both neoplastic transformation and neurodegenerative 
disease, with the purpose of highlighting common molecular mechanisms. The first part of 
this study will focus on the role of the chromatin remodelling machinery, and in particular 
of the bromodomain-containing protein BRD7, in regulating p53 oncosuppressive 
functions following oncogenic stress. In the second part we will investigate the role of the 
prolyl-isomerase Pin1 in regulating activation of p53 apoptotic function in Huntington’s 
Disease.  
These studies, conducted with the aim of achieving greater knowledge on the regulation of 
the p53 pathway in both contexts and of underscoring similarities and differences, might 
be relevant for designing new targeted treatments for neoplastic and neurodegenerative 
disorders. 
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5. RESULTS PART 1 
Dissecting the tumour suppressive roles of the 
 bromodomain-containing protein BRD7 
 
As mentioned in the Introduction, the p53 pathway plays a central role in the maintenance 
of genomic integrity and in tumour suppression. Alterations (polymorphisms, mutations or 
deletions) in genes of the p53 network, encoding for factors that sense cellular stress and 
modulate p53 activity, can have a role in tumorigenesis determining fundamental aspects 
of neoplastic disease such as incidence, age of onset, prognosis and response to therapy of 
specific tumour types. Indeed the identification of novel p53 cofactors and of their possible 
alterations in human malignancies is particularly important because it may provide new 
prognostic markers but also potential therapeutic targets to develop specific anticancer 
therapies.  
By means of Yeast Two-Hybrid screening we identified the bromodomain-containing 
protein 7, BRD7, as a novel interactor of p53. Moreover at the same time a loss-of-
function screening in primary human BJ fibroblasts expressing inducible oncogenic 
HRasV12 (BJ/ET/RasV12ER cells) suggested a potential role of BRD7 in regulating 
oncogene-induced senescence.  
Based on these evidences, we decided to dissect the relationship between BRD7 and p53 
from a functional point of view. 
 
 
BRD7 interacts physically with p53 and regulates oncogene-induced senescence 
 
By means of co-immunoprecipitation analysis, we first demonstrated that the expression of 
RasV12 in BJ/ET cells was able to increase the interaction between endogenous BRD7 and 
p53 (Figure 13A); moreover, by proliferation assays we also confirmed that BRD7 
cooperated in the induction of p53-mediated oncogene-induced senescence (Figure 13B). 
 
 
 
	   	   	  	   	   RESULTS	  AND	  DISCUSSION	  PART	  1	  
	   54	  
 
Figure 13. BRD7 interacts physically with p53 and cooperates in the induction of oncogene-induced 
senescence. 
A) Co-immunoprecipitation of endogenous BRD7 and p53 in BJ/ET/RasV12ER cells cultured in the absence 
(–) or presence (+RasV12) of 4OHT. Lysates were immunoprecipitated with anti-BRD7 antibody. Control IP 
(C) was performed with anti-HA antibody. The migration of immunoglobulin heavy chains is shown. 
B) GFP-growth competition assays of BJ/ET/p14ARF KD/RasV12ER transduced with the indicated pRetroSuper 
(pRS) knockdown vectors and cultured in the presence of 4OHT (+RasV12).  
 
BRD7 is required for the transcriptional activation of a subset of p53 target genes 
 
As BRD7 is known to bind acetylated lysines in histones through its bromodomain (Peng 
et al., 2006; Sun et al., 2007) and has also been found to be a component of chromatin-
remodelling complexes (Kaeser et al., 2008; Tae et al., 2011), we investigated whether 
BRD7 was required for the transcriptional activation of p53 target genes involved in cell 
cycle arrest. We performed mRNA-expression array analysis comparing RasV12-expressing 
BJ/ET cells containing either one of two different BRD7KD constructs, a p53KD construct, 
or a control vector. Gene-ontology (GO-) analysis revealed that BRD7KD significantly 
affected the expression of several p53 target genes, among those p21 (CDKN1A) and 
HDM2 (Figure 14A), leaving unvaried pro-apoptotic genes such as Puma, Fas and Bax. 
As BRD7 might act as a transcriptional cofactor of p53 for a subset of target genes, we 
determined whether it was found within transcriptional complexes loaded on the p53 
cognate sites in these promoters. Chromatin IP (ChIP) for BRD7 from BJ/ET cells 
expressing RasV12 showed specific binding of BRD7 at the upstream (-2.3 kb) p53-binding 
site in the p21 promoter, and within the p53-binding region of the HDM2 gene (Figure 
14B), which both require BRD7 for efficient transcriptional activation. In search for a 
mechanism of BRD7 activity on p53-target promoters, we determined the acetylation 
status of histone 3 at lysine 9 (H3K9), a marker of active chromatin (Kouzarides, 2007). 
ChIP analysis revealed that loss of BRD7 expression resulted in a great reduction of H3K9 
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acetylation around p53-binding sites in the p21 and HDM2 promoters induced by either 
RasV12 expression or etoposide treatment (Figure 14C).   
Activated p53 induces the p21 promoter by recruiting p300, as well as other histone-acetyl 
transferases (HATs), to modify histone tails (Barlev et al., 2001; Espinosa et al., 2003; 
Zhao et al., 2006). We demonstrated that endogenous BRD7 and p300 proteins are found 
in complex in RasV12-expressing BJ/ET cells. Interestingly, we also demonstrated that loss 
of BRD7 resulted in a marked reduction of p300 loading on the p21 promoter in RasV12-
expressing BJ/ET cells, event that led to a decrease in histones acetylation and in p53 
acetylation on K382 (model in Figure 14D), a key lysine modified by p300/CBP after 
RasV12 induction (Pearson et al., 2000) and important for p21 transcription (Dornan et al., 
2003; Pearson et al., 2000). 
 
 
Figure 14. BRD7 is required for efficient transcriptional activation of a specific subset of p53 target 
genes, binds to selected p53 target gene promoters in a p53-dependent fashion and affects histone 
acetylation. 
A) Representation of genes downregulated specifically in p53KD or BRD7KD cells, or downregulated genes 
shared by the two genetic backgrounds. Numbers represent the amount of genes present in that GO-cluster. 
B) BJ/ET/RasV12ER cells containing a control vector, BRD7KD vector (BRD7#4), or p53KD vector were 
cultured in the presence of 4OHT for 48 hrs and subjected to ChIP for BRD7.  
C) BJ/ET/RasV12ER cells expressing the indicated knockdowns were cultured in the presence or absence of 
4OHT or treated with etoposide, and subjected to ChIP with antibodies against acetylated H3K9 or total H3 
histone.  
D) A schematic model showing how BRD7 may serve as a p53 cofactor to regulate the transcriptional 
activity of p53 target genes. 
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Inhibition of BRD7 cooperates in oncogene-induced transformation of epithelial 
mammary cells 
 
 
BRD7 is encoded in a locus on chromosome 16q12 that is a well-known hotspot for LOH 
in breast cancer (Argos et al., 2008), a tumour in which p53 is frequently wild-type. 
Prompted by this observation, analysing CGH data of a group of 68 sporadic breast 
tumours in which the p53 status was determined by sequence analysis it emerged that the 
clearest significant difference was a loss on chromosome arm 16q. Importantly, the 
genomic position of BRD7 is at 48.9 Mb, at the centre of the first differential loss (Figure 
15A). However, our data does not exclude that other genes in this region are involved.  
Based on these evidence, we decided to employ a common cellular model of breast 
carcinogenesis, the normal mammary epithelial cells MCF10A (bearing wild-type p53) 
transduced with the oncogene RasV12 (Datta et al., 2007), to investigate the role of BRD7 in 
imposing a barrier to neoplastic transformation in normal breast cells. MCF10A cells are 
spontaneously immortalized and bear a deletion in the locus 9q21, which contains the 
oncosuppressors INK4A/p16 and ARF/p14 (Kadota et al., 2010; Soule et al., 1990); 
moreover MCF10A cells also display MYC amplification (Kadota et al., 2010; Soule et al., 
1990). In this context we tested whether loss of BRD7 was sufficient to inactivate the p53 
pathway and induce cellular transformation, evaluated by the ability to grow anchorage-
independently in semi-solid medium (soft agar assay). Notably, knockdown of BRD7 
resulted in efficient colony formation (Figure 15B) demonstrating that efficient activation 
of p53 by oncogenes, as a mechanism against transformation, requires BRD7. 
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Figure 15. BRD7 expression is lost in a subset of breast tumours containing wild-type p53 and BRD7 
knockdown enhances oncogene-induced transformation of MCF10A cells. 
A) Kernel Smoothed Estimate (KSE) curves of 31 p53 mutated (blue) and 35 p53 wild-type (grey) sporadic 
breast tumours. The curves for gains and losses were determined separately by KC-SMART. Significant 
differences between the two groups were determined by comparative-KC-SMART. Genomic regions with a 
significantly greater gain or loss in the p53 wild-type tumours (compared to the p53 mutant tumours) are 
depicted with a green bar on top or below the figure, respectively, and with a green line in the grey KSE 
curves. The significant changes in p53 mutant tumours (compared to p53 wild-type) are shown in red.  
B) Normal MCF10A breast epithelial cells stably expressing the indicated knockdowns were transduced with 
pLPC-puro-HRasV12 or with the empty vector. After selection the cells were seeded in soft agar and colonies 
were counted 2 weeks later. Histograms show the percentage of colony-forming cells and represent mean and 
s.d. of three independent experiments. 
 
 
 
The results reported in this part have been published in the original article:    
Drost, J.*, Mantovani, F.*, Tocco, F., Elkon, R., Comel, A., Holstege, H., Kerkhoven, R., 
Jonkers, J., Voorhoeve, M., Agami, R., and Del Sal, G. (2010). BRD7 is a candidate 
tumour suppressor gene required for p53 function. Nat. Cell Biol. 12, 380-389. *Equal 
contribution 
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The expression of BRD7 is decreased in high-grade breast cancer relative to normal 
tissue or low-grade breast cancer 
 
Starting from the abovementioned gene expression analysis that we performed in BJ/ET 
human fibroblasts expressing RasV12 (Figure 14A) we analysed the functional categories of 
the genes repressed only by BRD7 knockdown. Interestingly, these genes appear to be 
involved in the processes of cancer progression (blood vessel morphogenesis and 
development) and metastasis (cell chemotaxis, migration and motility). This prompted us 
to investigate the roles of BRD7 in repressing breast cancer aggressive phenotypes as for 
example the capacity to metastasize and relapse after chemotherapy.  
Due to the poor quality of the BRD7 probe employed on microarray platforms, the analysis 
of BRD7 mRNA levels in publicly available datasets has been highly problematic and 
unreliable. For this reason we decided to analyse the methylation status of BRD7 promoter 
on genomic DNA from breast cancer samples. A CpG island was recently identified in the 
BRD7 gene that is methylated in a large percentage of NPC tumours (Liu et al., 2008), 
therefore we performed the analysis of the methylation of BRD7 promoter from genomic 
DNA of a subset of 104 primary breast cancers (Girardini et al., 2011); this analysis 
pointed out that BRD7 promoter methylation is significantly more frequent in G3 (and thus 
more aggressive) tumours (Figure 16B).  
Due to the intrinsic heterogeneity of breast cancer, BRD7 may be lost only in some cells of 
the tumour mass (Polyak, 2011); to verify this hypothesis we decided to examine BRD7 
expression by immunohistochemistry in different subsets of breast cancer tissues. 
Although the analysis is still being performed, we observed that in part of breast cancer 
tissues, BRD7 is lost or localizes in the cytoplasm in some cells (Figure 16C). 
Interestingly, there are also some tumours that bear enhanced levels of BRD7 expression. 
Further studies will be performed to complete the statistical analysis and to assess the 
correlation of BRD7 levels with cancer aggressiveness. 
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Figure 16. BRD7 loss fosters the acquisition of an aggressive tumour phenotype in breast cancer.  
A) Analysis of BRD7 promoter methylation was performed on genomic DNA from a cohort of 104 primary 
breast cancer samples. B) The analysis unveils BRD7 loss in G3 tumours in respect to G1 tumours. 
C) Staining of BRD7 by IHC shows clear nuclear localization of the protein in healthy control tissue and 
low-grade tumours, whereas in high-grade tumours BRD7 is either lost (3) or overexpressed (4). In some 
cases of triple negative breast cancer, BRD7 also displays a strong cytoplasmic localization (5). All the 
pictures were acquired with a 10X objective except picture (5) that was acquired with a 40X objective to 
better show the cytoplasmic localization. 
 
Downregulation of BRD7 fosters the acquisition of a transformed phenotype in 
normal breast epithelial cells subjected to oncogenic stress 
 
To dissect the role of BRD7 in repressing breast cancer aggressive phenotypes we took 
advantage of the already used normal mammary epithelial cells (MCF10A) in which we 
overexpressed the oncogene HRasV12, a well-known model of mammary transformation 
(Datta et al., 2007): as shown in Figure 17B, we observed that the cells depleted of BRD7 
upon HRasV12 overexpression acquired an enhanced fibroblast-like, mesenchymal 
phenotype compared to the control cells, and that this process can be assimilated to that of 
epithelial-to-mesenchymal transition (EMT) (Kalluri and Weinberg, 2009). This was 
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confirmed by analysis of EMT markers (reduction of the epithelial marker E-cadherin and 
induction of mesenchymal markers, in particular Vimentin) by WB, qRT-PCR and IF  
(Figure 17C-E). 
 
 
Figure 17. BRD7 loss fosters the acquisition of fibroblast-like, mesenchymal phenotype in MCF10A-
HRasV12 cells. 
MCF10A cells stably silenced for BRD7 expression were transduced with HRASV12; Western blot analysis 
was performed to detect BRD7, Ras and actin (loading control) (panel A). After 10 days phase-contrast 
images of the cells were acquired (panel B) and the status of EMT markers (E-cadherin: epithelial marker; 
vimentin, fibronectin and N-cadherin: mesenchymal markers) was evaluated by WB (panel C), qRT-PCR 
(panel D) and immunofluorescence (panel E). 
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As the process of EMT has been associated with increased cell motility and invasion, we 
analysed the role of BRD7 in suppressing oncogene-induced migration and invasion of 
breast epithelial cells. Indeed, BRD7 downregulation resulted in an increase of at least 3-
fold in the ability of MCF10A HRasV12 cells to migrate as compared to the effect induced 
by HRasV12 expression alone (Figure 18A). Similarly, knockdown of BRD7 was able to 
foster MCF10A HRasV12 invasion across a transwell membrane (Figure 18B).   
 
 
 
 
Figure 18. BRD7 inhibits migration and invasion of MCF10A HRasV12 cells.  
A) MCF10A cells stably silenced for BRD7 expression were transduced with HRASV12. After 10 days the 
cells were seeded in 8-µm pore transwell filters and allowed to migrate towards their bottom side for 16 
hours.  
B) The same cells of the experiment in panel A) were subjected to invasion assay with transwell filters 
coated with matrigel. 
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Downregulation of BRD7 impacts on cancer stem cell content and affects acinar 
structure of MCF10A HRasV12 cells 
 
Referring to the recent findings that EMT can promote the acquisition of stem cell traits 
(Mani et al., 2008) and that the progression to more malignant stages is accompanied by an 
increased proportion of cancer stem cells within tumours (Pece et al., 2010), we 
investigated whether BRD7 could regulate the formation and propagation of cancer stem 
cells. At first we observed that stable silencing of BRD7 in both normal MCF10A and 
MCF10A HRasV12 cells fosters the appearance of a large subpopulation characterized by 
stem-cell epithelial surface markers (high levels of CD44 and low levels of CD24) (data 
not shown). Prompted by this indication, we assessed the self-renewing potential of these 
cells in vitro by performing a mammosphere formation assay (Dontu et al., 2003). As can 
be seen in Figure 19, depletion of BRD7 can foster Ras-induced formation of both primary 
and secondary mammospheres in a manner comparable to the silencing of p53, an essential 
regulator of breast cancer stem cell propagation (Cicalese et al., 2009). 
 
 
 
Figure 19. BRD7 loss increases oncogene-induced mammosphere formation. Mammosphere assays were 
conducted in normal MCF10A breast epithelial cells stably expressing the indicated knockdowns and 
HRasV12 or control empty vector; after one week of primary culture (panel A), mammospheres were 
disgregated, replated and allowed to form secondary mammospheres for an additional week (panel B). At 
each passage only mammospheres > 50µm were counted. The data are reported as mammosphere formation 
efficiency normalized to the control.  
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MCF10A mammary epithelial cells, when grown on a reconstituted basement membrane 
(3D culture), form polarized, growth-arrested acini-like spheroids that recapitulate several 
aspects of glandular architecture in vivo. Introduction of oncogenes into MCF10A cells 
disrupts this morphogenetic process (Debnath et al., 2003), and allows for modelling the 
biological activities of cancer genes, with particular regard to their ability to disrupt the 
epithelial architecture during the early steps of carcinoma progression (Debnath et al., 
2003). We performed 3D culture assays on MCF10A cells transduced with RasV12 and 
silenced for BRD7 expression; as can be seen in Figure 20, HRasV12 expression per se is 
able to disrupt the acinar structure as expected. BRD7 depletion fosters the acquisition of a 
highly disorganized acinar morphology thus promoting the formation of markedly invasive 
stellate structures (Figure 20). We are currently investigating whether in the absence of 
oncogenic stimuli BRD7 can predispose the acini to oncogenic transformation by leading 
to disorganized cell polarity. 
 
 
 
Figure 20. BRD7 loss fosters the disruption of the normal acinar structure of MCF10A cells grown in 
3D culture after HRasV12 infection. Normal MCF10A cells form organized spherical acinus-like structures 
when grown for 3 weeks in 3D culture (see arrow). After HRasV12 infection the cells lose the acinar 
organization and this results in the acquisition of a “stellate” morphology (square). BRD7 loss fosters this 
phenotype by increasing the amount of cells that acquire the aberrant morphology and increasing the size of 
the outgrowths (arrow heads).  
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In sum, we demonstrated by different means that BRD7 acts as a negative regulator of the 
process of EMT and of associated aggressive features including migration/invasion and 
cancer stem cell expansion. Notably, we observed the same phenotypes also by inducing 
EMT and transformation through overexpression of oncogenes such as TWIST and c-
MYC (data not shown). This suggests a general role of BRD7 in controlling the acquisition 
of EMT-related traits during the transformation process. 
 
BRD7 impacts on the transcriptional program of MCF10A and MCF10A HRasV12 
cells  
 
At this point we wanted to get insight into the cellular pathways and mechanisms by which 
BRD7 may negatively act on transformed cell features. Given the well-assessed role of 
BRD7 as a regulator of transcription we decided to analyse the consequences of BRD7 
knockdown on global gene expression in MCF10A and MCF10A HRasV12 cells. In the 
normal cells and in their transformed counterpart we silenced BRD7 expression by 
transfecting twice a specific BRD7 siRNA or a control siRNA and after 48h the RNA was 
collected for the analysis (Figure 21A). We performed a global sequencing of polyA+ 
transcripts in order to obtain a precise evaluation not only of mRNA expression but also of 
splice variants and lncRNAs with polyA-tail. After the sequencing, the data obtained have 
been uploaded on the server of the European Bioinformatics Institute (EBI) and analysed 
by imposing a fold enrichment cut-off of 1,5 and a p-value cut-off of 0,000001. As 
expected, overexpression of the oncogene HRasV12 alone was able to modulate the 
transcription of thousands of genes (Figure 24B). In addition, the analysis of the profile of 
polyA+ transcripts after BRD7 depletion, both in normal and oncogene-expressing cells, 
unveiled that BRD7 knockdown altered the expression of hundreds of genes. Interestingly, 
the majority of genes were upregulated upon BRD7 depletion, suggesting that BRD7 may 
normally act mainly as a transcriptional repressor. In particular, we identified 528 genes 
that were upregulated and 148 genes that were downregulated by depletion of BRD7 in 
normal MCF10A cells, and 423 genes that were upregulated and 149 genes that were 
downregulated in transformed MCF10A RasV12 cells (Figure 21B). The number of BRD7 
regulated transcripts was comparable and overlapping between normal and transformed 
conditions, even if the quantity of transcripts influenced by BRD7 knockdown was slightly 
	   	   	  	   	   RESULTS	  AND	  DISCUSSION	  PART	  1	  
	   65	  
higher in the experiment performed in the absence of oncogenic stress. Moreover, it is 
noteworthy that an important fraction of genes upregulated by BRD7 silencing in normal 
conditions are also regulated in the same direction by HRasV12 overexpression, thus 
suggesting that BRD7 loss can partially mimic the effects of oncogene overexpression in 
inducing processes that promote transformation. 
 
 
 
 
 
Figure 21. BRD7 silencing induces global alterations of gene expression. Normal MCF10A cells and 
HRasV12 transformed cells were silenced for BRD7 expression as shown in panel A. The analysis of polyA+ 
transcripts pointed out that BRD7 loss leads to differential expression of the indicated numbers of genes 
(panel B).  
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BRD7 regulates a transcriptional program in MCF10A cells that is linked to cancer 
progression 
 
In order to understand which cellular processes BRD7 may putatively regulate in the 
conditions examined, we took advantage of a bioinformatic tool for gene annotation, 
Ingenuity Pathway Analysis (IPA – Ingenuity® Systems, www.ingenuity.com). This 
program is based on the Ingenuity Knowledge Base, a database that contains biological 
and chemical interactions and functional annotations created from millions of individually 
modelled relationships between proteins, genes, complexes, cells, tissues, drugs, and 
diseases. Each relationship originates from reported experimental facts from primary 
literature sources, including peer-reviewed journal articles, review articles and textbooks.  
We loaded the whole results of our differential gene expression analysis (upregulated and 
downregulated genes with a 1.5 fold change) into IPA. The program is able to integrate the 
whole data from the transcriptome and create a list of processes modulated in the given 
experimental conditions along with their p-value and activation z score. Notably, as can be 
seen in Figure 22A, both in the normal and transformed context BRD7 loss results in the 
induction of many cellular processes, while the pathways that appear to be repressed are 
only few.  Moreover, a detailed clustering of the single modulated transcripts in specific 
processes unveiled that BRD7 loss activates programs involved in tumorigenesis, abnormal 
cellular growth and proliferation, development and inflammatory response (Figure 22B). 
Of note, the only category significantly repressed by BRD7 relates to cell death. 
Interestingly, when comparing the list of processes regulated by BRD7 in MCF10A and 
MCF10A HRasV12 cells, we can notice that they completely overlap, with the exception of 
metabolic pathways that appear to be regulated by BRD7 only in normal conditions.  
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Figure 22. Global gene expression analysis unveils several cancer-related processes regulated by BRD7 
in normal and transformed cells. Analysis of functional annotation of the genes differentially expressed 
upon BRD7 KD in normal and transformed contexts was performed by means of Ingenuity Pathway Analysis 
to obtain an indication of regulated processes. 
A) Heatmap representing significative process activation/repression after BRD7 depletion. Many changes, 
especially in the upregulated functions, are shared between normal and transformed cells. Bigger squares 
correspond to smaller p-Value. Color coding bar based on the activation z score: orange, process activation; 
blue, function repression.  
B) Gene ontology analysis of differentially expressed genes from siBRD7 vs siControl cells in normal and 
transformed conditions. Top categories include “cellular movement” and “inflammatory response”. Bars 
represent the –Log of the over-representation p-value, as calculated by the IPA algorithm. For the sake of 
clarity only the first 15 results for each condition have been shown. 
 
It is important to underline that this analysis revealed new processes putatively regulated 
by BRD7 that are likely to be a hallmark of its loss. In this context, inflammation appears 
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as an important gene ontology category that emerges as regulated by BRD7 also with other 
tools for gene annotation (e.g. David Functional Annotation Tool (Dennis et al., 2003)). A 
considerable part of the genes included in this group encode for secreted proteins, in 
particular cytokines and chemokines. Given that an emerging hallmark of cancer is the 
ability to evade from immune surveillance and induce pro-tumour inflammation (Hanahan 
and Weinberg, 2011) and considering that the inflammatory response can stimulate several 
pro-tumoral phenotypes that we demonstrated to be induced also by BRD7 loss, including 
proliferation, EMT, invasion and metastasis (Grivennikov et al., 2010; Porta et al., 2009) , 
we decided to focus on this process for further validation. 
 
BRD7 regulates a subset of inflammatory genes that are overexpressed in cancer 
 
In order to understand the mediators of the processes that we were investigating, we 
constructed a “BRD7 inflammatory signature” based on IPA output manually curated to 
include new hits possibly important for the process (Figure 23A). This signature 
comprises, among the others, several cytokines and chemokines such as CXCL1, CXCL2, 
IL6, IL1β and IL8. We analysed some of these inflammatory signature genes for the 
expression in breast cancer datasets taking advantage of ONCOMINE, a publicly available 
cancer microarray database and integrated data-mining platform that collects global 
genome DNA copy number alteration and microarray expression data from different 
human cancer patients’ datasets (Rhodes et al., 2004). To date, ONCOMINE database 
includes 715 datasets comprising 86733 samples: through this tool it is possible to verify if 
a gene or group of genes results significantly differentially expressed within these datasets 
giving an hint for a functional significance in vivo. Data are compared between cancer and 
normal tissue or between different cancer subtypes or by clinical-based and pathology-
based classifications. Interestingly, the inflammatory signature genes resulted significantly 
upregulated in several datasets (i.e. comparing gene expression between cancer and normal 
samples) belonging to different tumour types including brain and central nervous system, 
oesophageal, head and neck, liver, ovarian and pancreatic cancer. Focusing on breast 
cancer, that is the malignancy in which we constructed the signature, we found that it was 
strongly upregulated in basal-like breast carcinomas (Figure 23B) and triple negative 
breast cancers (Figure 23C), which represent breast cancer subtypes characterized by 
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highly aggressive phenotype and poor prognosis due mainly to relapse from chemotherapy. 
Additionally, this signature was found upregulated in Grade 3 versus Grade 2 breast 
tumours and in samples derived from patients showing a metastatic event in 3 years after 
diagnosis. This holds true for inflammation signatures derived from both MCF10A and 
MCF10A HRasV12 cells.  
Hence, this analysis suggests that BRD7 depletion induces a transcriptional program 
related to inflammation that is found enriched in human tumours, and particularly in highly 
aggressive cancer subtypes.  
 
 
 
 
Figure 23. The “BRD7 inflammatory signature” is found upregulated in most aggressive breast cancer 
subtypes. 
A) List of genes upregulated by BRD7 that belong to the inflammation category. 
B) and C) Analysis of differential expression of the BRD7 inflammatory signature in human cancer datasets 
within the ONCOMINE database highlighted a significant enrichment of those genes in two datasets 
comparing basal versus luminal breast tumours (B) and triple-negative breast cancer versus other receptor 
status (C).  
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BRD7 regulates the expression of important cancer-related inflammatory genes in 
MCF10A cells 
 
Prompted by the strong association found in ONCOMINE between the BRD7 
inflammatory signature and high-grade breast cancer, we decided to better investigate the 
extent of the regulation exerted by BRD7 on inflammatory genes. As some of these genes 
are strongly induced by HRasV12 overexpression per se and this robust induction could 
cover BRD7 effect, we chose to perform the experiments in non-transformed MCF10A 
cells. From the whole gene list (shown in Figure 23A) we first selected the genes that from 
literature emerged as relevant for the acquisition of aggressive cancer phenotypes. Among 
these there are genes that had been previously linked to cancer progression, in particular in 
the breast context; for example IL6 is linked to breast cancer stem cell survival (Marotta et 
al., 2011) while IL1β induces breast cancer cell migration and invasion (Ma et al., 2012). 
Moreover it has been reported that the IL8/CXCR1 (IL-8 receptor) axis plays an important 
role in regulation and survival of normal and malignant mammary epithelial 
stem/progenitor cell population (Ginestier et al., 2010), and in addition all the cluster of 
CXC chemokines (composed by IL8, CXCL1, CXCL2, CXCL3 and CXCL5) is found 
upregulated in breast cancer and this increased expression correlates with aggressiveness 
and bad prognosis (Bieche et al., 2007). Recent reports also associate overexpression of 
CCL20 with breast cancer, demonstrating that CCL20 induces migration and proliferation 
of breast epithelial cells (Marsigliante et al., 2013). Also S100A8 plays a pivotal role in 
this context; indeed it has been involved in a paracrine loop with CXCL1 and CXCL2 
between cancer cells and myeloid cells and this communication has been shown to induce 
chemoresistance and metastasis of breast cancer cells (Acharyya et al., 2012). Moreover, 
the expression of other two BRD7 repressed genes, MMP9 and COX2, leads to the 
destruction of the normal acinar structure in three-dimensional culture of MCF10A cells 
(Chimal-Ramirez et al., 2013; Prasad et al., 2013). 
We transfected MCF10A cells with two different siRNA oligonucleotides targeting the 
BRD7 coding sequence and performed qRT-PCR analysis of the selected transcripts to 
validate BRD7 effect. As shown in Figure 24 efficient BRD7 knockdown with either 
siRNA was able to induce a significant increase in the expression levels of all the genes 
analysed, confirming RNA sequencing data.  
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Figure 24. BRD7 silencing induces the expression of cancer-related inflammatory genes.  
Validation of the effect of BRD7 depletion on induction of inflammatory-related genes in MCF10A and 
MCF10A HRasV12 cells. 
 
SWI/SNF PBAF and PRC2 activity represses a subset of BRD7 target genes 
 
Since BRD7 is a component of the SWI/SNF PBAF chromatin remodeling complex 
(Kaeser et al., 2008) and it is also known to interact with the PRC2 subunit EZH2 affecting 
its methylation activity on target genes (Tae et al., 2011), we sought to investigate whether 
the effect of BRD7 on the gene signature analysed above may involve these epigenetic 
regulatory complexes. First of all we compared the list of BRD7 regulated genes with 
0"
1"
2"
3"
4"
5"
6"
7"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
,n
%
CXCL2%
0"
1"
2"
3"
4"
5"
6"
7"
8"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
tin
%
CXCL3%
0"
5"
10"
15"
20"
25"
30"
35"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
tin
%
COX2%
0"
2"
4"
6"
8"
10"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
tin
%
MMP9%
0"
1"
2"
3"
4"
5"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
,n
%
S100A8%
0"
0,5"
1"
1,5"
2"
2,5"
3"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
tin
%
IL6%
0"
10"
20"
30"
40"
50"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
tin
%
IL8%
0"
1"
2"
3"
4"
5"
6"
7"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
,n
%
CCL20%
0"
5"
10"
15"
20"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
,n
%
CXCL1%
0"
1"
2"
3"
4"
5"
6"
7"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
s%β
ac
,n
%
IL1β%
0"
2"
4"
6"
8"
10"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
tin
%
CXCL5%
0"
0,2"
0,4"
0,6"
0,8"
1"
1,2"
siC
Q
"
siB
RD
7#
1"
siB
RD
7#
4"
pLPC"
m
RN
A%
le
ve
ls
%re
la
,v
e%
to
%β
ac
tin
% BRD7%
	   	   	  	   	   RESULTS	  AND	  DISCUSSION	  PART	  1	  
	   72	  
genes that were previously shown to be bound by the SWI/SNF complex in ChIP-
sequencing experiments (Euskirchen et al., 2011). This chromatin-remodeling complex 
localizes on a very large number of promoters and interestingly almost half of BRD7 
regulated genes were found within this list; among the genes whose promoter is bound by 
the SWI/SNF complex we found also some of the genes validated above including CCL20, 
CXCL2, CXCL3, COX2, IL6 and IL8 (Figure 25A). 
Therefore we proceeded with evaluating the impact of depleting some components of 
SWI/SNF PBAF and PRC2 complexes on the expression of a subset of BRD7 regulated 
genes. To this aim we separately knocked-down the expression of several of these proteins 
in MCF10A cells by means of siRNA oligonucleotide transfection, including the ATPase 
subunit of the SWI/SNF complex BRG1, the PBAF-specific subunits ARID2 and BAF180, 
and the PRC2 Polycomb catalytic subunit EZH2 (Figure 25B). 
As shown in Figure 25C, there are genes showing dependence for different regulatory 
proteins among those tested: CXCL1 and COX2 expression appears to be regulated by 
both SWI/SNF and PRC2 complexes and in particular it is induced upon silencing of all 
the subunits analysed, instead IL8 expression appears to be influenced more by the 
SWI/SNF complex than by the PRC2 complex. Finally, IL1β levels do not change 
significantly upon silencing of either SWI/SNF complex subunits or EZH2. 
Interestingly, IL8 and COX2 promoters were shown to be bound by SWI/SNF in HeLa 
cells (Euskirchen et al., 2011): the result of our experiment suggests that this binding could 
be associated to a repressive effect of the SWI/SNF complex on the transcription of these 
inflammation-related genes. The other two genes analysed, IL1β and CXCL1 instead did 
not emerge as SWI/SNF targets in the published ChIP-sequencing experiment: 
interestingly, here we have observed that IL1β expression is not significantly influenced by 
SWI/SNF. Instead, CXCL1, even if not previously shown to be a target of SWI/SNF, 
appears to be repressed by this chromatin-remodeling machinery in our experimental 
system. 
Thus from the data presented above we can conclude that SWI/SNF and PRC2 complexes 
could act with BRD7 to repress transcription of a subset of its inflammatory signature 
genes. 
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Figure 25. SWI/SNF PBAF complex and PRC2 cooperate with BRD7 in regulating several genes 
involved in the inflammatory process. 
A) Intersection between published SWI/SNF ChIP-sequencing data and genes regulated by BRD7 in 
MCF10A cells. B) Schemes showing the composition of the SWI/SNF PBAF and PRC2 complexes. 
C) qRT-PCR analysis of a subset of BRD7 regulated genes upon RNAi-mediated depletion of SWI/SNF 
subunits BRG1, ARID2 and BAF180 or PRC2 catalytic subunit EZH2. The analysis was performed in 
MCF10A cells; the mean and s.d. of three independent experiments are shown.  
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Transfac® and ExPlain™ analysis unveils possible interaction of BRD7 with 
important transcription factors  
 
As BRD7 has been shown to act as a transcriptional cofactor for several master regulators 
of major tumorigenic processes, we sought to investigate which transcription factor(s) 
could be responsible for induction of the identified signatures and the observed phenotypes 
upon BRD7 depletion. Importantly, this analysis holds the potential to unveil novel 
unreported connections between oncogenic pathways. For this task we took advantage of 
ExPlain™, which is a unique data analysis system that combines promoter and pathway 
analysis tools. ExPlain™ employs TRANSFAC® derived transcription factor binding site 
positional weight matrices to identify transcription factors affecting gene expression in 
microarray and RNA sequencing experiments. First of all we annotated the promoters of 
the genes regulated by BRD7 in order to find common motifs (Figure 26A); after the 
annotation, we used ExPlain™ to identify transcription factors whose binding sites were 
enriched in the promoters of the genes affected by BRD7 knockdown both in normal and 
transformed conditions (Figure 26B). It is important to underline that for the analysis, we 
selected promoter regions (from 1000 bp upstream to the transcription start site) of genes 
belonging to the set upregulated and downregulated by BRD7 depletion. As a background 
dataset we used the promoters of genes whose expression was not altered by BRD7 
depletion in the RNA sequencing data. As the diagram in figure 26B shows, Explain™ 
analysis identified a high number of transcription factors whose binding sites are predicted 
as enriched in the “BRD7 knockdown set” in respect to background set. Notably, most of 
these transcription factors are common between normal and transformed conditions. 
Among enriched transcription factors there are proteins involved in processes related to 
cancer progression such as inflammation (e.g. NF-κB), cell movement (e.g. ZEB1), 
metabolism (e.g. SREBP), differentiation and development (e.g. SMAD3) and stemness 
(e.g. OCT1). 
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Figure 26. Unveiling transcription factors putatively involved in the activation of BRD7-regulated 
genes through analysis of their promoter sequences with ExplainTM tool. 
A) Graphical example of the alignment of promoter sequences and search for common transcription factors 
binding motifs.  
B) Venn diagram showing transcription factors enriched in the promoters of genes regulated by BRD7 
silencing in both normal and transformed conditions. 
 
Interestingly, in our analysis we found proteins already reported as partners of BRD7 in 
transcription regulation, such as BRCA (Harte et al., 2010), while we found also a number 
of novel putative BRD7 interactors, master regulators of the processes of inflammation, 
cell cycle progression, cell movement, metabolism, differentiation/development and 
stemness. Importantly, our analysis also allowed us to find new putative activators of 
classes of genes (e.g. inflammatory genes), thus providing new regulators to processes 
connected to cancer development. 
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BRD7 loss unleashes the expression of inflammatory genes via NF-κB mediated 
transcription 
 
The Explain™ analysis predicted an enrichment of NF-κB binding sites among BRD7 
regulated genes in both normal and oncogene-transformed MCF10A cells. Moreover, also 
the analysis performed with IPA indicated NF-κB and TNF-α as strong upstream activators 
of the BRD7 signature. To confirm this result, we performed a comparison between the 
genes regulated by BRD7 in our RNA sequencing experiments and a list of all published 
NF-κB target genes: this analysis indeed highlighted a strong overlap between NF-κB 
targets and BRD7 regulated transcripts (Figure 27A). 
Interestingly, it is also well established that the chromatin remodeling activity of the 
SWI/SNF complex is required for enhanced chromatin accessibility to NF-κB binding 
during activation of the “delayed subset” of its target genes (Natoli, 2009). It this therefore 
conceivable that BRD7 associates with SWI/SNF complex PBAF to regulate NF-κB 
transcriptional activity. 
 
Figure 27. Induction of a subset of inflammatory genes regulated by BRD7 requires the transcription 
factor NF-κB. 
A) Venn diagram showing the intersection between known NF-κB targets and BRD7 regulated genes.  
B) qRT-PCR analysis of the mRNA expression levels of BRD7 regulated genes involved in the inflammatory 
response upon RNAi-mediated knockdown of BRD7, p65 or both.  
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In order to understand if BRD7 effect on transcription of inflammatory genes was 
dependent on NF-κB, we knocked down BRD7 and p65 expression either alone or in 
combination and performed qRT-PCR analysis of selected genes. The results, reported in 
Figure 27B, showed that the expression of some BRD7 signature genes (CCL20, IL1β, IL8 
and S100A8) appeared to be dependent on the presence of NF-κB in our experimental 
system. Moreover, induction of these genes upon BRD7 depletion was lost in cells lacking 
p65. The same results were obtained for CXCL2 and CXCL3 genes (data not shown). This 
suggests that BRD7 may act by repressing NF-κB-dependent activation of these genes.  
On the contrary, CXCL1, CXCL5 and COX2 are still induced upon BRD7 depletion in 
cells lacking p65, suggesting that in this case another transcription factor may be involved. 
In summary, this set of experiments allowed us to demonstrate that a subset of BRD7 
inflammatory signature genes is represented by NF-κB target genes and that p65 is 
functional for their induction upon BRD7 depletion in MCF10A cells. 
 
 DISCUSSION PART 1 
 
In the first part of the work we have identified BRD7 as a potential tumour suppressor 
gene whose interaction with p53 is stimulated by RasV12 expression, and that is required 
for activation of a subset of p53 target genes, in particular those involved in cell cycle 
arrest. p53 recruits several cofactors to activate its target promoters, including the 
p300/CBP acetyltransferases. We have shown that BRD7 interacts with p300 and is critical 
for its recruitment and for efficient histone acetylation at p53 arrest-specific target 
promoters. It is conceivable that BRD7, which binds acetylated histones through its 
bromodomain, helps to sustain a proper acetylation status of histones surrounding the p53 
binding sites and could thereby contribute to efficient transcriptional regulation during 
oncogene-induced senescence. Theoretically, tumours that have inactivated the p53 
pathway by loss of BRD7 should still be sensitive to apoptosis. It is therefore likely that 
these tumours have to complement BRD7 loss with genetic events affecting the apoptotic 
response, for example by overexpression of Bcl-2 or Bcl-xL. Intriguingly, on chromosome 
16q12, next to BRD7, the cylindromatosis (CYLD) gene is encoded. CYLD is a well-
known pro-apoptotic factor and tumour suppressive activity has been ascribed to it. 
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Therefore, deleting 16q12 would endow tumours with the means to interfere with both OIS 
and induction of apoptosis by loss of BRD7 and CYLD, respectively. The frequent loss of 
16q12 observed in breast cancer and its correlation with retention of wild-type p53 support 
such notion. In addition to p53, BRD7 could also serve as a transcriptional cofactor for 
other proteins. It was shown that BRD7 transcriptionally regulates components of the 
RAS/MEK/ERK and Rb/E2F pathways (Peng et al., 2007; Zhou et al., 2004). Therefore, 
besides its important role in the p53 pathway, BRD7 may also modulate transcription of 
other genes involved in cell cycle regulation. Furthermore, many differentially expressed 
genes in BRD7KD cells are not p53 target genes.  
Driven by the evidence of BRD7 loss in a subset of breast cancers and by our preliminary 
indications that this loss is associated with high-grade tumours and thereby with aggressive 
phenotypes, in the second part of this work we analysed the impact of BRD7 loss on a 
model of mammary cell transformation in vitro generated taking advantage of the 
immortalized MCF10A cell line and its transformed counterpart expressing HRasV12. 
Thanks to this tool, we were able to assess that BRD7 loss is able to foster the process of 
epithelial-to-mesenchymal transition and also impacts on cancer stem cell number. By 
performing RNA sequencing analysis of polyA+ transcripts differentially expressed upon 
BRD7 silencing, we determined that BRD7 appears to normally repress the expression of a 
high number of genes, connected to different processes involved in cancer progression. 
One of most prevalent processes was the inflammatory response. Interestingly, the 
“inflammatory signature” regulated by BRD7 was found to be enriched in highly 
aggressive breast cancer subtypes, namely triple negative breast cancer, and to be 
associated with negative clinical outcomes. We validated the effect of BRD7 depletion on 
the regulation of the most relevant genes by means of qRT-PCR; to ascertain that BRD7 
has a repressive effect on the transcription of these genes we will rescue BRD7 expression 
in silenced cells. In addition, since BRD7 has been identified as a component of a Brg1-
specific SWI/SNF PBAF (polybromo BRG1-associated factor) and PRC2 chromatin-
remodelling complexes (Kaeser et al., 2008; Tae et al., 2011), we demonstrated that some 
of these BRD7 target genes are upregulated also by knockdown of SWI/SNF and PRC2 
subunits, suggesting that BRD7 may act on these genes through epigenetic regulating 
complexes. It will be interesting to verify if the induction of the genes that are targets of 
SWI/SNF or PRC2 complexes is accompanied by modulation of epigenetic marks on their 
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promoters; therefore we will evaluate the changes of histone modifications after BRD7 
depletion through chromatin-immunoprecipitation of specific histone marks.  
To explore which transcription factors may be involved in the regulation of BRD7 target 
genes we obtained a bioinformatics prediction of transcription factor enrichment on 
selected promoters. By ExPlain™ tool we found both known and novel transcription factors 
that may be responsible for regulating the gene signatures that we identified as controlled 
by BRD7; we are currently validating these findings by ChIP and qRT-PCR experiments. 
As a proof of principle of the reliability of the predictions made by ExPlain™, we 
compared the results with a list of experimentally validated targets of the master 
transcription factor of inflammatory genes NF-κB. Indeed we were able to validate the 
involvement of NF-κB in inducing the “inflammatory signature”. Further experiments will 
be needed to evaluate if the effect of BRD7 on NF-κB activity occurs at the target genes’ 
promoters or rather relies on the regulation of NF-κB stability or subcellular localization. 
We have also performed a proteomic analysis of BRD7 interactors in MCF10A HRasV12 
cells that highlighted a clear binding of BRD7 to the protein PML. This discovery is 
particularly interesting because it has recently emerged that PML plays a dual role in 
breast cancer both as tumor suppressor and as an oncogene impacting on metabolism of 
breast cancer cells (Carracedo et al., 2012). Our discovery opens the intriguing possibility 
that BRD7 could also play an oncogenic role in the subset of tumours that display 
augmented levels of the protein. 
We are also inspecting the data about polyA+ non-coding transcripts regulated by BRD7. 
Interestingly some of these transcripts are involved in the maintenance of chromatin 
structure and this finding suggests that BRD7 loss may contribute to breast carcinogenesis 
not only via transcriptional regulation of selected gene signatures but also by globally 
impacting on chromatin structure, as it was previously reported for the protein BRCA (Zhu 
et al., 2011). 
Interestingly, a very recent report showed that BRD7 is required to repress 
Phosphoinositide 3-kinase (PI3K) signalling (Chiu et al., 2014) after serum or insulin 
stimulation. This finding is in line with the tumour suppressive roles that we propose for 
BRD7, and is also particularly intriguing because we demonstrated that BRD7 is lost in a 
percentage of high-grade breast cancers. It is conceivable that ablation of BRD7 could 
concomitantly impair p53 tumour suppressive response and activate PI3K oncogenic 
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activity, thus fostering the acquisition of highly transformed traits. We will verify the 
status of PI3K pathway activation in our cellular system and its possible contribution to the 
observed phenotypes. 
One main open question is whether BRD7 exerts the activities highlighted via its 
participation in the chromatin remodelling complexes or by an independent function. 
SWI/SNF complexes constitute a highly related family of multisubunit complexes that 
remodel nucleosome structure and are capable of mobilizing nucleosomes both by sliding 
and by catalysing the ejection and insertion of histone octamers (Saha et al., 2006). In 
mammals, multiple complexes falling in the SWI/SNF class exist, including the BRG1-
associated factor (BAF) complexes and the polybromo BRG1-associated factor (PBAF) 
complexes. BRD7 was found to belong to the PBAF complex, that bears BRG1 as catalytic 
subunit (Harte et al., 2010). Interestingly, recurrent mutations in subunits of the complex 
have been defined in various cancers, providing a novel link between chromatin 
remodelling and tumour suppression. Interestingly, many of these alterations have been 
reported to affect the same processes controlled by BRD7, suggesting a possible common 
regulation of the same cellular functions. For example BRG1, whose expression is absent 
in 10-50% of human primary non-small-cell lung cancer (NSCLC) samples and whose 
heterozygosity in mice results in mammary tumours in 10% of the cases, has been reported 
to be involved in the processes regulated by BRD7. First of all BRG1 knockdown results 
in decreased binding of p53 to the p21 promoter (Xu et al., 2007); moreover, BRG1 has 
been reported to bind BRCA1 (Bochar et al., 2000) and to modulate its response to UV 
radiation (Zhang et al., 2013). Interestingly, it was demonstrated that the interaction 
between BRG1 and BRCA1 was regulated during Ras-induced senescence (Tu et al., 
2013). In this context the interaction is disrupted during senescence, and this correlates 
with the dissociation of BRCA1 from chromatin and an enhanced association of BRG1 
with chromatin. Moreover, knockdown of BRG1 inhibited the formation of SAHF induced 
by oncogenic RasV12. However, BRG1 did not dissociate BRCA1 from chromatin but acts 
downstream of BRCA1 to promote SAHF formation during senescence.  
Also another specific subunit of the SWI/SNF PBAF complex, BAF180, has been found 
involved in the process of senescence along with BRD7 (Burrows et al., 2010). 
Interestingly, mutations in PBRM1 (which encodes for BAF180) were identified in 41% of 
renal cell carcinomas (Varela et al., 2011) and also in a small minority of breast cancers 
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(Xia et al., 2008). 
Importantly, the SWI/SNF complex PFAF could be involved also in the regulation exerted 
by BRD7 on the processes of EMT and inflammation. Indeed although S. cerevisiae 
SWI/SNF complexes were identified on the basis of their roles in the activation of 
transcription, evidence indicates that mammalian SWI/SNF complexes contribute to both 
repression and activation. In embryonic stem (ES) cells, BRG1 most commonly acts as a 
repressor to inhibit programmes that are associated with differentiation, but it also 
facilitates the expression of core pluripotency programmes (Ho et al., 2009). Contributing 
to the mechanism of repression, SWI/SNF complexes are capable of recruiting histone 
deacetylases (HDACs), which remove activating acetyl marks from histone tails. For 
example, SNF5, a PBAF core subunit, represses cyclin D1 (CCND1) in an 
HDAC1-dependent manner (Zhang et al., 2002b). These seemingly opposing activities 
may actually be similarly achieved, by positioning nucleosomes away from binding sites to 
facilitate factor binding or by moving nucleosomes over sites to prevent binding.  
Evidence from SWI/SNF-mutant cancers suggests that the aberrant activation of gene 
programmes that are involved in cellular motility may contribute to invasion and 
metastasis. SWI/SNF complexes have roles in the regulation of the actin cytoskeleton. The 
SNF5 subunit of SWI/SNF is inactivated via biallelic mutations, including deletion, 
nonsense, missense and frameshift mutations, in nearly all malignant rhabdoid tumours 
(RTs), which are aggressive cancers that occur in young children (Versteege et al., 1998).	  
In particular, SNF5 regulates RHOA-mediated control of cytoskeletal structure, so 
knockdown of SNF5 increases RHOA activity and stimulates migration (Caramel et al., 
2008). RHOA regulates cell migration by stimulating stress fibre formation and 
contractility, and its overexpression in cancer has been shown to correlate with poor 
prognosis (Karlsson et al., 2009). Similarly, alterations in cytoskeleton function have also 
been implicated in BRG1-deficient tumours. Specifically, reducing BRG1 levels in a 
BRG1-expressing pancreatic carcinoma cell line led to an increase in the number of actin 
stress fibres (Rosson et al., 2005).  
Moreover, the SWI/SNF complex has been also involved in the inflammatory response. 
Indeed both NF-κB recruitment on target genes and their activation depend on SWI/SNF 
(Hargreaves et al., 2009; Kayama et al., 2008; Ramirez-Carrozzi et al., 2006). It was 
demonstrated, for example, that BAF180 is a repressor of IL10 transcription in T helper 
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lymphocytes (Th2) (Wurster et al., 2012), where it binds directly to regulatory elements in 
the IL10 locus but is replaced by BAF250 containing BAF complexes when absent, 
resulting in increased histone acetylation and CBP recruitment to the IL10 locus. This 
suggests that the differential recruitment of different SWI/SNF subtypes can have direct 
consequences on chromatin structure and gene transcription.	  
Recent findings have provided new hints on the mechanisms by which SWI/SNF 
complexes contribute to the fine control of gene expression by uncovering a functionally 
antagonistic relationship with Polycomb group (PcG) proteins. These proteins covalently 
modify histones and have roles in regulating gene expression during essential cell fate 
decisions. They have been divided into polycomb repressive complex 1 (PRC1) and PRC2. 
The catalytic subunit of the PRC2 complexes EZH2 mediates tri-methylation of histone H3 
at lysine 27 (Cao and Zhang, 2004), a silencing mark, which in turn is a histone binding 
site for PRC1 complexes, cooperatively leading to the formation of a repressive chromatin 
environment. SWI/SNF was found to suppress defects that were conferred by mutations in 
PcG proteins (Kennison and Tamkun, 1988; Tamkun et al., 1992). The functions of PRC2 
complex have been recently linked to cancer; indeed the expression of EZH2 is frequently 
elevated in a wide range of cancers, including breast cancers, prostate cancers and 
lymphomas, and this overexpression is often correlated with advanced stages of disease 
progression and a poor prognosis (Simon and Lange, 2008).  
Interestingly, EZH2 expression is elevated in primary SNF5-deficient tumours, suggesting 
the hyperactivation of PcG function in these tumours (Kia et al., 2008). The antagonistic 
relationship is further supported by increased levels of trimethylation of lysine 27 of 
histone 3, the epigenetic mark that is added by EZH2, in the absence of SNF5. 
Interestingly, overexpression of EZH2 has also been implicated in the pathogenesis of 
ovarian and renal carcinomas, two tumour types that have recurrent SWI/SNF mutations 
(Lu et al., 2010; Wagener et al., 2008). Such findings suggest that there could be a 
complex interplay between SWI/SNF and PRC2 complexes in normal and cancer cells and 
that BRD7, being part of both complexes, could drive their interplay at promoters. 
Interestingly it was shown that EZH2 regulates NF-κB dependent transcription in breast 
cancer (Lee et al., 2011), in particular promoting the transcription of the NF-κB target 
genes IL6 and TNF in basal-like breast cancer and repressing their transcription in ER-
positive breast cancers. In this scenario, it may not be unlikely that the presence of 
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bromodomain-containing proteins such as BRD7 could be essential to drive the choice to 
either transcribe or not NF-κB target genes.  
All these evidences point towards a transcriptional cooperation between BRD7 and both 
SWI/SNF and Polycomb complexes. This may open the possibility to extend the 
knowledge gained through the study of BRD7 to all the tumours and also other diseases 
bearing alterations in the chromatin remodelling machinery, thus providing new prognostic 
markers and targets for therapy. 
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6. RESULTS PART 2 
Pin1 mediated isomerization stimulates p53-dependent apoptosis induced 
 by mutant Huntingtin 
 
In this part of the thesis we sought to investigate the role of common events that activate 
p53 under oncogenic stess, namely Ser46 phosphorylation and Pin1-mediated prolyl-
isomerisation, in regulating activation of p53 apoptotic function in Huntington’s Disease.  
Huntington’s disease (HD) is a dominantly inherited neurodegenerative disorder that is 
caused by an unstable expansion of a CAG repeat within the coding region of the IT-15 
gene (The Huntington's Disease Collaborative Research Group (1993). The gene encodes 
for a protein called Huntingtin, and the mutation results in an elongated stretch of 
glutamines near the NH2 terminus of the protein. Prevalence of the mutation is 4–10 cases 
per 100,000 in populations of Western European descent, with many more at risk of having 
inherited the mutant gene. Over time, the consequence of carrying the HD mutation is a 
massive brain neurodegeneration characterized by the prevalent loss of efferent medium 
spiny neurons in the striatum (caudate nucleus and putamen) of the basal ganglia, which is 
primarily responsible for the typical HD symptoms, characterized by motor abnormalities 
and cognitive decline (Vonsattel et al., 2011). 
Toxic properties of mutant Huntingtin (mHtt) are believed to cause HD and as a 
demonstration the introduction of the mutant gene into non-human primate, mouse, fly, 
fish, and worm has generated disease models (Zuccato et al., 2010). Several mechanisms 
have been proposed by which mutant Huntingtin (mHtt) may trigger striatal 
neurodegeneration, including mitochondrial dysfunction, oxidative stress and apoptosis. 
Interestingly, expression of full-length mHtt protein and N-terminal fragments containing 
the polyQ expansion, that are produced during the pathogenic process through cleavage of 
the protein by caspases and calpains, elicit a DNA damage response, with activation of the 
ATM/ATR pathways (Illuzzi et al., 2009) and their downstream effectors, including the 
tumour suppressor p53 (Bae et al., 2005; Illuzzi et al., 2011). Mutant Huntingtin was found 
to bind p53 and increase its levels and transcriptional activity, leading to the upregulation 
of two pro-apoptotic downstream targets, Bax and Puma, as well as to mitochondrial 
membrane depolarization. Indeed p53 mediates mitochondrial dysfunction and cytotoxicity 
in HD cells and in transgenic animal models, whereas its inhibition prevents these 
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phenotypes (Bae et al., 2005). Given the pivotal role of p53 pro-apoptotic pathway for the 
neuronal loss in HD, we sought to investigate the signalling network responsible for p53 
activation in neuronal cells, a topic that is still largely unknown. From cancer biology it is 
known that regulation of p53 activities relies on a complex network of post-translational 
modifications and protein interactions (Vousden and Prives, 2009) and entails site-specific 
phosphorylation by several DNA damage-activated protein kinases, including, among 
others, ataxia telangiectasia mutated (ATM), ATM and Rad3-related (ATR), 
homeodomain-interacting protein kinase 2 (HIPK2), and PKCδ. The subsequent 
transduction of stress-dependent phosphorylation into specific conformational changes of 
p53 that fully unleash its apoptotic activity is performed by the prolyl-isomerase Pin1. 
Upon genotoxic insults, Pin1 binds multiple sites on p53, promoting its accumulation in 
stressed cells, the activation of its transcriptional functions, and the induction of its 
apoptotic activity (Zacchi et al., 2002; Zheng et al., 2002a). Based on the importance of 
specific p53 phosphorylation and Pin1-catalyzed isomerisation for p53 tumour suppressive 
functions, we investigated whether this pathway may be aberrantly activated also in 
neuronal cells upon genotoxic stress produced by mHtt activities. 
 
Expression of mutant Huntingtin promotes the interaction of p53 with Pin1 
 
Previous work performed in collaboration with the group of F. Persichetti at SISSA Trieste 
was aimed at analysing p53 content and post-translational modifications in post-mortem 
brains of HD patients. This analysis revealed high levels of p53 in HD brains relative to 
healthy controls, in agreement with previous reports (DiFiglia et al., 1997). To study the 
stress pathways responsible for p53 activation in HD neurons, p53 phosphorylation was 
then analysed. Interestingly, in HD brains p53 was phosphorylated on Ser46, a 
modification that has been associated with activation of its apoptotic function upon stress 
(Mantovani et al., 2007).  
Nuclear accumulation of mHtt N-terminal fragments is observed in HD brains and animal 
models (DiFiglia et al., 1997). Expression of these truncated forms recapitulates many 
molecular and neurological HD phenotypes (Schilling et al., 1999). The N-terminal 
fragment (residues 1–171) of either wild-type or mutant Htt (bearing 21 and 150 polyQ, 
respectively – Figure 28A) were thus expressed in p53-null H1299 cells along with wild-
	   	   	  	   	   RESULTS	  AND	  DISCUSSION	  PART	  2	  
	   86	  
type p53 to verify whether p53 Ser46 phosphorylation was a consequence of mHtt 
expression. Interestingly, mutant but not wild-type Htt induced the phosphorylation of 
transfected p53 on Ser46 (Figure 28B). Because Ser46 phosphorylation generates a target 
site for the prolyl isomerase Pin1 (Mantovani et al., 2007; Zacchi et al., 2002), we asked 
whether Pin1 might play a role in mediating activation of p53 upon mHtt expression. 
Strikingly mHtt expression stimulated direct interaction of p53 with Pin1 as demonstrated 
by GST-Pin1 pull-down assays (Figure 28C), and this effect was proportional to the 
amount of mHtt. To confirm that the phosphorylation pathway was active also in neuronal 
cells, we took advantage of SH-SY5Y human neuroblastoma cells in which we transfected 
either the wild-type or mutant Htt. Also in this cellular system mutant but not wild-type Htt 
induced the phosphorylation of endogenous p53 on Ser46 (Figure 28D), in addition to the 
previously reported phosphorylation of Ser15(Illuzzi et al., 2011). Of note, we were able to 
reproduce this result also in other neuronal (SK-N-SH) and cancer (U2-OS) cell lines 
bearing endogenous wild-type p53 (data not shown). 
 
Figure 28. Expression of mutant Huntingtin induces p53 phosphorylation on Serine 46 and its 
interaction with Pin1. 
A) Schematic representation of the wild-type and mutant forms of the amino-terminal fragments of 
Huntingtin used for this study. 
B) H1299 cells were transfected with constructs expressing p53 and Htt(1–171) fragments bearing either 21Q 
WB:$p53$$
WB:$p53$$
WB:$H)$$
GST-Pin1$
inputs$
H1299%cells%
$
$$$$$$$H)$150Q-GFP$$$$$$$$$-$
$$$$$$$p53 $$+$$$$$$$+$$$$$$$$$+$$
GST-Pin1$(Ponceau$staining)$
WB:$p53$P-Ser46$
WB:$AcDn$
WB:$p53$
WB:$H)$
p53:$$$$$$$$$+$$$$$$$$$+$$$$$$$$+$$
H):$$$$$$$$$$-$$$$$$Q21$$$$Q150$
H)
$21
Q$-
GF
P$
H)
$15
0Q
-GF
P$
WB:p53$P-Ser46$
WB:$p53$$
WB:$h)$
–$
WB:$acDn$
1$
PolyQ%
171$
H)$(1-171)$
21Q$
150Q$
WT$
MUT$
H1299%cells% SH/SY5Y%cells%
A% B%
C% D%
	   	   	  	   	   RESULTS	  AND	  DISCUSSION	  PART	  2	  
	   87	  
or 150Q. Total cell lysates were analyzed by Western blot with antibodies specific for Ser46-phosphorylated 
and for total p53.  
C) H1299 cells were transfected with indicated constructs, and the interaction of p53 with recombinant Pin1 
protein was analyzed by GST pull-down of cell lysates normalized for p53 levels. 
D) SH-SY5Y cells were transfected with constructs expressing the N-terminal 1–171 Htt fragment with 
either 21Q or 150Q. p53 was immunoprecipitated from equal amounts of total cell lysates and analyzed by 
Western blot with antibodies specific for phosphorylated Ser46 and total p53. The levels of actin and Htt 
proteins in input lysates are shown.  
 
Pin1 mediates the activation of the p53 pathway by mHtt 
 
It had been previously shown that expression of mHtt in SH-SY5Y cells triggers a p53-
dependent response involving the activation of apoptotic genes, including Bax and Puma 
(Bae et al., 2005). As shown in Figure 29A and in accordance with previous reports, 
expression of mHtt in SH-SY5Y cells provoked apoptosis, which was reduced by 50% 
upon silencing p53 expression. Importantly, the same effect was observed upon silencing 
of Pin1, and this points towards a functional role of Pin1 in promoting p53-dependent 
apoptosis. Importantly, mHtt induced apoptosis could be re-established in Pin1-depleted 
cells by overexpression of a siRNA-resistant Pin1 construct; this was not effective in cells 
depleted of p53, suggesting that the effect of Pin1 relies on p53. It is noteworthy that 
expression of a catalytically inactive Pin1 mutant was unable to rescue knockdown of 
endogenous Pin1, proving that the prolyl isomerase activity is essential for transducing 
mHtt-dependent stress into p53 activation. 
We then analysed activation of the p53 response in the brains of HdhCAG knock-in mice 
in which the glutamine tract of mouse Htt is extended to 111 residues (HdhQ111)(White et 
al., 1997). These mice show striatal neurodegeneration, reactive gliosis, and gait 
abnormalities at older age (after 24 months)(Wheeler et al., 2002). However, we observed 
stabilization of p53 in brain extracts and the consequent transcriptional induction of the 
p53 target gene p21WAF1 in the striatum of 12-mo-oldHdhQ111 mice compared to their 
wild-type littermates, HdhQ7 (Figure 29B). This finding suggests that activation of the p53 
pathway by mHtt-associated stress is an early event in HD pathogenesis and could precede 
neurological symptoms. HdhQ111 mice were then crossed with Pin1KO mice (Atchison 
and Means, 2003) to verify whether Pin1 is required for p53 activation. Importantly, in 
contrast to HdhQ111/Pin1WT mice, p53 transcriptional activity was not induced in 
HdhQ111/Pin1KO mice (Figure 29B). These results indicate that Pin1 plays a critical role 
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for p53 activation in response to mHtt expression in striatal neurons of a mouse model of 
HD pathogenesis. 
 
 
 
Figure 29. Pin1 activity is required for induction of p53-dependent apoptosis by mHtt. 
A) SH-SY5Y cells were transfected with the indicated combinations of constructs expressing mHtt(1–
171)150Q-GFP, Pin1 siRNA oligonucleotides, and siRNA-resistant wild-type Pin1-HA (WT) or the 
catalytically inactive mutant S67E (CI). Apoptosis of mHtt GFP-expressing cells was evaluated by TUNEL 
assay after 48 h. The histograms show mean and SD of three independent experiments. 
B) Expression of p21WAF1 mRNA was analyzed by qRT-PCR from the striatum of 12-mo-old mice of the 
indicated genotypes (at least three mice for each genotype), normalizing for expression of β-actin. A t-test 
was performed using homoschedastic variance through groups and one tail parameter. p53 was 
immunoprecipitated from equal amounts of brain lysates of the same mice and analyzed by Western blot. 
Actin protein levels in input lysates are shown.  
 
 
Phosphorylation of p53 on Ser46 by HIPK2 is an upstream event in the mHtt-Pin1-
p53 pathway 
 
Our observations indicated that phosphorylation of p53 on Ser46 is triggered by mHtt. To 
define whether this or other phosphorylations are responsible for activating p53 apoptotic 
response upon expression of mHtt, we used p53 phosphorylation mutants with single and 
multiple substitutions of Ser/Thr with Ala residues within Pin1 binding sites(Mantovani et 
al., 2007) (Figure 30A). Expression of these proteins in p53-null H1299 cells demonstrated 
that Ser46 is required for mHtt induced apoptosis, because a Ser46-Ala p53 mutant was 
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unable to cause apoptosis in response to mHtt expression (Figure 30B). In contrast, a p53 
mutant (p53 3M-S46wt) that lacked the remaining three major Pin1 binding sites (i.e., 
Ser33, Thr81, and Ser315) could efficiently induce apoptosis downstream to mHtt 
expression. This protein was phosphorylated on Ser46 in cells expressing mHtt, and Pin1 
potentiated its apoptotic activity (Figure 30B). Both p53 WT and p53 3M-S46wt were then 
able to induce the pro-apoptotic p53 target Puma upon transfection of mHtt, whereas p53 
S46A was almost inactive (data not shown). Therefore, we concluded that phosphorylation 
of p53 on Ser46 is a crucial event in the pathway leading to neuronal death induced by 
mHtt in human and mouse cells. Our data also indicate that modification at this site is 
sufficient for Pin1 to enhance p53’s apoptotic function in cells expressing mHtt. Among 
the protein kinases that catalyse phosphorylation of p53 on Ser46, HIPK2 plays a key role 
in unleashing p53’s apoptotic activity upon DNA damage (Di Stefano et al., 2004). HIPK2 
is induced by cytotoxic stimuli through the ATM/ATR pathway(Winter et al., 2008), 
which becomes activated upon mHtt-dependent stress (Illuzzi et al., 2009). Interestingly, 
expression of mHtt was sufficient to up-regulate HIPK2 protein levels in SH-SY5Y cells, 
and this effect required ATM kinase activity because it was prevented by treatment with 
the ATM-specific inhibitor KU55933 (Figure 30C). We thus inhibited HIPK2 expression 
by RNAi, which dampened mHtt-dependent phosphorylation of p53 on Ser46 with 
concomitant decrease of apoptosis (data non shown). This result indicates a major role for 
HIPK2 in the activation of p53 by mHtt. Interestingly, depletion of HIPK2 did not fully 
prevent Ser46 phosphorylation triggered by mHtt, implying the involvement of other 
kinases in inducing apoptosis downstream of mHtt. 
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Figure 30. p53 Ser46 phosphorylation promoted by mHtt through ATM and HIPK2 is required for 
apoptosis induction by Pin1. 
 A) p53 scheme indicating Pin1 consensus sites (phospho–Ser/Thr-Pro). DBD, DNA binding domain; NLS, 
nuclear localization signal; TA, transactivation domain. p53 mutants have Ser/Thr-to-Ala substitutions in 
Pin1 consensus sites at residue 46 (p53 S46A) or at the three other major Pin1-binding sites at residues 33, 
81, and 315 (p53 3MS46wt). 
B) p53-null H1299 cells were transfected with the indicated constructs (see also A). Apoptosis of mHtt GFP-
expressing cells was evaluated by TUNEL assay after 48 h. The histograms show mean and SD of three 
independent experiments. 
C) SH-SY5Y cells were transfected with mHtt(1–171)150Q-GFP and treated with the ATM inhibitor KU-
55933 10 µM for 24 h. HIPK2 protein levels were evaluated by Western blot.  
D) Model of the phosphorylation events that may occur following mHtt expression. 
 
 
Interfering with p53 activation by Pin1 prevents apoptosis downstream of mHtt 
 
Given that p53 activation mediates the cytotoxic effects of mHtt, we hypothesized that 
pharmacologic inhibition of catalytic activity of the kinases that phosphorylate p53 on the 
Pin1 target site Ser46 could prove effective in preventing mHtt-induced apoptosis. Because 
specific inhibitors of HIPK2 are not available, we attempted to pharmacologically interfere 
with this pathway by inhibiting the upstream kinases. Treatment of SH-SY5Y cells with 
caffeine, a well-known inhibitor of ATM/ATR activities, strongly reduced mHtt-dependent 
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cellular toxicity and Ser46 phosphorylation (Figure 31A). We then focused on ATM, 
which, besides inducing HIPK2, directly phosphorylates p53 on Ser46, in addition to Ser15 
(Kodama et al., 2010). Strikingly, the ATM-specific inhibitor KU55933 was effective in 
preventing mHtt-induced apoptosis by reducing phosphorylation of p53 on both Ser46 and 
Ser15 (Figure 31B). It is important to underline that we also demonstrated that specific 
inhibition of either the PKCδ kinase, that also phosphorylates p53 on Ser46 after mHtt 
stress, or of Pin1 catalytic activity was able to strongly reduce mHtt-induced apoptosis 
(data not shown). 
Together, all the experimental evidences support a model where stress generated by mHtt 
triggers activation of ATM, HIPK2, and PKCδ kinases, which lead to phosphorylation of 
p53 on Ser46. This process preludes Pin1-dependent prolyl-isomerization and consequent 
induction of p53 pro-apoptotic genes (Figure 31C). 
 
Figure 31. Inhibition of p53 phosphorylation on Ser46 reduces mHtt-dependent apoptosis. 
A and B) SH-SY5Y cells were transfected with a construct expressing mHtt(1–171)150Q-GFP and treated 
with the ATM/ATR inhibitor caffeine, 3 mM (A), the ATM-specific inhibitor KU-55933,10 µM (B), or with 
same amount of solvent as a control (–). Apoptosis of mHtt GFP-expressing cells was evaluated by TUNEL 
assay after 24 h. Graphs show means and SD of three independent experiments. To detect p53 
phosphorylation, p53 was immunoprecipitated from equal amounts of total cell lysates and analyzed by 
Western blot. The protein levels of Pin1, actin, and mHtt in input lysates are shown. 
C) Model for regulation of p53 by Pin1 upon cellular stress generated by mutant Huntingtin. In cells 
expressing mHtt, the activities of ATM and HIPK2 lead to phosphorylation of p53 on Ser46. Subsequent 
prolyl isomerization of the phospho–Ser46-Pro47 site by Pin1 leads to induction of apoptotic genes. 
Pharmacologic interference with this pathway can be accomplished by use of small-molecule inhibitors that 
target ATM, thereby preventing p53 cytotoxic activity. 
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The results reported in this part have been published in the original article:    
Grison, A.*, Mantovani, F.*, Comel, A., Agostoni, E., Gustincich, S., Persichetti, F., and 
Del Sal, G. Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of 
p53 are key events in p53-dependent apoptosis induced by mutant huntingtin. PNAS 2011 
: 1106198108v1-201106198. *Equal contribution 
 
DISCUSSION PART 2 
 
The majority of therapeutics currently used to treat HD patients are designed to ameliorate 
the primary symptoms of the HD condition itself, i.e., psychiatric agents for the control of 
behavioural symptoms, motor sedatives, cognitive enhancers, and neuroprotective agents 
(Handley et al., 2006). These drugs have limited benefits, however, and do not alter the 
inexorable disease progression. Unluckily, as discussed previously, neuronal dysfunction 
and cell death in HD are due to a combination of interrelated pathogenic processes and 
targeting only one aspect may not be sufficient to avoid neuronal loss; this is particularly 
true if considering that the vast majority of the therapies that have been proposed so far are 
designed to target either the phenotypic manifestations of the disease or single downstream 
events such as excitotoxicity, caspase cleavage of mHtt and aggregates or mitochondrial 
dysfunction. In this context, deciphering the codes of activation of cell death pathways 
from the upstream events to the final outcome becomes a main goal of research as it may 
provide important hints for HD treatment. 
In this work, we decided to focus on an emerging model of HD pathogenesis, where mHtt 
evokes a canonical DNA damage response in neuronal cells, with induction of ATM/ATR 
kinases and consequent activation of p53 (Illuzzi et al., 2009). Therefore, we took 
advantage of the vast knowledge available on the p53 pathway to dissect possible upstream 
pathogenic events in HD. We demonstrated that p53 activation entails its phosphorylation 
on Serine 46 driven by ATM/ATR activated kinases and is necessary and sufficient for 
p53-dependent induction of apoptosis. Importantly, we also examined the contribution of 
the prolyl-isomerase Pin1, a well-known modulator of p53-dependent stress responses, to 
the observed phenotype. We observed that mHtt expression in neuronal cells is able to 
trigger the binding of p53 to Pin1 and that Pin1 catalytic activity is required to efficiently 
unleash p53 apoptotic response.  
The model emerging from our data is particularly intriguing because it unveils as 
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mediators of mHtt induced pathogenesis important enzymes that could represent novel 
druggable targets for HD therapy. Indeed we demonstrated that inhibiting the activity of 
apical kinases, which lead to Ser46 phosphorylation either directly or indirectly, in an in 
vitro model of neurodegeneration, is able to prevent cell death. Indeed protein kinases are a 
growing drug target class for diseases of peripheral tissues, and several candidate 
therapeutics targeting CNS kinases are now in various stages of preclinical and clinical 
development. For instance, specific inhibitors of PKCδ have shown preclinical in vivo 
efficacy in treatment of PD(Chico et al., 2009).  
Moreover in the same in vitro experimental setting small-molecule inhibitors of Pin1 can 
protect neuronal cells from mHtt-induced apoptosis and may therefore be effective as a 
therapeutic strategy for treatment of HD, although it is arguable that development of 
clinically useful inhibitors of Pin1 awaits further improvement. 
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7. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Despite the strong effort posed in trying to understand the molecular pathways underlying 
two of the most life-threatening pathologies worldwide, namely cancer and 
neurodegenerative diseases, in order to find effective therapies, adequate cures are still 
lacking for most of the subtypes of each category. Indeed, many targeted therapies based 
on drugs targeting key proteins with tumour- or neurodegeneration-driving functions have 
partially failed due to either development of resistance or strong side effects. Nowadays, it 
is emerging the concept of developing drugs or drug combinations that may target complex 
multicomponent cellular machineries – including chromatin modifiers, different kinase 
cascades or the proteasome – thus simultaneously inhibiting multiple signalling 
intermediates (an approach referred to as “polypharmacology” (Knight et al., 2010)). This 
approach may overcome the plasticity of tumours and enhance inhibitory effects in 
neurodegenerative disease, thus decelerating disease progression.  
Data obtained from epidemiologic studies in the last two decades have unveiled an inverse 
comorbidity between cancer and CNS disorders, and single-genes studies (Plun-Favreau et 
al., 2010) but also recent high-throughput analyses suggest that this inverse correlation is 
due to the deregulation of the same signalling pathways but in opposite direction (Ibanez et 
al., 2014), e.g. the proteasome activity that is hyperactivated in tumours but downregulated 
in neurodegenerative diseases. These observations unveil the intriguing possibility that 
knowledge and strategies developed for the treatment of one disease could be exploitable 
also for the other pathology and vice versa. Prompted by this remark, in this thesis we 
focused on p53, a transcription factor best known for its tumour suppressive activities but 
recently found activated also in the most frequent neurodegenerative diseases. We aimed at 
dissecting the involvement of p53 and of the signalling pathways and machineries that 
modulate its activation and functions in both neurodegeneration and cancer, with the 
purpose of exploiting the knowledge acquired in a field for the other.  
As a model of neurodegeneration we employed Huntington’s Disease, in which neuronal 
death was previously reported to largely depend on p53 (Bae et al., 2005). We have 
focused on an emerging model of HD pathogenesis, where the expression of mutant 
Huntingtin (mHtt) protein, that is the causative agent of HD, evokes a canonical DNA 
damage response in neuronal cells, with induction of ATM/ATR kinases and consequent 
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activation of p53 (Illuzzi et al., 2009). In this context we demonstrated that mHtt-induced  
signalling events, converging on p53 also under genotoxic stress, namely phosphorylation 
of Serine 46 and Pin1-mediated prolyl-isomerization, drive p53-dependent neuronal cell 
death. Importantly, we also demonstrated that concerted inhibition of these pathways was 
able to avoid neuronal cell loss in an in vitro system.  
On the other hand, in the context of oncosuppressive p53 activities, we analysed the 
contribution of a protein belonging to the chromatin remodelling family, BRD7, to one of 
the main tumour suppressive activities driven by p53 in vivo, oncogene-induced 
senescence (OIS). In this context we discovered that BRD7 was not only required for p53-
dependent OIS induction thus imposing a barrier to tumorigenesis, but also to restrain the 
acquisition of highly malignant phenotypes, such as the ability to migrate and acquire 
cancer stem cell-like traits, in response to active oncogene expression but independently of 
p53. Moreover concomitantly we observed also a strong induction of inflammatory genes 
after BRD7 depletion in presence or absence of oncogenic stress, whose contribution to the 
observed processes and mechanism of regulation is still under investigation. Interestingly, 
BRD7 was shown to belong to important epigenetic regulatory complexes such as 
SWI/SNF and PRC2, whose multicomponent composition will be the ideal target for a 
polypharmacological approach. Thus, the knowledge generated in the cancer context 
would be exploitable also for neurodegenerative diseases; indeed global alterations of 
chromatin have been found in Alzheimer’s Disease (Frost et al., 2014) and in other CNS 
disorders. For example recent studies point to aberrant histone acetylation status as a key 
mechanism underlying acquisition of inappropriate alterations of genome structure and 
function in post-mitotic neurons during neurodegenerative processes (Pirooznia and 
Elefant, 2013). It is therefore conceivable that targeting or restoring the functions of some 
members of the class of chromatin modifiers may provide benefit not only for cancer 
patients but also for people affected by neurodegenerative disorders. 
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8. MATERIALS AND METHODS 
 
DNA manipulation techniques 
DNA and siRNA transfection: Cells were transfected with Lipofectamine 2000 
(Invitrogen). For RNAi, cells were transfected with Lipofectamine RNAiMAX 
(Invitrogen). 
 
Calcium phosphate-mediated transfection of 293GP cells: In order to obtain the 
retroviruses for the generation of MCF10A stable clones 293GP cells were transfected 
with the vector of interest and the vector carrying the envelope sequence of the vesicular 
stomatitis virus. For calcium-phosphate transfection of 293GP cells a solution of calcium-
chloride and DNA in water is prepared and added drop by drop to an equal volume of 
HBS: after 30 minutes of incubation DNA-salt precipitates were added to the cells. 
 
Protein manipulation techniques 
SDS-PAGE (SDS-polyacrylamide gel electrophoresis): For the electrophoretic separation 
of protein samples in SDS-PAGE the running gel was composed by 12,5% acrylamide, 
0,1% bisacrylamide, 0,374M Tris-HCl pH 8,7, 0,1% SDS. The stacking gel composition 
was: 5% acrylamide, 0,14% bisacrylamide, 0,125M Tris-HCl pH 6,9, 0,1% SDS. The 
electrophoretic run was performed applying a constant potential difference of 80V while 
the samples were in the stacking gel, increasing it to 180V for the running gel run. 
 
Electrotransferring of proteins from gel to nitrocellulose membrane: For the transfer of 
proteins on nitrocellulose membrane the Wet transfer cell (BioRad) was used: the blotting 
buffer is composed by 00,2 M Tris, 0,2M Glycine). The protein transfer is achieved 
applying a constant potential difference of 100V for 1 hour and 30 minutes. 
 
Western blot: After incubation of nitrocellulose membrane for 30 minutes in blotto tween 
(5% milk, 0,2% Tween20 in PBS), the membranes were incubated with the primary 
antibodies diluted in blotto tween for 1 hour or overnight. After three washes the 
membranes were incubated with the secondary antibodies (conjugated with HRPO) that 
target the constant region of the species of the corresponding primary antibody. After 30 
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minutes the membranes were washed three times with blotto tween and twice with PBS. 
For the western blot development ECL plus (Pierce) or ECL (Amersham) were used. 
 
RNA manipulation techniques 
Total RNA extraction: For total RNA extraction the Qiagen lysis reagent was used: it is 
composed by phenol and guanidine isothiocyanate and allows the extraction of RNA, DNA 
and proteins. After chloroform addition there is the separation in three phases: taken the 
supernatant isopropanol addition allows RNA precipitation. Removed the supernatant the 
RNA pellets were washed with ethanol 75%, air-dried and resuspended in water. 
To guarantee an increased RNA quality the steps with chloroform and ethanol were 
repeated twice. 
 
RNA retrotranscription: The retrotranscription was performed using the QuantiTect 
Reverse Transcription kit (Qiagen). This kit allows the retrotranscription of extracted RNA 
through two sequential steps, a first step of genomic DNA removal and a second one of 
retrotranscription with a mix containing poliT and random primers. cDNA obtained were 
then diluted 1:10 in water in order to proceed with qRT-PCR. 
 
Immunofluorescence 
Cells grown on coverslips for one day were washed with PBS, fixed with 3% 
paraformaldehyde in PBS for 20 minutes and incubated with glycine for 5 minutes. Cells 
were then permeabilized through incubation with TritonX-100 0,1% in PBS for 5 minutes, 
washed with PBS and incubated for 20 minutes with BSA 10% in PBS. Antibodies were 
diluted in PBS-BSA 10% and the incubation was performed at 37°C for 45 minutes. After 
washing with PBS, cells were incubated for 30 minutes with secondary antibodies 
conjugated to FITC or TRITC. After washing with PBS nuclei were stained with Hoechst 
(2µg/ml in PBS) for 5 minutes. After two washes with PBS and one with water the 
coverslips were mounted through Mowiol application on a glass slide. The epifluorescence 
microscope Leica DM4000B was used with a 630X magnitude. 
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MATERIALS AND METHODS PART 1 
 
Cell culture, treatments and transfections 
Cell culture conditions: BJ/ET and U2-OS cells were cultured in DMEM (Sigma) 
supplemented with 10% FCS and antibiotics. MCF10A cells were grown in DMEM/F12 
Ham’s (1:1, Sigma) medium supplemented with 5% horse serum (Gibco), insulin (10 
µg/ml; Sigma), hydrocortisone (0.5 µg/ml), EGF (20 ng/ml; Peprotech), penicillin (100 
U/mL) and streptomycin (100 µg/mL). To detach cells it has been used Trypsin/EDTA 
(0.05% Trypsin, 0.53 mM EDTA - GIBCO). 
 
Transient silencing: Cells were transiently silenced using Lipofectamine RNAiMAX 
reagent (Invitrogen): siRNAs duplex and Lipofectamine were resuspended in Optimem 
medium, mixed together and after 20 minutes added to the cell medium. The final 
concentration of siRNAs in the cell medium was 36 nM.  
siRNAs sequences are listed in the Table: 
 
Target siRNA sense sequence 
Control AllStars Neg.Control siRNA Qiagen #1027281 
BRD7 (siRNA#1) 5'-GUACUAAUGCCAUGAUUUA-3' 
BRD7 (siRNA#4) 5'-GCACGUAUGGAGUUCGAAA-3' 
p53 5’-GACUCCAGUGGUAAUCUAC-3’ 
ARID2 5’-CGUACCUGUCUUCGUUUCC-3’ 
BAF180 5’-UAUAGAGUUCAUGGCACACGGC-3’ 
BRG1 5’-GCAGAGAAGCUGUAGGACU-3’ 
EZH2 5’-AAGACUCUGAAUGCAGU-3’ 
p65 5'-GCCCUAUCCCUUUACGUCA-3' 
 
For expression data 650.000 cells were plated on a 10 cm dish, silenced twice (the second 
transfection 24 hours after the first) and RNA was isolated 48 hours after the second 
siRNA transfection. 
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Constructs for DNA transfection. pRS-p53#2 containing the short hairpin for p53 silencing 
was previously described (Voorhoeve and Agami, 2003). BRD7 shRNA sequences were 
cloned into pRS-YFP, pRS-hygro, or pRS-blast. Targeting sequences are the same shown 
in the Table above. 
pcDNA3-Flag-BRD7 has been previously described (Kzhyshkowska et al., 2003). From 
these, pEGFP-BRD7 was obtained by subcloning. pMSCV-BRD7 was obtained by PCR 
amplification on pcDNA3-Flag-BRD7 and put into pMSCV. This was used as a template 
to obtain pMSCV-BRD7Δ1/128, and pMSCV-BRD7Δ361/651. The plasmids for bacterial 
expression of MBP-BRD7 fusion proteins were all obtained by PCR amplification of the 
entire BRD7 ORF, or its portions using pCDNA3-Flag BRD7 as a template, and cloning in 
frame with Maltose binding protein (MBP) gene of pMAL-C2X vector (NEB).  
 
Quantitative RT-PCR 
qRT-PCR was performed using the SsoAdvanced SYBR Green Supermix (BIORAD) 
reagent. The qRT-PCR program is composed of a first step of denaturation (30 seconds at 
95°C) and then 40 cycles of denaturation (95°C for 5 seconds), annealing and extension 
(60°C for 30 seconds) and dissociation. The instrument used is the BIORAD CFX96 
Touch™ Real-Time PCR Detection System termocycler. The quantification is based on the 
2-ΔΔCt method using the housekeeping gene βactin as normalizer. Primers sequences are 
listed below. 
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Protein Production and In Vitro Binding Assays 
MBP-BRD7 fusion proteins and MBP were extracted in Column buffer (20 mM Tris-HCl 
pH 7.5, 200 mM NaCl, 1 mM EDTA pH8, and 10 mM b-mercaptoethanol) and purified 
with amylose resin (NEB E8021S) following the manufacturer’s instructions (NEB). In 
vitro translation of proteins was performed according to the standard protocol (Promega) in 
the presence of [35S]methionine. The proteins were diluted in MBP-PD buffer (150 mM 
βactin Fw TTTACAAGCTGCCTTCACCACA
Rev TTCACACCATTAAGGCTGGCACAC
ARID2 Fw TCCGGACGAGCGGAGAAAGGG
Rev AAAGGCGACCCTCTGCTGTGGT
BAF180 Fw ACCACCTCCATATCCCGGCCC
Rev GCGTCTTCGAGCTGCCAGTGT
BRD7 Fw CTGGAGATGCCGAAGCACAC
Rev TGGGATCCACAGGATGGAGA
BRG1 Fw GCGGCTGACCTGTGAGGAGGA
Rev TGCAGAACTGAAGGCCACGCT
CCL20 Fw CAGTGCTGCTACTCCACCTC
Rev AAAGTTGCTTGCTGCTTCTGA
COX2 Fw GTTCCACCCGCAGTACAGAA
Rev AGGGCTTCAGCATAAAGCGT
CXCL1 Fw TTGCCTCAATCCTGCATCCC
Rev TTGGATTTGTCACTGTTCAGCA
CXCL2 Fw TCACAGTGTGTGGTCAACAT
Rev ACACAGAGGGAAACACTGCAT
CXCL3 Fw ACCGAAGTCATAGCCACACTC
Rev ACCCTGCAGGAAGTGTCAAT
CXCL5 Fw ACGCAAGGAGTTCATCCCAA
Rev TCTTCAGGGAGGCTACCACTT
EZH2 Fw TGCTTCCTACATCGT
Rev GGACGTTTTGGTGGG
IL1b Fw GCCTGAAGCCCTTGC
Rev GCGGCATCCAGCTACGAAT
IL6 Fw CTGCACAGCTCTGGCTTGTTCCT
Rev AAAGCAGCAGCAAAGAGGCACTGGCA
IL8 Fw GGCAGCCTTCCTGATTTCTG
Rev CTTGGCAAAACTGCACCTTCA
MMP9 Fw GCCTTTGGACACGCACGACGT
Rev GCAGGACGGGAGCCCTAGTC
p65 Fw GGGGACTACGACCTGAATGC
Rev TTGGGGGCACGATTGTCAAA
S100A8 Fw TGTCTTTCAGAAGACCTGGTGG
Rev GAGGACACTCGGTCTCTAGC
Vimentin Fwd GAGAACTTTGCCGTTGAAGC
Rev GCTTCCTGTAGGTGGCAATC
E(cadherin Fwd TGCCCCCAATACCCCAGCGT
Rev ACGGTGGCTGTGGAGGTGGT
Fibronectin1 Fwd CAGTGGGAGACCTCGAGAAG
Rev TCCCTCGGAACATCAGAAAC
N(cadherin Fwd ACAGTGGCCACCTACAAAGG
Rev CCGAGATGGGGTTGATAATG
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Tris pH=7.5, 1% NP40, 10% glycerol) and incubated with 2.5 µg of MBP-BRD7 fusion 
constructs or MBP. 
 
Immunoprecipitation 
Co-immunoprecipitation of BRD7 and p53 was performed in 50 mM Tris-HCl pH 8, 100 
mM NaCl, 1% NP-40, 1mM EDTA, 5% glycerol with protease inhibitor cocktail (Sigma), 
1 mM PMSF, 5 mM NaF, 1 mM Na3VO4, 1 µM TSA and 5 µM Nicotinamide, using 2 mg 
of total lysate and 3 µg of anti-BRD7 polyclonal antibody or anti-HA antibody as control. 
Antibodies were covalently bound to protein A–Sepharose (Amersham) using 5 mg/ml 
dimethylpimelimidate (Pierce). 
 
Antibodies 
Antibodies against p53 (DO1), p21 (F5), Ras (F235) were purchased from Santa Cruz 
Biotechnology; anti-BRD7 rabbit polyclonal serum was raised against the C-terminal 
portion (aa 361-651) of human BRD7 expressed in bacteria and affinity purified by 
standard procedures. Anti-GFP rabbit polyclonal serum was raised against GST-GFP 
fusion protein expressed in bacteria and affinity purified by standard procedures. Other 
antibodies were anti–acetyl-Lys382-p53 (Cell Signaling Technology and Abcam), anti-
p300 (NM11; BD-Pharmingen), anti-acetyl-Histone-H3 (Lys 9) (#07-352, Millipore), anti-
Histone-H3 (ab1791, Abcam), anti-E-cadherin (BD Pharmaceutic) and anti-vimentin 
(ab8069, Abcam). 
 
Chromatin immunoprecipitation assay 
To exclude the possibility that differences in promoter binding occur in BRD7 and p53 
knockdown cells because of their effect on the cell cycle, we performed the ChIP 
experiments within the first 48 hrs upon RasV12 induction when the differences in 
proliferation rate between control and knockdown cells are minimal. 
Cells were crosslinked with 1% formaldehyde for 15 min., neutralized with 125 mM 
glycine pH 2.5 and washed in PBS. For BRD7 ChIP, FA crosslinking was preceded by 
protein-protein crosslinking with 2 mM DSG (disuccinimidyl glutarate) for 30 min. Nuclei 
were prepared by hypotonic lysis (5mM Pipes pH 6.8, 85 mM Kcl, 0.5% NP40) and 
centrifugation, and resuspended in RIPA-100 buffer (20 mM Tris HCl, pH 7.5, 100 mM 
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NaCl 1 mM EDTA 0.5% Nonidet P-40 0.5% deoxycholate 0.1% SDS) with protease 
inhibitor cocktail (Sigma), 1mM PMSF, phosphatase inhibitors (NaF 5mM and Na3VO4 
1mM), and deacetylase inhibitors (TSA 1µM and Nicotinamide 1µM). Chromatin was 
sonicated with Bioruptor (Diagenode) to 500-1000 bp average fragment size and cleared 
by centrifugation. IP was performed overnight at 4°C with the indicated antibodies. A 
negative control was performed in the presence of isotype-specific unrelated Ab. DNA–
protein complexes were recovered by protein A/G PLUS-Agarose (Santa Cruz Biotech.) 
and washed sequentially with RIPA-100 buffer, RIPA-250 buffer (20 mM Tris HCl, pH 
7.5, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.5% deoxycholate, 0.1% SDS) and LiCl 
solution (10 mM Tris-HCl pH 8, 1mM EDTA, 250 mM LiCl, 0.5% Na-Deoxycholate, 
0.5% NP40), then resuspended in TE, digested with 2U Dnase-free Rnase (Calbiochem) 
for 30 min. at 37°C, and incubated o/n at 68°C with 300 mg/ml Proteinase K (Invitrogen) 
in 0.5% SDS, 100 mM NaCl to digest proteins and reverse crosslinks. After purification by 
phenol-chloroform extraction and ethanol precipitation, DNA was resuspended in H2O and 
1/10 volume was used for quantification. Antibodies were as follows: anti-p53 FL-393 
(Santa Cruz Biotechnology); anti-BRD7 polyclonal antibody (homemade); anti–acetyl-
Lys382-p53 (Abcam); anti-p300 NM11 (BD-Pharmingen); anti-acetyl-Histone-H3 (Lys9) 
(#07-352, Millipore), anti-Histone-H3 (ab1791, Abcam). DNA–protein complexes were 
recovered with protein A/G PLUS-Agarose (Santa Cruz Biotechnology). Real-time PCR 
was performed on an StepOne Plus cycler (Applied Biosystems), using SYBR Green 
Universal PCR Master Mix (Applied Biosystems). Promoter occupancy was calculated as 
the percentage of input chromatin immunoprecipitated using the 2-ΔΔCt method. Primers 
used are listed below. 
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Bisulphite sequencing and methylation specific PCR 
The upstream regulatory region of BRD7 was searched for CpG islands using 
EMBOSSCpGPlot (http://www.ebi.ac.uk/Tools/emboss/cpgplot/). A CpG island was 
identified between nucleotides -273 to +581, relative to the transcription start site of 
BRD7. Primer sequences for methylation specific PCR (MSP) were designed using 
methprimer (http://www.urogene.org/methprimer/). Primer sequences and location relative 
to the transcriptional start site are as follows: unmethylated forward 5' 
TTGTTTTTTTGAGAGGGGTATTG 3', unmethylated reverse 5' 
ACCCTCATAAAAATATTTATCCAAC 3'; methylated forward 5' 
TCGTTTTTTTGAGAGGGGTATC 3'; methylated reverse 5' 
ACCCTCGTAAAAATATTTATCCGAC 3'. Genomic DNA was isolated from 10 micron 
tissue sections using proteinase K. Bisulphite conversion of genomic DNA was carried out 
using the Epitect Bisulfite kit (Qiagen). This process converts unmethylated cytosine 
residues to uracil while methylated cytosine residues remain unchanged. MSP was then 
carried out to determine the methylation status of BRD7. Bisulphite modified DNA was 
used as a template for MSP with primers specific for methylated or unmethylated 
sequences. Totally methylated DNA and normal human unmethylated DNA (Control DNA 
Set, Qiagen) were used as positive and negative controls, respectively. Cycling conditions 
were as follows: 95ºC for 2 min followed by 40 cycles of 95ºC for 1 min, 58ºC for 1 min 
and 72ºC for 1 min, then a final extension at 72ºC for 5 min. PCR products were 
electrophoresed through 2% agarose gels, stained with ethidium bromide and visualised 
using a transilluminator. 
 
Immunohistochemistry of tissue samples 
Tissue sections were pretreated in citrate buffer (10mM, pH 6.0) in a pressure cooker 
(96°C) for 40 min. Non-specific staining was blocked by incubation with BSA and slides 
were treated with primary anti-BRD7 homemade antibody (1:250) overnight at 4°C. Super 
Sensitive Polymer HRP IHC Detection System from BioGenex was used during the second 
day of staining.  
 
Soft agar assay 
Normal MCF10A breast epithelial cells stably expressing BRD7 or p53 knockdowns were 
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transduced with pLPC-puro-RasV12 or with the empty vector. After selection the cells were  
resuspended in a top layer of culture medium with  0.25% agarose (Gellyphor, Euroclone), 
at 20,000 cells per 6 cm dish and plated on a bottom layer of culture medium containing 
1% agarose. Every 2 days fresh growth factors were added. After two weeks the colonies 
were counted with a 20X objective on an Olympus CK30 microscope. 
 
Transwell migration and invasion assay 
For the transwell migration assay 100.000 cells were seeded on 8 µm pore transwell filters 
and allowed to migrate towards the bottom side for 15 hours. Inserts were then washed 
with PBS, cells that did not migrate were eliminated and migrated cells were fixed through 
incubation with 3% paraformaldehyde in PBS for 20 minutes. After two washes with PBS 
cells were stained with Crystal Violet 0,05%. After some hours inserts were washed with 
water, air-dried, cut and mounted on glass slices. Migrated cells were counted using the 
optical microscope Olympus CK30 with a 200X magnitude. 
The same protocol was used for transwell invasion assay, where cells were seeded on 
transwell filters coated with Matrigel. 
 
Mammosphere formation assay 
Cells grown in 2D-colture were trypsinized and passed through a cell strainer with 40 µm 
pores in order to obtain a single cell suspension. Viable cells were counted after staining 
with Trypan blue and plated on ultra-low attachment (Corning) 24-multiwells. 5.000 cells 
were seeded in each well. Cells were then grown in non-adherent conditions for 15 days. 
The culture medium is constituted by MEBM (Mammary Epithelial Basal Medium-Serum 
free) (Lonza), supplemented with B27 (Invitrogen), 20 ng/ml EGF (PROSPEC), 20 ng/ml 
β-FGF (BD Biosciences), 4 µg/ml heparin (StemCell Technologies Inc), 0.5 µg/ml 
hydrocortisone (Sigma) and 5 µg/ml insulin (Sigma). In this way primary mammopheres 
(diameter ≥ 50µm) were obtained: they were then counted, collected, enzymatically 
disgregated and plated in the same conditions described above in order to obtain secondary 
mammospheres. Mammosphere formation efficiency is calculated as the number of 
secondary mammospheres divided for the number of plated cells, expressed then as a 
percentage. Mammospheres were counted using the Olympus CK30 microscope. 
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3D Morphogenesis assay 
Cells grown in 2D-colture were trypsinized and passed through a cell strainer with 40 µm 
pores in order to obtain a single cell suspension. Viable cells were counted after staining 
with Trypan blue. 1.500 cells were seeded in a 24-multiwell covered with BD basement 
matrix according to (Debnath et al., 2003) and allowed to grow for 14 days. 
 
Bioinformatical analysis 
IPA functional analysis: The entire RNA sequencing data with their associated annotation 
(when present) with overall FDR, and the post-hoc P-value of each comparison were 
uploaded into IPA. The entire RNA sequencing was used as background or reference 
dataset for enrichment calculation of enriched functions. Each annotated gene was mapped 
to its corresponding gene object in the IPA Knowledge Base. The analysis was run using 
the following setting in IPA: all defaults setting for the selection of dataset, 1.5 fold-
change cut-off, P-value = 0.001 and no FDR cut-off. The simple P-value for the 
enrichment was considered and reported. All functions were used except the one related to 
diseases. 
 
ONCOMINE analysis: The gene lists were submitted in ONCOMINE for evaluation of 
their expression levels in different datasets. The gene expression data were log 
transformed, median cantered per array and the standard deviation was normalized to one 
per array. The threshold selected for the analysis were the following: odd ratio >2,0 and 
p.value ≤1E-4. 
 
ExplainTM promoter analysis: Promoter analysis was performed using the online tool 
Explain 3.0 (http://explain.biobase-international.com/) for detection of overrepresented 
transcription factor binding sites. For the analysis, we selected regions from 1,000-bp 
upstream to the transcription start site of each BRD7 target gene (Yes set) and the same 
promoter region of an equal amount of genes whose expression did not result influenced 
by BRD7 silencing in RNA sequencing data (No set). The entire vertebrate non-redundant 
set of transcription factors matrix from the TRANSFAC database was used for scanning 
potential binding sites. 
 
	   	   	  	   	   MATERIALS	  AND	  METHODS	  
	   106	  
MATERIALS AND METHODS PART 2 
 
Cell culture, treatments and transfections 
Cell culture conditions. SHSY5Y cells were maintained in MEM (Sigma #M4655) and 
F12 Ham’s medium (Sigma #N6658) 1:1, supplemented with 15% foetal bovine serum 
(Euroclone #ECS0180L), 0,5% GlutaMAX (Gibco #35050), 1% Non-essential ammino 
acid solution (Sigma #M7145), 1% Pen-Strep (Lonza #DE17-602E). H1299 human lung 
carcinoma cells were cultured in RPMI with 10% FCS and antibiotics. Caffein and KU-
55933 were purchased form Sigma. 
 
Transient silencing. For RNA interference, cells were transfected with 36 nM of siRNA 
oligonucleotides using Lipofectamine RNAiMax (Invitrogen). 
siRNAs sequences are listed in the Table: 
 
Target siRNA sense sequence 
Control AllStars Negative control siRNA Qiagen 
#1027281 
Pin1 5’-CGGGAGAGGAGGACUUUGA-3’ 
p53 5’-GACUCCAGUGGUAAUCUAC-3’ 
Murine Pin1 siGENOME SMART POOL PIN1 
M-040655-01-005  
HIPK2 Hs_HIPK2_9 Qiagen #SI04439386 
PKCδ 5’-CUCUACCGUGCCACGUUUU-3’ 
 
Constructs for DNA transfection. pcDNA3-htt(1-171)21Q-GFP and pcDNA3-htt(1-
171)150Q-GFP encode the amino-terminal 171 aminoacids of human Huntingtin protein 
with 21 and 150 glutamines respectively, fused in frame at the carboxy-terminus with GFP. 
pGEX-Pin1, pcDNA3-Pin1-HA and pcDNA3-p53-S46A were described previously 
(Zacchi et al., 2002). pcDNA3-HAPin1SR and pcDNA3-HAPin1SR-S67E were generated 
introducing silent mutations in the region targeted by Pin1 siRNA by site directed 
mutagenesis of pcDNA3-HAPin1 or pcDNA3-HAPin1S67E (Rustighi et al., 2009). 
pcDNA3-p53-3M-Ser46 wt was generated from pcDNA3-p53 4M (Mantovani et al., 2007) 
by site-directed mutagenesis.  
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Quantitative RT-PCR 
Total RNA was extracted with Qiazol and cDNA was transcribed using QuantiTect 
Reverse Transcription kit (Qiagen). To determine mRNA expression levels, real-time PCR 
was performed on a StepOne Plus instrument (Applied Biosystems) with QuantiFast 
SYBR Green PCR Kit (Qiagen). Primer sequences are reported below. 
 
Gene Forward Reverse 
Murine p21 GTGGGTCTGACTCCAGCCC CCTTCTCGTGAGACGCTTAC 
Murine β-actin CACACCCGCCACCAGTTC CCCATTCCCACCATCACACC 
 
 
In vitro binding 
For GST pull-down, H1299 cells were transfected with 1 µg of pcDNA3-p53 along with 
increasing amounts (4, 6, 8 µg) of pcDNA3-Htt(1-171)150Q-GFP or empty vector. After 
48h cells were lysed and protein extracts were incubated with 2.5 µg of GST-Pin1 protein 
or GST to detect p53 binding as described (Zacchi et al., 2002).  
 
Antibodies  
The used antibodies were: anti-Pin1 rabbit polyclonal antiserum(Zacchi et al., 2002), anti-
Huntingtin MAB5490 (Millipore), anti-p53 DO-1 and FL-393, anti-p53 Pab240 
monoclonal antibodies and anti-HSP90 F-8 (Santa Cruz Biotech); anti–phospho-Ser15-p53 
and anti–phospho-Ser46-p53 (Cell Signaling Technology); anti–phospho-Ser46-p53 (BD 
PharmingenTM), rabbit polyclonal anti-Puma ab-9643 (Abcam), rabbit polyclonal anti-actin 
(Sigma). Anti-HIPK2 monoclonal antibody was a gift of L. Schmitz (University of 
Giessen, Giessen, Germany). 
 
Mice strains 
HdhQ111 knock-in mice expressing the complete endogenous Htt gene with 111 polyQ 
and their wild-type littermates (HdhQ7) in C57Bl background were provided by Dr. 
M.MacDonald (MGH, Boston). A colony of Pin1 KO mice in C57Bl background 
(Atchison and Means, 2003) was obtained from Dr. A. Means (Duke University, Durham 
NC). Mice containing one knock-in allele for HdhQ111 (HdhQ111/Q7) were crossed with 
Pin1+/- mice to generate cohorts of HdhQ111/Pin1wt or HdhQ111/Pin1-/- mice; mouse 
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genotype was determined by PCR on tail DNA. For detection of RNA levels in mouse, 
total brains of 12-months-old HdhQ111 mice were homogenized in Qiazol (Qiagen) and 
RNA was extracted with standard protocol. 
 
TUNEL assays 
Cells seeded on polylysine-coated coverslips were fixed with 3% paraformaldehyde and 
permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate. TUNEL assays were 
performed with TMR red In Situ Cell Death Detection Kit (Roche) and analysed with 
Leica DM4000B fluorescence microscope. 
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